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PREFACE 
In chapter 1 a concise overview of thrombolytic therapy for acute myocardial 
infarction is given. Many questions remain unanswered and research looking at various 
aspects of this treatment modality continues. Although thrombolytic therapy for acute 
myocardial infarction is not at all new and was used already more than 25 years ago, 
progress in this field has been rapid during the last years. Reports of new trials are peing 
published shortly after each other. In the review only randomized trials have been 
referred to and unpublished data or results of very small trials have been ignored. The 
main clinical trial results are summarized in tables. For more detailed information on 
each trial the reader is referred to the abstract booklet [1]. 
In chapters 2 to 6 the clinical effects of rt-PA are described. Unlike other 
thrombolytic agents as streptokinase and urokinase, tissue plasminogen activator was 
found to be mainly active at the site of the thrombus (fibrin-specific), thereby saving 
circulating fibrinogen and other clotting factors. In chapter 2, the fibrin-specificity, 
earlier studied with in vitro and animal experiments or in healthy volunteers, was studied 
in the clinical setting. In chapter 3 the efficacy of rt-PA in terms of enzymatic infarct 
size reduction and improvement of left ventricular ejection fraction was studied. 
Chapters 4 and 5 deal with the value of immediate percutaneous transluminal coronary 
angioplasty (PTCA) in addition to thrombolytic therapy. 
In chapter 7 patient selection for thrombolytic therapy is addressed. Since 
mortality after acute myocardial infarction is low in certain subsets of patients and 
thrombolytic therapy may result in intracerebral bleeding and since benefits of 
thrombolytic therapy are related to treatment delay, patients should be carefully selected 
for thrombolytic therapy. In chapter 8 the value of coronary angiography for risk 
stratification of patients with and without thrombolytic therapy for acute myocardial 
infarction before hospital discharge is assessed. 
Reference 
1. Arnold AER, Ferdinand RF, Soward AL, Schmidt WG, Lubsen J. Thrombolysis in suspected 
acute myocardial infarction- a summary. Universimed, Frankfurt (Main), 1990. 

Introduction 
CHAPTER 1 
TREATMENT STRATEGIES 
FOR ACUTE MYOCARDIAL INFARCTION 
A REVIEW 
Acute myocardial infarction remains one of the most common causes of death 
in the western world. With the development of coronary care units allowing prompt 
recognition and treatment of potentially lethal cardiac arrhythmias, the extent of 
myocardial damage remains an important determinant of morbidity and mortality. 
Accordingly much interest and research in recent years has focused on limitation of 
infarct size. In most patients with acute myocardial infarction, the coronary artery 
supplying the infarct region is occluded by thrombus at a site of atherosclerotic plaque. 
Early restoration of coronary blood flow by thrombolytic therapy results in smaller 
infarct size, improved left ventricular function and reduced mortality. Recanalization can 
occur spontaneously but prompt intervention with thrombolytic therapy has had dramatic 
results, particular when given within the ftrst few hours after onset of coronary 
occlusion. 
Thrombolytic agents 
Physiologic clot lysis occurs by conversion of plasminogen to the proteolytic 
enzyme plasmin at the site of the thrombus. Plasmin breaks down ftbrin in the thrombus 
and produces lysis. Any circulating plasmin is inactivated by alpha-2-antiplasmin and 
a systemic thrombolytic effect does not occur under normal circumstances [1]. 
Thrombolytic agents also result in clot dissolution through activation of native plasmin 
(ftgure 1). Circulating as well as clot-bound plasminogen may be converted to plasmin 
and act not only on fibrin within the thrombus, but also on circulating fibrinogen and 
clotting factors such as factors V and VIII producing a systemic fibrinolytic effect, 
increasing the risk of hemorrhagic complications. Streptokinase is inactive until it has 
formed a complex with plasminogen. It is this complex which splits another molecule 
of plasminogen to plasmin [1]. Urokinase, recombinant tissue plasminogen activator (rt-
PA or alteplase), pro-urokinase (scu-PA or saruplase) and anisoylated plasminogen 
streptokinase activator complex (APSAC or anistreplase) activate plasminogen directly. 
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The action of streptokinase, urokinase and APSAC is non-specific and results in 
systemic conversion of plasminogen to plasmin and depletion of circulating fibrinogen 
for 12 to 36 hours. Rt-PA and scu-PA on the other hand, are relatively fibrin-specific 
with little effect on circulating fibrinogen and other clotting factors. Rt-PA acts 
predominantly upon fibrin-bound plasminogen within the thrombus and has little effect 
on circulating plasminogen, unless high doses are given [1]. Scu-PA is probably 
protected against circulating plasminogen by an unknown substance in human plasma 
that is inactivated by fibrin [1]. Streptokinase is produced by beta-hemolytic streptococci 
(Lancefield C) which also commonly cause throat infections. Therefore antibodies are 
frequently present,especially after repeated use, and may limit the efficacy of 
streptokinase therapy. Side effects include hypotension and allergic reactions varying 
from rash to anaphylactic shock and autoimmune vasculitis. APSAC is a complex of 
streptokinase and plasminogen isolated from donor blood, inactivated by the addition of 
an anisoyl group. In the circulation APSAC is gradually activated by deacylation, giving 
it a plasma half time of 90 minutes which is much longer than that of the parent 
streptokinase. APSAC can be administered as a bolus in 4 to 6 minutes whereas 1.5 
million units streptokinase requires an infusion time of 30 to 60 minutes. Side effects 
are similar to those of streptokinase. Urokinase, originally isolated from human urine, 
and the other naturally occurring plasminogen activators have no antigenic properties 
and thus lack many of the side effects of streptokinase and APSAC. Scu-PA is the 
inactive precursor of urokinase. Scu-PA can be activated into urokinase by plasminogen. 
As is the case for rt-PA, scu-PA can be produced by genetic engineering. Tissue-type 
plasminogen activator is a naturally occurring plasminogen activator. The initial 
genetically engineered rt-PA was predominantly in the double chain form, but most rt-
p A in current use is single chain. The latter has a shorter plasma half life and higher 
doses are needed to yield similar coronary patency rates [2]. 
Clinical trials 
Clinical trials of thrombolytic therapy have investigated effects on coronary 
patency (without pre-treatment coronary angiography), recanalization (trials with pre-
treatment coronary angiography), enzymatic infarct size, left ventricular function 
(contrast or radionuclide angiography) and early and late mortality. The benefit of 
thrombolytic therapy must be finally evaluated in terms of clinical outcome (functional 
status and mortality). Intermediate endpoints related to clinical outcome (patency, 
enzymatic infarct size and left ventricular ejection fraction) have the advantage that 
smaller trial sizes suffice, while for mortality trials more patients are needed to 
demonstrate a treatment effect. Furthermore, intermediate endpoint assessment helps to 
elucidate pathophysiologic mechanisms. The pathophysiologic model for thrombolytic 
therapy in acute myocardial infarction (coronary artery recanalization results in 
limitation of infarct size, preservation of left ventricular function and mortality reduction 
would not exist without trials in which intermediate endpoints were assessed together 
with mortality. 
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Coronary patency and recanalization 
In about 80 to 85% of patients with symptoms of acute myocardial infarction an 
occluded infarct-related coronary artery is found when coronary angiography is 
performed within 4 hours after onset of symptoms [3]. Without thrombolytic treatment 
recanalization occurs in some patients probably due to physiologic fibrinolysis, and at 
12 to 24 hours after onset of symptoms only approximately 65% have an occluded 
infarct related vessel. Studies directly comparing all thrombolytic agents have not been 
performed. Comparative conclusions regarding individual agents from existing trials are 
weakened by the limitations imposed by comparing different trials. The impact of 
physiologic thrombolysis in different patient groups, variations in the timing and number 
of angiographic contrast injections (which may induce recanalization mechanically), and 
lack of uniformity in the definition of coronary patency are examples of factors which 
interfere with direct comparison. Trials with coronary angiography performed 
approximately 90 minutes after start of treatment are documented in tables I and II. 
Initial trials dealt with recanalization rather than with coronary patency. Later on, 
investigators considered treatment delay, caused by baseline coronary angiography, not 
justifiable. Coronary patency and recanalization at 90 minutes are interrelated. The 
former can be derived from the latter on the assumption that 15 to 20% of patients have 
a patent vessel before thrombolysis. After intracoronary streptokinase about 85% of 
patients have a patent infarct related artery at 90 minutes after start of the infusion. 
Intravenous rt-PA and scu-PA produce coronary patency in approximately 75%, and 
intravenous streptokinase in 50% of cases. Data on APSAC are not always consistent 
since APSAC was reported to be similarly effective in terms of coronary patency at 90 
minutes as intravenous streptokinase (see table I) and somewhat less efficacious in 
inducing coronary recanalization as intracoronary streptokinase (see table II). 
Angiographic reocclusion 
Reliable assessment of reocclusion is difficult for two reasons. Firstly, a 
thrombus is the result of a dynamic process of clot formation and lysis. This may result 
in opening, closure and reopening of the coronary vessel [4]. Even with repeated 
coronary angiography reocclusion may be missed. Secondly, repeated catheterization 
carries significant risks and may not be possible in some of the patients due to refusal, 
cardiac contraindications, or intercurrent revascularization procedures. Reocclusion could 
predispose to such an unstable clinical state, thereby distorting the estimation of the 
reocclusion rate. In a pooled analysis of trials with intracoronary streptokinase 
reocclusion within two weeks occurred in 17% of patients [4]. Initially, reocclusion after 
rt-PA was reported to occur in about one third of the patients shortly after cessation of 
rt-PA infusion, especially if a severe stenosis remained in the infarct related vessel [5,6]. 
In subsequent larger trials reocclusion after 1 to 24 hours was found in 7 to 10% of 
patients and after 1 to 2 weeks in 12 to 18% of patients (see table III), when full 
heparinization was given. The need for concomitant heparin administration was recently 
reported by Bleich et al [7]. They found considerably higher 48 to 72 hours coronary 
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patency when rt-PA was combined with heparin than after rt-PA alone (72% versus 
43%). Similar results were found in the Heparin Aspirin Reperfusion Trial [8]. The 
European Cooperative Study Group reported recently on the superior patency at 48 to 
120 hours after the combination ofrt-PA and heparin (83.4%) than rt-PA alone (74.7%) 
in a larger trial with 652 patients. Since there was no effect of heparin on initial 
coronary patency in TAMI V (table I), reocclusion has most likely played an important 
role. The effect of prolonged rt-PA infusion on reocclusion was assessed in two trials 
with very similar protocols (table III). In the frrst trial using double chain rt-PA there 
was no benefit from long term rt-PA infusion. In the other trial prolonged infusion of 
single chain rt-PA prevented most reocclusions. For APSAC similar reocclusion rates 
were published (5% and 8%). The latter trial must be interpreted with caution since 34% 
of patients with successful recanalization after 90 min were excluded because of other 
revascularization procedures or additional thrombolytic therapy (table III). 
Enzymatic infarct size 
Infarct size can be estimated by cumulative release of cardiac enzymes. Peak 
plasma levels may give an unreliable estimate of infarct size: because of a more rapid 
enzyme release after thrombolysis, peak levels are reached earlier and the peak may be 
higher despite of a lower cumulative release compared to conventional therapy. 
Enzymatic infarct size from cumulative release is assessed in a limited number of 
studies listed in table IV. Intracoronary streptokinase reduces enzymatic infarct size by 
30% whereas intravenous rt-PA, APSAC and intravenous streptokinase produce 20%, 
19% and 9% reduction respectively. The relative efficacy of these thrombolytic agents 
in terms of enzymatic infarct size seems to correlate with the relative efficacy in 
restoration of coronary patency. Benefit was most pronounced when treatment was 
started early. In patients treated with intravenous streptokinase within 3 hours after onset 
of symptoms, infarct size was 16% smaller [9]. After treatment with intracoronary 
streptokinase within 2 hours reduction was even 51% [10]. 
Left ventricular function 
Global left ventricular ejection fraction as determined by contrast or radionuclide 
ventriculography is a rather insensitive parameter for assessing efficacy of thrombolytic 
therapy. Left ventricular ejection fraction measurement is subject to considerable error 
due to compensatory hyperkinesia in the noninfarcted myocardium, which may be 
blunted in some patients by previous myocardial infarction. An assessment of regional 
left ventricular wall motion would seem a more accurate measure of determining effect 
on left ventricular function. In addition, a systematic error may occur in the 
determination of left ventricular function due to the fact that in each trial 
ventriculography is lacking in up to 30% of patients. Inability to assess left ventricular 
function is more likely to occur in patients with larger infarctions. Since these patients 
are more common in the group receiving the least effective thrombolytic drug, exclusion 
of these patients could result in underestimation of the difference in thrombolytic 
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efficacy between the treatment strategies in a trial. In addition, patients with larger 
infarctions are more likely to be studied at a later stage than patients with smaller, 
uncomplicated infarctions. As a consequence, infarct "healing" in patients with large 
infarctions is more complete, which also may result in underestimation of the true 
difference in efficacy of thrombolytic strategies. Despite these limitations, benefit has 
been demonstrated for nearly all thrombolytic agents (table V). The wide variance of left 
ventricular ejection fraction among placebo groups of the various trials dictate that one 
trial may not be compared directly with another. 
Mortality 
In table VI and VII trials reporting mortality are recorded. For intravenous and 
intracoronary streptokinase, APSAC and rt-PA, sufficient evidence is available to 
conclude that all reduce mortality. Mortality in the placebo groups varies substantially 
principally due to differences in entry criteria (age, previous myocardial infarction, etc.) 
and concomitant therapy again making direct comparisons of thrombolytic agents 
unreliable. Intravenous streptokinase and rt-PA have been compared in the large, 
multicenter trial of the International Study Group (including GISSI-2) [11]. No 
additional benefit could be ascribed to either agent. Heparin was administered 
subcutaneously 12 hours after start of thrombolytic therapy to half of the patients. Since 
the anticoagulant effect of subcutaneous heparin is delayed 12 to 24 hours after 
administration, most patients would have experienced little effect from heparin during 
the first 24 hours when reocclusion and reinfarction are most likely to occur. The 
importance of full heparinization to prevent reocclusion after rt-PA is outlined above. 
The question remains whether a strategy of rt-PA together with immediate and full 
intravenous heparinization produces a greater mortality reduction than a strategy of 
intravenous streptokinase. 
Benefit of thrombolytic therapy in relation to treatment delay 
In nearly every thrombolytic trial mortality reduction is greatest when treatment 
is given soon after the onset of symptoms. In GISSI-1 mortality reduction at 3 weeks 
in patients treated 3 hours or less after onset of symptoms was 3 per hundred patients, 
from 3 to 6 hours 2 per hundred and from 6 to 9 hours only 1 per hundred. In patients 
with 9 to 12 hours treatment delay mortality was adversely affected with 3 weeks 
mortality increased from 14% to 16% [12]. Hemorrhage in the infarct territory, occurring 
more frequently after thrombolytic therapy than without [13] and especially in patients 
treated after 3 hours delay [14], might play a role. In ISIS-2 some benefit was still 
present when treatment started after a delay of 12 to 24 hours [15]. However this trial 
has been criticized for having studied a heterogenous group of patients, resulting from 
loose entry criteria. In order to include a patient in the trial it sufficed that the 
investigator considered myocardial infarction likely. It might be that the 6 to 24 hours 
subgroup partly consisted of patients in whom the time of onset of symptoms was not 
exactly known, but well within 6 hours before start of treatment, e.g. because the actual 
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myocardial infarction was preceded by a period of unstable angina. These patients were 
excluded in other trials. Because thrombolytic therapy may result in serious side effects, 
treatment after a delay of 6 hours cannot be recommended until other clinical trials 
provide further evidence. 
Concomitant therapy 
In the first 6 to 12 hours of the acute phase of myocardial infarction, when 
ischemic myocardium is converted into necrotic tissue, limitation of oxygen demand 
may improve clinical outcome. Indeed, in the acute phase undue tachycardia and 
hypertension on one hand and raised ventricular diastolic pressure on the other hand may 
further deteriorate the balance of oxygen demand and supply. Early hemodyn_arnic 
optimalization by beta-blockade, nitrates, inotropics or intra-aortic balloon pumping (in 
case of heart failure) may limit infarct size, but proof from randomized clinical trials is 
lacking. Although the pathophysiologic mechanism remains unclear, in-hospital mortality 
was reduced by immediate (intravenous) beta-blockade [16,17]. In ISIS-2 aspirin reduced 
5 week mortality by 2 patients per hundred, when given immediately on admission and 
continued for 1 month [15]. Benefit of aspirin was additive to that of intravenous 
streptokinase and, interestingly, not related to the treatment delay. This suggests a 
different pathophysiologic mechanism than for thrombolytic agents, e.g. prevention of 
reocclusion. Heparin may not only reduce coronary reocclusion after rt-PA, but also 
reduces stroke after myocardial infarction by 50% [18]. Although a subcutaneous 
regimen have been successful for the latter [19,20], intravenous and full heparinization 
seems necessary to prevent reocclusion after rt-PA [7,8]. Long term coumarins may 
contribute to improved survival and less frequent reinfarction [21]. Prevention of late 
recurrent ischemic events and death with beta-blockade for at least one year is 
sufficiently proven [22-24]. 
Risks of thrombolytic therapy 
Thrombolytic agents do not discriminate clots at a potential bleeding site from 
a clot in an occluded coronary artery. Indeed, hemorrhages are a feared complication 
after thrombolytic therapy for acute myocardial infarction. Patients with increased 
bleeding risk, e.g. extensive cardio-pulmonary resuscitation or trauma (especially head), 
recent gastrointestinal bleeding, cerebrovascular accident, major surgery or hemostatic 
disorders, were excluded in nearly all trials. Bleeding complications, depending on 
definitions and treatment protocol used (immediate catheterization) were reported in 20% 
to 40% of patients, most frequently being hematoma formation and prolonged bleeding 
at puncture sites. The most serious complication is intracerebral hemorrhage. The risk 
of intracerebral bleeding is probably underestimated in mortality trials due to their nature 
(simple protocols and collection of few clinical data) and because computerized 
tomography or obduction was not performed in all patients with stroke. For example, 
in ISIS-2 only 17% of cases with stroke on day 0 and 1 were proven to be hemorraghic 
by CT-scanning or necropsy, while data from the pre-thrombolysis era suggest that non-
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hemorraghic strokes tend to become manifest later on [25]. The most accurate estimate 
is that intracerebral bleeding occurs in about 0.5% of patients [9,11,26,27]. The 
International Study Group found that the risk of stroke was 1.3% with rt-PA as 
compared to 1.0% with streptokinase. However, in 30% of cases the cause of stroke was 
not established. If these were ischemic, they might be prevented by adequate intravenous 
heparinization. Forrt-PA a dose-dependence is reported; after 150 mg single chain rt-PA 
an intracerebral bleeding occurred in 5 out of 311 patients (1.6%), after 100 mg in 15 
out of 3768 patients (0.4%) [28]. Furthermore, bleeding was reported to be less frequent 
in a weight adjusted dosage scheme than after a fixed dose [29] and in patients with less 
serum levels of fibrinogen degradation products [30]. 
Life threatening arrhythmias during myocardial reperfusion, often encountered in animal 
experiments, were not frequently encountered in clinical trials. Periods of accelerated 
idioventricular rhythm without hemodynamic consequence are often seen at the time of 
coronary recanalization. Ventricular tachycardia and fibrillation are most frequently 
secondary to poor left ventricular function and more common in patients not treated with 
thrombolytic treatment [9,26]. 
Thrombolytic therapy for all patients with suspected acute myocardial infarction? 
In most thrombolysis trials 75% of patients presenting with acute myocardial 
infarction were excluded, predominantly due to delayed admission and advanced age. 
Thrombolytic therapy is associated with intracerebral bleeding in approximately 0.5% 
of patients, irrespective of which thrombolytic agent is used. Half of these are lethal 
[9,15,26,27]. Clinicians thus need to balance the risks and expected benefits of 
thrombolytic therapy. Overall results of clinical trials cannot be automatically 
extrapolated to individual patient care and the decision to treat patients with 
thrombolytic therapy is not as simple as suggested in some publications. Reliable 
determination of patients' "baseline risk" (defined as the predicted outcome in the 
absence of thrombolytic therapy), of expected benefit of thrombolytic therapy and 
identification of predictors of intracerebral bleeding after thrombolytic therapy are 
prerequisites for good clinical decision making and need the full attention of present and 
future investigators. In the mean time the adage "in dubio abstine" still holds. 
Role of routine coronary angioplasty 
Recovery of left ventricular function [31] and the incidence of reocclusion 
[32,33] were reported to be related to the degree of residual stenosis after thrombolysis 
and small randomized trials, assessing immediate angioplasty with and without 
intracoronary streptokinase, suggested that recovery of left ventricular function might 
be improved by angioplasty [34,35]. However, large randomized trials have failed to 
confmn this. There was no additional benefit in terms of enzymatic infarct size or left 
ventricular function of immediate [36-38] or delayed (18-48 hours) angioplasty [39] in 
patients treated with rt-PA (table Vlli), probably due to reocclusion or reinfarction 
following further destabilization of the infarct related atherosclerotic lesion, caused by 
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the balloon dilatation [ 40]. 
Conclusion 
Most data are consistent with the hypothesis that early coronary recanalization 
results in limitation of infarct size, preserves left ventricular function and reduces 
mortality. Earlier administration of a thrombolytic agent improves the clinical outcome. 
Rt-PA, scu-PA and possibly APSAC are more efficacious in restoring coronary patency 
than intravenous streptokinase. However, in terms of clinical benefit, it remains unclear 
which is best, also after the report of The International Study Group (GISSI-2). The 
latter trial learned us that we should not discuss differences in efficacy of different 
thrombolytic drugs, but rather of different thrombolytic strategies. 
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TABLES 
If no comments on treatment regimens are made in the tables, 
standard treatment schedules were used: 
intravenous streptokinase 1.5 million U over one hour; 
recombinant tisue-type plasminogen activator (rt-PA or 
alteplase) 100 mg over three hours (unless indicated 
otherwise rt-PA refers to the single chain form). 
anisoylated plasminogen streptokinase activator complex 
(APSAC or anistreplase) 30 mg bolus over 4-6 min. 
The abstract numbers in the tables refer to the list of main 
clinical trial publications on page 27 to 29, to provide quick 
reference. For more detailed information on each trial the reader 
is referred to the abstract booklet: 
Arnold AER, Ferdinand RF, Soward AL, Schmidt WG, Lubsen 
J. Thrombolysis in suspected acute myocardial infarction - a 
summary. Universimed, Frankfurt (Main), 1990. 
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Table I. Studies in which patency within 2 hrs was assessed. 
Patency: SK IC vs standard therapy 
Acronym Nr of Time to Evaluation SKIC Patency 95% CI 
(abstr nr) pts therapy after dose SK vs control 
Anderson (1) 50 <4 hrs <100 min <300,000 u 79% vs*%1 63 to 95% 
ICIN2 (13) 533 <4 hrs 60-90 min <250,000 u 85% vs *%1 80 to 90% 
Patency: rt-PA (double chain) vs placebo 
Acronym Nrof Time to Evaluation rt-PA Patency Difference 
(abstr nr) pts therapy after dose rt-PA vs plac (95% CI) 
European 129 <6 hrs 90 min 0.75 mg/kg 61 VS 21% +40% 
Cooperative-I (22 to 56%) 
(11) 
Patency: rt-PA (double chain) vs SK IV 
Acronym Nr of Time to Evaluation rt-PA Patency DifferencP 
(abstr nr) pts therapy after dose rt-PA vs plac (95% Cl) 
European 129 <6 hrs 90min 0.75 mg/kg 70 VS 55% +15% 
Cooperative-2 (-3 to 32%) 
(12) 
Patency: rt-PA with vs without heparin IV 
Acronym Nr of Time to Evaluation rt-PA Heparin Patency with vs Difference 
(abstr nr) pts therapy after dose dose without heparin (95% CI) 
TAMI-3 134 <4-6 hrs 90min <90 10,000 u 79 vs 79% +1% 
(50) mg (-13 to+ 15%) 
Patency: rt-PA vs UK IV 
Acronym Nr of Time to Evaluation UK Patency Difference 
(abstr nr) pts therapy after dose rt-PA vs UK (95% CI) 
GAUS 246 <6 hrs 90min 3,000,000 u 69 vs 66% +3% 
(45) (-9to+14%) 
Patency: Dose finding study of a combination of UK and rt-PA 
Acronym Nr of Time to Evaluation UK rt-PA Patency 95% CI 
(abstr nr) pts therapy after dose 
TAMI-23 146 <4-6 hrs 90min 0.5 million U 25 mg 36% 11 to 61% 
(49) 1.0 million U 25 mg 42% 19 to 61% 
0.5 or 1.0 or 1.0 mg/kg 73%4 66 to 83% 
2.0 million U 
Patency: APSAC IV vs SK IV 
Acronym Nr of Time to Evaluation 
(abstr or) pts therapy after 
IRS-2 116 <6 hrs 1.75 hrs 
(26) 
Hogg 128 <6 hrs 90min 
(66) 
Patency: scn-PA vs SKIV 
Acronym Nr of Time to Evaluation scn-PA 
(abstr or) pts therapy after dose 
PRIMI 401 <4 hrs 90min 80mg 
(61) 
I * not measured. 
2 SK IC was preceded by 500,000 U SK IV in 117 cases. 
3 Difference for 25 mg rt-PA vs 1.0 mg/kg: 36% (95% CI: 18 to 55%). 
4 Only overall outcome given. 
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Patency Difference 
APSACvs SK (95% Cl) 
70 vs 51% + 19% 
(+1 to+38%) 
55 VS 53% +3% 
(-14to+20%) 
Patency Difference 
scn-PA vs SK (95% CI) 
71 vs 64% +7% 
(-2to+17%) 
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Table II. Studies in which recanalization was assessed. 
Recanalization: SK IC vs control 
Acronym Nrof Time to Evalu- SKIC Recanalization Difference 
(abstr nr) pts therapy ation dose SK IC vs control (95% Cl) 
Western 250 < 12 hrs during <350,000 u. 68 VS *%I 59 to 76% 
Washington (4) therapy 
Recanalization: SK IC vs placebo 
Acronym Nrof Time to Evalu- SKIC Recanalization Difference 
(abstr nr) pts .therapy ation dose SK IC vs placebo (95% CI) 
Khaja 40 <6 hrs 55 min 250,000 u 60 vs 10% +50% 
(2) (+ 20 to+ 80o/o) 
Recanalization: SK IC vs NTG IC 
Acronym Nrof Time to Evalu- SKIC NTGIC Recanalization Diff. 
(abstr nr) pts therapy ation dose dose SKvsNTG (95% CI) 
Leiboff 55 <4 hrs 90min <300,000 u <1 mg2 69% vs 17% +52% 
(6) (20 to 83%) 
Recanalization: SK-IC vs SK-IC + NTG-IC vs NTG-IC 
Acronym Time to Evaluation Treatment Nr of Recanalization 95% CI 
(abstr nr) therapy patients 
Mount <12 hrs during SK-IC 240,000 U 3 67 60% 40 to 72% 
Sinai-2 (59) therapy SK-IC 240,000 U 3 62 63% 51 to 75% 
+ NTG-IC 0.01 mg/min 
NTG-IC 0.01 mg/min 3 65 8% 1 to 14% 
Recanalization: SK IV vs standard therapy4 
Acronym Nr of Time to Evalu- SKIV Recanalization Difference 
(abstr nr) pts therapy ation dose SKvsNTG (95% Cl) 
Cribier 28 <4 hrs 2 hrs 1,500,000 u 50 vs 61% -11% 
(16) (-50 to+ 28%) 
Recanalization: SK IV vs SK IC5 
Acronym Nrof Time to Evalu- SKIV SKIC Recanalization Diff. 
(abstr nr) pts therapy ation dose dose SK IVvs IC (95% CI) 
Rogers 51 <12 hrs 75 min 1,000,000 u 240,000 u 31 vs 76% -45% 
(3) (-73 to -18%) 
Recanalization: SK IV vs SK IC 
Acronym Nr of Time to Evalu- SKIV SKIC Recanalization Diff. 
(abstr nr) pts therapy ation dose dose SKIVvsSKIC (95% CI) 
Alderman 28 3 hrs 90min 725,205 u 343,375 u 62 vs 73% + 11% 
(5) (- 24 to+ 47%) 
Recanalization: UK IV vs placebo 
Acronym Nrof Time to Evalu- UKIV Recanalization Difference 
(abstr nr) pts therapy ation dose UK vs placebo (95% Cl) 
UK Double 210 <6 hrs 45 min <960,000 u 74 vs 14% +60% 
Blind (38) (+ 47 to+ 74%) 
Recanalization: rt-PA vs SK IV 
Acronym Nr of Time to Evalu- rt-PA Recanalization Difference 
(abstr nr) pts therapy ation dose rt-PA vs SK (95% Cl) 
TIMI-1 316 <7hrs 45min 80 mg6 62 vs 31% +31% 
(33) (+ 19 to+ 42%) 
Recanalization: APSAC IV vs SK IC 
Acronym Nr of Time to Evaluation SKIC Recanalization Difference 
(abstr nr) pts therapy dose APSAC vs SK IC (95% Cl) 
Bonnier 85 <4hrs 90 min 250,000 u 64 VS 68% -4% 
(23) (- 26 to+ 18%) 
Kaspar 16 <6 hrs 90min 250,000 u 83 VS 63% +20% 
(29) (- 29 to+ 71%) 
APSAC 258 <4 hrs APSAC90 min 180,000 u 5[ VS 60% -9% 
(41) SK60 min (-21 to +4%) 
Recanalization: UK IV vs SK IC 
Acronym Nr of Time to Evalu- SKIC UKIC Recanalization Diff. 
(abstr nr) pts therapy ation dose dose SKvsUK (95% CI) 
Tennant 143 <12 hrs <2 hrs 240,000 u 720,000 u 57 vs 60% -3% 
(9) (- 25 to+ 19%) 
Recanalization: pro-UK IC vs UK IC 
Acronym Nr of Time to Evaluation Treatment Recanalization 95% CI 
(abstr nr) pts therapy 
Kambara 148 <6 hrs 45min pro UK7 90% 82 to 98% 
(47) 6,000 u 
pro UK 59% 45 to 74% 
3,000 u 
UKIC7 61% 48 to74% 
960,000 u 
Recanalization: Immediate PTCA vs SK IC 
Acronym Nrof Time to Evaluation SKIC Recanalization Diff. 
(abstr nr) pts therapy dose PTCAvsSKIC (95% CI) 
O'Neill 56 <12 hrs after therapy 250,000- 83 vs 85% -2% 
(21) 350,000 u (-22 to+ 17%) 
I not measured 
2 5 boluses ofl00-200 microgram IC in 75 min. 
3 SK-IC was given until recanalization was achieved, up to a maximal dose of240,000 U over 2 hrs. Difference be-
tween SK-IC or SK-IC + NTG-IC treated patients and patients treated with NTG-IC only: 54% (95% CI: 39% to 
68%) 
4 Standard therapy included heparin at 0.35 U /kg/min for at least I hour. After 1 hour patency was assessed in both 
treatment groups. In case of occlusion SK IC was administerd at 4,000 U /min for 1 hour, after which recanalization 
was assessed. 
If no thrombolysis was noted angiographically, 120,000 U of SKIC were administered. 
6 Double chain rt-PA. 
7 Difference between pro-UK IC (6,000 U) and UK IC (960,000 U): + 29% (95% CI: + 12 to+ 46%). 
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Table III. Studies in which reocclusion was assessed. 
Reocclusion: double chain rt-PA followed by heparin with or without rt-PA 
Acronym Nrof Time to Evaluation Reocclusion Difference 
(abstr nr) pts therapy after rt-PA vs placebo (95% Cl) 
European 122 <4 hrs 6-24 hrs 6 VS 5% 0% 
Cooperative-31 (24) (-11to-11%) 
Reocclusion: single chain rt-PA followed by heparin with or without rt-PA 
Acronym Nrof Time to Evaluation Reocclusion Difference 
(abstr nr) pts therapy after rt-PA vs control (95% Cl) 
Johns2 68 <6 hrs 150 min 0 vs 19% -19% 
(46) (-5 to-32%) 
Reocclusion: APSAC IV vs SK IC 
Acronym Nr of Time to Evaluation SKIC Reocclusion Difference 
(abstr nr) pts therapy after dose APSAC IV vs SK IC (95% Cl) 
Bonnier 85 <4 hrs 24 hrs 250,000 u 5 vs 17% -13% 
(23) (- 31 to+ 6o/o) 
APSAC 258 <4 hrs 24 hrs 180,000 u 8 vs 3% +5% 
(41) (- 5.2 to+ 14.8%) 
Reocclusion: UK dose finding study 
Acronym Nrof Time to Evaluation UK rt-PA Reocclusion 95% CI 
(abstr nr) pts therapy after dose dose 
TAMI-2 146 <4-6 hrs 7 days 0.5 million U 25 mg 0% 
(49) 
l.Omillion U 25 mg 20% 2 to 38% 
0.5 million U 1.0 mg/kg 11% 0 to 26% 
1.0 million U 1.0 mg/kg 6% 0 to 14% 
2.0 million U 1.0 mg/kg 11% 3 to 19% 
Reocclusion: SK IV+IC with and without PTCA 
Acronym Nr of Time to Evaluation SKIV SKIC Reocclusion Diff. 
(abstr nr) pts therapy after PTCA vs control (95% Cl) 
Erbel 162 <6 hrs in-hospital 250,000 u 200,000 u 14 VS 20% -6% 
(17) (-18 to+7%) 
Reocclusion: rt-PA +immediate PTCA vs delayed PTCA 
Acronym Nr of Time to Evaluation Reocclusion Difference 
(abstr nr) pts therapy after Immediate vs delayed PTCA (95% Cl) 
TAMI-l 386 <4-6 hrs 24 hrs 11 VS 13% -2% 
(32) (- 13 to+ 10%) 
1 The initial dose ofrt-PA was 40 mg in 90 min. Patients with a patent infarct related vessel were randomized to 
receive either 30 mg rt-PA or placebo in 6 hrs in addition to 1,000 IU/hr heparin. 
2 The initial dose of single chain rt-PA was 1.0 mg/kg in 90 min. Patients with a patent vessel were randomized to 
receive either 0.8 mg rt-PA in 4 hrs with heparin 1,000 IU/hr or heparin only. 
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Table IV. Studies in which enzymatic infarct size was assessed. 
Acronym Nr of Time to Therapy Enzymatic Infarct Relative 
(abstr nr) pts therapy size difference 
ISAM 1741 <6 hrs SK IV vs placebo CK-MB 1701 YS -9% 
(20) 1869 U/1/h 
ICIN 533 <4 hrs SK IC or IC+IVI vs Median HBDH-Q72 -30% 
(13) standard therapy 770 YS 1100 UII 
European 721 <5 hrs rt-PA IV vs placebo Median HBDH-Q72 -20% 
Cooperative-4 ( 43) 694 YS 867 u II 
Ikram 149 <4 hrs APSAC IV vs standard CK-Q48 1588 YS -19% 
(19) therapy 1951 u 
European 367 <5 hrs PICA vs standard Median HBDH-Q72 +6% 
Cooperative-S ( 44) therapy after rt-PA IV 703 YS 665 u II 
I SK IC up to 250,000 U, preceded by 500,000 U SK IV in 117 pts. 
22 Table V. Studies in which left ventricular ejection fraction 
was measured. 
LVEF: SK IC vs placebo 
Acronym Nr of Time to Evaluation SK dose LVEF 
(abstr nr) pts therapy after SK IC vs plac. 
Khaja 40 <6 hrs 1 hr 250,000 u 51 vs 49% 
(2) 
2 days 250,000 u 45 vs 36% 
LVEF: SK IC vs placebo 
Acronym Nr of Time to Evaluation SK dose LVEF 
(abstr nr) pts therapy after SK IC vs control 
ICWestern 250 < 12 hrs 8-9 weeks <350,000 u 46 vs 46% 
Washington (4) 
Anderson 50 <4 hrs 10 days <300,000 u 47 vs 39% 
(1) 
Leiboffl ( 6) 55 <4 hrs 2 weeks <300.00 u 43 vs 42% 
ICIN2 533 <4 hrs 2 weeks <250,000 u 50 vs 43% 
(13) 
LVEF: SK IV vs placebo 
Acronym Nrof Time of Evaluation LVEF 
(abstr nr) pts therapy after SK IV vs placebo 
ISAM 1741 <6 hrs 1 month 57 vs 54% 
(20) 
White3 219 <4 hrs 3 weeks 59 VS 53% 
(39) 
LVEF: SK IV vs standard therapy 
Acronym Nr ofpts Time to Evaluation LVEF 
(abstr nr) randomized therapy after SK IV vs control 
IV Western 368 <6 hrs 2 weeks 54 VS 51% 
Washington (54) 
LVEF: rt·PA vs placebo 
Acronym Nr of Time to Evaluation LVEF 
(abstr nr) pts therapy after rt-PA vs placebo 
TPAT4 118 <3.75 hrs 4 hrs 49 vs 45% 
(62) 
9 days 54 VS 48% 
National Heart 144 <4hrs 1 week 58 vs 52% 
Foundation of 
Australia ( 48) 
European 721 <5 hrs 10-22 days 51 vs 49% 
Cooperative-4 ( 43) 
TICO 147 <2.5 hrs 3 weeks 61 vs 54% 
(51) 
3 weeks 52 vs 48%5 
SK IC versus Nitroglycerin IC. Data of 40 pts with occluded infarct-related artery at base-line. 
SK IC was preceded by 500,000 U SK IV in 117 cases. 
3 Patients with first infarction. 
Difference 
(95% CI) 
+2.0 
(-6.2 to +10.2) 
+9.0 
( +0.5 to+ 17.5) 
Difference 
(95% Cl) 
0,0 
(-3.7 to +3.7) 
+8.0 
(+1.7 to+ 14.3) 
(no SD given) 
+6.0 
+3.1 to +9.1) 
Difference 
(95% Cl) 
+2.9 
(+2.8 to +3.0) 
+6.0 
(+2.8 to +9.3) 
Difference 
(95% CI) 
+3.0 
(- 0.1 to+ 6.1) 
Difference 
(95% CI) 
+4.2 
(+0.6 to +7.8) 
+6.0 
(+ 5.3 to+ 6.8) 
+6.0 
(-0.1 to+12.1) 
+2.2 
(+0.3 to +3.7) 
+7.0 
(+2.2 to +11.8) 
+4.0 
( -0.6 to +8.6) 
LVEF: rt-PA VS SKIV 
Acronym Nr of Time of Evaluation rt-PA LVEF Difference 
(abstr nr) pts therapy after dose rt-PA VS SK IV (95% Cl) 
PAlMS 171 <3 hrs 4 days lOOmg 55 vs 53% +2.0 
(60) (-1.4 to +5.4) 
TIMI-16 316 <7 hrs before 80 mg 46 vs 45% +1.0 
(33) discharge (-2.3 to +4.3) 
LVEF: rt-PA vs UK IV 
Acronym Nrof Time to Evaluation rt-PA UK LVEF Difference 
(abstr nr) pts therapy after dose dose rt-PA VS UK (95% CI) 
GAUS 246 <6 hrs 10 days 70mg 3,000,000 u 53 vs 52% +1.0 
(45) ( -2.9 to 4.9) 
LVEF: rt-PA with vs without heparin 
Acronym Nrof Time to Evaluation rt-PA heparin LVEFwith vs Difference 
(abstr nr) pts therapy after dose dose without heparin (95% Cl) 
TAMI-3 134 <4-6 hrs 1 week max 10,000 u 49 vs 50% -1.0 
(50) 90mg (-4.6 to +2.6) 
LVEF: APSAC IV vs heparin 
Acronym Nrof Time to Evaluation heparin LVEF Difference 
(abstr nr) pts therapy after dose APSAC vs heparin (95% Cl) 
APSIM (55) 231 <6 hrs 2-7 days 5,000 U (bolus) 53 VS 47% +6.0 (+2.6 to +9.4) 
2-3 weeks 43 VS 39% +4.0 (+0.9 to +7.1) 
LVEF: PTCA (immediate) vs SK IC 
Acronym Nrof Time to Evaluation SKIC LVEF Difference 
(abstr nr) pts therapy dose PTCAvsSKIC (95% Cl) 
O'Neill 56 < 12 hrs pre- 250,000- 50 vs 53% -3.0 
(21) discharge 350,000 u ( -10.6 to +4.6) 
LVEF: PTCA + SK-IC vs SK-IC 
Acronym Nrof Time to Evaluation SK LVEF Difference 
(abstr nr) pts therapy dose PTCA + SK vs SK (95% CI) 
Erbel (17) 162 <6 hrs 3-4 weeks SK-IV 250,000 U 55 vs 55% 0.0 
SK-IC 250,000 U ( -5.2 to +5.2) 
LVEF: PTCA + rt-PA VS rt-PA 
Acronym Nr of Time to Evaluation rt-PA LVEF Difference 
(abstr nr) pts therapy after dose PTCA vs control (95% Cl) 
TAMI-l 386 <4-6 hrs 1 week 150mg 53 vs 56% -3.0 
(32) (-6.4 to +0.4) 
European 367 <5 hrs 2 weeks lOOmg 51 vs 51% (no SD given) 
Cooperative-5 ( 44) 
TIMI-2A (52) 389 <4 hrs pre-discharge 150 or 100 mg 50 vs 49% (no SD given) 
TIMI-2B (35) 3262 <4hrs 6 weeks 150 or 100 mg 50 vs 50% (no SD given) 
4 39 pts received 0.4 MU/kg intravenous double-chain rt-PA in the first hr, 0.14 MU!kg in the second hr and 0.03 
MU!kg/hr in the subsequent 8 hrs. 79 pts received 0.4 MU/kg in the first hr, 0.08 MU/kg in the second hr and 
0.03 MU /kg/hr in the subsequent 4 hrs. 
5 Measured by radionuclide angiography. 
6 Double chain rt-PA. 
23 
24 
Table VI. Mortality Studies (mortality within 3 months). 
Mortality: Aspirin! vs placebo 
Acronym Nr of Time to Evaluation Aspirin Mortality Difference 
(abstr nr) pts therapy after dose Aspirin vs plac. (95% Cl) 
ISIS-2 17187 <24 hrs 5 weeks 162.5 9 vs 12% -3% 
(27) mg/day2 (-4 to -2%) 
Mortality: SK IC vs standard therapy 
Acronym Nr of Time. to Evaluation SKIC Mortality Difference 
(abstr nr) pts therapy after dose SK IC vs control (95% Cl) 
ICWestern 250 < 12 hrs 1 month <350,000 u 4 VS 11% -7% 
Washington (4) (-14% to -1%) 
ICIN 533 <4 hrs 1 month 250,000 u 6 VS 12% -6% 
(13) (-11 to -1%) 
Mortality: SK IV vs placebo 
Acronym Nr of Time to Evaluation Mortality Difference 
(abstr nr) pts therapy after SK IV vs placebo (95% Cl) 
ISIS-2 17187 <24 hrs 5 weeks 9 VS 12% -3% 
(27) (-4 to-2%) 
8592 5 weeks 8 vs 13%3 -5% 
(-6 to -4%) 
White 219 <4 hrs 3 weeks 3 VS 13% -11% 
(39) (-3 to -18%) 
!SAM 1741 <6 hrs 3 weeks 6 vs7% -1% 
(20) (-3to+1%) 
Mortality: SK IV vs standard therapy 
Acronym Nrof Time to Evaluation Mortality Difference 
(abstr nr) pts therapy after SK IV vs control (95% CI) 
GISSI-1 11806 < 12 hrs 3 weeks 11 VS 13% -2% 
(18) (-3 to -1%) 
Mortality: rt-PA vs placebo 
Acronym Nr of Time to Evaluation Mortality Difference 
(abstr nr) pts therapy after rt-PA vs placebo (95% Cl) 
European 721 <5 hrs 2 weeks 3 vs 6% -3% 
Cooperative-4 ( 43) (-6 to 0%) 
3 months 5 vs 8% -3% 
(-7 to -1%) 
ASSET 5011 <5 hrs 1 month 7 vs 10% -3% 
(42) (-5 to -2%) 
Mortality: APSAC IV vs placebo 
Acronym Nr of Time to Evaluation Mortality Difference 
(abstr nr) pts therapy after APSAC vs placebo (95% CI) 
AIMS 1258 <6 hrs 1 month 6 vs 12% -6% 
(22) (-9 to-3%) 
Mortality: rt-PA vs SK IV 
Acronym Nrof Time to Evaluation rt-PA Heparin Mortality 
(abstr nr) pts therapy after dose dose rt-PA VS SK IV 
TIMI-14 316 <7 hrs 3 weeks 80 mg 4 VS 5% 
(33) 
GISSI-2 20749 in-hospital 100 mg ou 8.7% vs 9.2% 
(65) 
12,500 u 9.2% vs 7.9% 
2 times daily 
Mortality: APSAC IV vs SK IC 
Acronym Nrof Time to Evaluation SKIC Mortality 
(abstr nr) pts therapy dose APSAC IV vs SK IC 
APSAC 258 <4 hrs in-hospital 180,000 u 4 VS 8% 
(41) 
Mortality: APSAC IV vs heparin 
Acronym Nr of Time to Evaluation Heparin Mortality 
(abstr nr) pts therapy after dose APSAC vs heparin 
APSAC 313 <4 hrs 1 month 5,000 u 6 vs 13% 
Multicenter (40) bolus 
(40) 
Mortality: PTCA (immediate)+ rt-PA vs rt-PA 
Acronym Nrof Time to Evaluation rt-PA Mortality 
(abstr nr) pts therapy after dose PTCA vs control 
TAMI-l 386 <4-6 hrs in-hospital 150mg 4vs 1% 
(32) 
European 367 <5 hrs 2 weeks 150 or 7vs 3% 
Cooperative-S 100mg 
(44) 3 months 8 VS 3% 
TIMI-2A 389 <4 hrs 3 weeks 100 or 7vs 6% 
(52) 150 mg 
Mortality: PTCA within 2 hrs + rt-PA vs PICA within 18-48 hrs + rt-PA 
Acronym Nr of Time to Evaluation 
(abstr nr) pts therapy after 
TIMI-2B 3262 <4 hrs 6 weeks 
(35) 
1 with or without randomly assigned streptokinase. 
2 During 1 month. 
3 SK IV+ Aspirin vs placebo. 
4 Double chain rt-PA. 
rt-PA Mortality 
dose immediate vs delayed 
100 mg 5 vs 5% 
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Difference 
(95% Cl) 
-1% 
(-6 to +3%) 
-1% 
(-5 to +2%) 
+1% 
(0 to+2%) 
Difference 
(95% CI) 
-4% 
(-10 to +2%) 
Difference 
(95% CI) 
-7% 
(-14 to -1%) 
Difference 
(95% Cl) 
+3% 
(-1 to +7%) 
+3% 
(-1 to +8%) 
+5% 
(0 to +10%) 
+1% 
(-4 to +6%) 
Difference 
(95% CI) 
0% 
(-2 to +2%) 
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Table VII. Mortality Studies (mortality> 6 months). 
Mortality: SK IC vs standard therapy 
Acronym Nr of Time to Evaluation SKIC Mortality Difference 
(abstr nr) pts therapy after dose SK IC vs control (95% CI) 
ICWestern 250 < 12 hrs 1 year <350,000 u 8 vs 14% -6% 
Washington (4) (-13 to +2%) 
ICIN 533 <4 hrs 3 years 250,000 u 13 vs 21% -8% 
(13) (-14 to -2%) 
Mortality: SK IV vs placebo 
Acronym Nr of Time to Evaluation Mortality Difference 
(abstr nr) pts therapy after SK IV vs placebo (95% CI) 
ISAM (20) 1741 <6 hrs 7 months 11 vs 11% 0%(-3to+3%) 
21 months 14 vs 16% -2% (-5 to+1%) 
Mortality: SK IV vs standard therapy 
Acronym Nr of Time to Evaluation Mortality Difference 
(abstr nr) pts therapy after (95% Cl) 
GISSI-1 11806 < 12 hrs 1 year 17 vs 19% -2% 
(18) (-3 to -1%) 
IV Western 368 <6 hrs 2 years 19 vs 35% -17% 
Washington (54) (-28 to -6%) 
Mortality: rt-PA vs placebo 
Acronym Nr of Time to Evaluation Mortality Difference 
(abstr nr) pts therapy after (95% Cl) 
ASSET (42) 5011 <5 hrs 1 year 13 VS 15% -2% (-4 to 0%) 
Mortality: APSAC IV vs placebo 
Acronym Nr of Time to Evaluation Mortality Difference 
(abstr nr) pts therapy after APSAC vs placebo (95% Cl) 
AIMS (22) 1258 <6 hrs 1 year 11vs18% -7% (-11 to -3%) 
Mortality: rt-PA vs SK IV 
Acronym Nrof Time to Evaluation rt-PA Mortality Difference 
(abstr nr) pts therapy after dose rt-PA VS SK IV (95% Cl) 
White (64) 270 <3 hrs 9 months 100mg 6 vs 9% -2% ( -8 to +4%) 
TIMI-1 (33) 316 <7 hrs 1 year 80mg 11 vs 12% -1% (-8 to +6%) 
1 Double chain rt-PA. 
Table VIII. PTCA trials. 
Trial Nrof Therapy 
(abstr nr) pts 
O'Neill 56 Immediate PICA vs SK-IC 
(21) 
Erbel 162 SK-IV + IC with or without PICA 
(17) 
TAMI-l 386 Immediate vs delayed (7 days) PICA 
(32) with rt-PAl 
TIMI-2A 389 Immediate (<2 hrs) vs delayed (18-48 
(52) hrs) PICA with rt-PA2 
European 367 PICA+ rt-PA vs rt-PA 
Cooperative-S 
(44) 
TIMI-2B 3262 PICA (18-48 hrs) 
(35) + rt-PA vs rt-PA only4 
150 mg rt-PA. 
2 100 mg in 83% ofpts, 150 mg in 17%. 
3 Median HBDH-Q72. 
4 520 pts received 150 mg rt-PA, 2742 pts received 100 mg. 
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Outcome measures 
recanalization after therapy: 83 vs 
85%. 
charge in LVEF 8 vs 1% 
Patency after therapy: 90 vs 86% 
in hospital reocclusion 14 vs 20% 
Predischarge LVEF 55 vs 55% 
24 hrs reocclusion 11 vs 13% 
in hospital mortality: 4 vs 1% 
1 wk LVEF 53 vs 56% 
predischarge patency 78 vs 80% 
predischarge LVEF 50 vs 49% 
3 wks mortality 7 vs 6% 
enz. infarct size 694 vs 867 U /P 
2 wks LVEF 51 vs 51% 
2 wks mortality 7 vs 3% 
6 wks LVEF 50 vs 50% 
6 wks mortality 5 vs 5% 
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LIST OF MAIN CLINICAL TRIALS 
ordered by year of publication 
Year Number Acronym or first author Main publication 
1983 1 Anderson JL N Engl J Med 1983;308: 
1312-8 
2 Khaja F N Engl J Med 1983;308: 
1305-11 
3 Rogers WJ Circulation 1983;68:1051-61 
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Intracoronary Streptokinase 
Trial N Engl J Med 1983;309:1477-
82 
1984 5 Aldennan EL Am J Cardiol 1984;54:14-9 
6 LeiboffRH Am J Cardiol 1984;53:404-7 
7 Mount Sinai- New York 
University Reperfusion 
Trial-1 N Engl J Med 1984;311:1457-
63 
8 Sutton JM, Taylor GJ Am J Cardiol 1986;57:1227-
31 
9 Tennant SN Circulation 1984;69:756-60 
10 Van de WerfF NEnglJMed 1984;310:609-13 
1985 11 European Cooperative Study 
for rt-PA in AMI-1 Lancet 1985;965-9 
12 European Cooperative Study 
for rt-PA in AMI-2 Lancet 1985;1:842-7 
13 ICIN Lancet 1985;ii:578-82 
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15 Tendera MP Circulation 1985;71:124-8 
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19 lkram S Brit Med J 1986;293:786-9 
20 ISAM New Engl J Med 1986;314: 
1465-71 
21 O'Neill W New Engl J Med 1986; 
314:812-8 
1987 22 AIMS Lancet 1988;545-9 
23 Bonnier JJRM Am J Cardiol 1988;62:25-30 
24 European Cooperative Study 
for rt-P A in AMI-3 Am J Cardiol 1987;60:231-7 
29 
25 European Multicenter 
Study, Belgian Group Drugs 1987;33 (Suppl.3):287-92 
26 IRS-2 Drugs 1987;33 (Suppl3):140-5 
27 ISIS-2 Lancet 1988;2:349-60 
28 Julian DG Drugs 1987;33 (Suppl.3): 
261-7 
29 KasparL Drugs 1987;33 (Suppl.3): 
179-82 
30 SWIFr Drugs 1987;33 (Suppl.3): 
229-30 
31 T AMI Pilot Study New Engl J Med 1987;1613-8 
32 TAMI-l New Engl J Med 1987; 
317:581-8 
33 TIMI-1 Circulation 1987;76:142-54 
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Study for rt-PA in AMI-5 Lancet 1988;197-203 
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Increased Serum Levels of Fibrinogen Degradation Products Due to 
Treatment With Recombinant Tissue-Type Plasminogen Activator for 
Acute Myocardial Infarction Are Related to Bleeding Complications, 
But Not to Coronary Patency 
ALFRED E. R. ARNOLD, MD,*t RONALD W. BROWER, PHD,t DESIRE COLLEN, MD,:j: 
GERRIT-ANNE VANES, MSc,t JACOBUS LUBSEN, MD,*t PATRICK W. SERRUYS, MD, FACC,t 
MAARTEN L SIMOONS, MD, FACC,t MARC VERSTRAETE, MD,:J: FOR THE EuRoPEAN 
Co-OPERATIVE STUDY GROUP FOR RT-PA 
Rotterdam, The Netherlands and Leuven, Belgium 
The association of increasing serum levels of fibrinogen 
degradation products after recombinant tissue-type plas-
minogen activator (rt-PA) therapy with bleeding and early 
coronary patency was assessed in 242 patients with acute 
myocardial infarction. After administration of 5,000 IV 
heparin, a median of 40 mg (range 35 to 60) of double chain 
rt-PA was given intravenously in 90 min. Bleeding occurred 
in 62 patients; in 73% of patients it was observed within the 
1st 24 h and 84% of events consisted of hematoma or 
prolonged bleeding, or both, at puncture sites. Bleeding 
events occurred 2.12 times as often in patients with serum 
levels of fibrinogen degradation products >85 mg/liter as in 
patients with serum levels <22 mg/liter (95% confidence 
interval 1.01 to 4.43). 
The infarct-related coronary vessel was patent in 65% of 
patients at 90 min after the start of rt-PA infusion. 1n 
patients with high serum levels of fibrin( ogen) degradation 
Recombinant human tissue-type plasminogen activator (rt-
PA) has been shown in the Thrombolysis in Myocardial 
Infarction (TIM! I) trial (!) to be twice as effective as 
intravenous administration of streptokinase to recanalize 
occluded infarct-related coronary arteries in patients with 
acute myocardial infarction and to yield more frequently 
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products, coronary patency at 90 min after the start of 
rt-PA infusion was not better (13% less, 95% confidence 
interval -33%, 13%) than in patients with low serum 
levels. This uncoupling of thrombolytic effect in terms of 
coronary patency and systemic fibrinogenolysis confirms 
the experimentally demonstrated fibrin specificity of double 
chain rt-PA in human subjects. Because fibrin specificity of 
single chain rt-PA is at least similar to that of double chain 
rt-PA, the observations in this analysis most likely hold also 
for single chain rt-PA. 
These findings suggest that a dose of rt-PA just below 
the threshold that causes systemic fibrinogenolysis might be 
optimal in terms of bleeding and coronary patency. Mea-
surements of fibrinogen degradation products during rt-PA 
infusion might help to titrate rt-PA dosing in individual 
patients. 
(JAm Coil Cardio/1989;14:581-8) 
patent coronary arteries 90 min after the start of treatment 
(2). Furthermore, rt-PA preserves left ventricular function 
(3,4) and reduces both enzymatic infarct size and mortality 
after myocardial infarction (3,5). 
It is a fibrin-specific thrombolytic agent: plasminogen is 
converted to plasmin primarily at the site of the thrombus. 
However, at high dosages used for treatment of acute 
myocardial infarction, this fibrin specificity is partly lost and 
fibrinogen breakdown in the circulation occurs in part of the 
patients (2,6). In patients treated with intracoronary strep-
tokinase or urokinase, increasing systemic fibrinogenolysis 
is associated with more frequent recanalization (7,8). It is 
unknown whether this sequence is similar for patients 
treated with rt-PA. Furthermore, it is unknown to which 
degree fibrinogen degradation products developing after 
0735-1097/89/$3.50 
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administration of rt-PA contribute to the occurrence of 
bleeding complications. 
In this analysis, the association of increasing serum levels 
of fibrinogen degradation products with bleeding and early 
coronary patency after rt-PA therapy in 242 patients with 
acute myocardial infarction is assessed. The influence of 
other known determinants of bleeding or coronary patency 
on this association (confounding) is eliminated by multivari-
ate logistic regression analysis. 
Methods 
Patients and management. The present investigation is 
based on data from patients treated with rt-PA in the first 
three trials of the European Co-operative Study Group for 
rt-PA (2,9,10) in which the protocols and methods for data 
collection were similar. All protocols were approved by 
institutional committees on human research and for all three 
trials only patients who gave informed consent were eligible 
for participation. The first trial (9) was a double-blind and 
randomized comparison of coronary patency after rt-PA 
(0. 75 mg rt-P A/kg body weight intravenously over 90 min) 
with coronary patency after placebo in 129 patients from six 
centers. In the second trial (2), coronary patency after 0.75 
mg rt-P A/kg body weight given intravenously over 90 min 
was compared with coronary patency after 1.5 million IU 
streptokinase given intravenously over 60 min in 129 patients 
from seven centers. In the third trial (10), coronary patency 
and the influence of a second infusion of 30 mg rt-PA over 
6 h on subsequent reocclusion at 6 to 24 h was assessed in 
123 patients from 11 centers treated with 40 mg rt-PA over90 
min. 
Patients between 21 and 70 years of age with 2:30 min of 
chest pain and ST segment elevation of 2:0.3 m V in two or 
more electrocardiographic (ECG) precordial leads or 2:0.2 
m V in two or more limb leads were eligible for inclusion, 
provided that rt-PA infusion could be started within 6 h from 
onset of symptoms in the first two trials and within 4 h in the 
third trial. In the first two trials, patients with a previous 
infarction were excluded, whereas a previous myocardial 
infarction in another territory did not disqualify the patient 
for the third study. Otherwise, exclusion criteria were iden-
tical. 
All consenting patients were immediately registered at an 
independent telephone service and received treatment allo-
cation from that service. After blood sampling for coagula-
tion assays, an intravenous bolus of 5,000 IU heparin was 
given. Thereafter, an intravenous infusion of rt-PA was 
given over 90 min. The same batch of primarily double chain 
rt-PA was used in all three studies (G-11021, manufactured 
by Genentech Inc. and supplied by Boehringer Ingelheim 
International GmbH). 
Coronary angiography. The first coronary angiogram of 
the infarct-related vessel was performed between 75 and 90 
min after the start of rt-PA infusion. In the patients of the 
third study, coronary angiography was repeated at 6 to 24 h. 
All coronary angiograms were centrally assessed by teams of 
three assessors, of whom two were always present to 
maintain consistency. The infarct-related segment was iden-
tified on the basis of ECG and angiographic evidence. 
Patency was defined as complete distal filling of the infarct-
related coronary artery, not through collateral vessels, 
within three cardiac cycles at the first adequate contrast 
injection. 
Bleeding events. The protocol required a detailed descrip-
tion of all bleeding complications at the end of the rt-PA 
infusion, after the first coronary angiogram and at discharge, 
including hematoma >5 em in diameter and prolonged 
bleeding of > 30 min duration. 
Hemostasis variables. Blood samples were collected be-
fore and at 60 and 90 min after the start of rt-PA infusion. 
Tubes for blood collection were provided containing 0.5 ml 
sodium citrate (final concentration 0.01 moVliter) and apro-
tinin to counteract proteolysis by in vitro plasmin formation 
(final concentration 150 KIU /ml) for the determination of 
levels of fibrinogen, fibrinogen degradation products and 
activated partial thromboplastin time. Blood samples were 
centrifuged within 1 h and stored at - 20'C. All hemostasis 
tests were performed centrally in the Central Coagulation 
Laboratory (Leuven). Methods of assessment have been 
described previously (11). The normal value for the plasma 
level of fibrinogen is 2 to 4 g/liter and for serum level of 
fibrin(ogen) degradation products is <8 mg/liter. 
Data analysis. Of the 251 patients allocated to rt-PA in 
the three European trials, 9 were excluded from this analy-
sis: 2 did not receive the full dose of rt-PA, 6 had unassess-
able 90 min angiograms, and 1 had bleeding that was 
noticed during rt-PA infusion and therefore could not be 
related to the serum level of fibrinogen degradation products 
after rt-PA administration. The remaining 242 patients re-
ceived the full dose of rt-PA and had assessable 90 min 
angiograms. 
Because the exact start of bleeding complications is often 
difficult to assess, all bleeding events throughout the hospital 
phase were included in this analysis. Bleeding rate was 
defined as the percent of patients with at least one bleeding 
event. When more than one bleeding event was reported for 
a patient, the time of the first noticed event was used. 
Patency rate was defined as the percent of patients with a 
patent infarct-related artery on the angiogram at the end of 
the 90 min rt-PA infusion. 
Patients were grouped in three equally sized subgroups 
according to the serum level of fibrinogen degradation prod-
ucts after rt-P A infusion. The chosen levels of fibrin( ogen) 
degradation products of 22 and 85 mg/liter are therefore 
arbitrary. Three groups were selected to enable assessment 
of trends in bleeding and coronary patency and because 
more groups would weaken strength of associations. Subse-
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Table I. Effect of rt-PA Infusion on Hemostasis Variables in 242 Patients 
1st Trial 2nd Trial 3rd Trial Total 
(n ~ 61) (n ~ 62) (n ~ 119) (n ~ 242)' 
rt-PA dosage (mgl 60 (40,60) 55 (35,60) 40 (40,401 40 (35,601 
Fibrinogen (g/literl 
Before infusion 2.7 (2.3 to 3.51 2.4 (2.0 to 2.81 2.6 (2.3 to 2.9) 2.6 (2.2 to 2.91 
At 60 min 2.0 (1.7 to 2.5) 1.8 (1.3 to 2.2) 2.3 (1.9 to 2.7) 2.1 (1.7 to 2.6) 
At 90 min 1.4 (0.9 to 2.31 1.3 (0.9 to 1.7) 1.8 ( 1.2 to 2.2) 1.5 (1.0 to 2.2) 
Fibrin(ogenl degradation products (mg/liter) 
Before infusion 5 (5 to 71 6 (5 to 121 3 (2 to 31 5 (3 to 5) 
At 60 min 15 (8 to 34) 20 (12 to 351 14 (9 to 27) 17 (9 to 31) 
At 90 min 38 (14 to 1551 40 (20 to 120) 36 (15 to 901 38(17to 1101 
Activated partial thromboplastin time {s) 
Before infusion 60 (51 to 751 61 (50 to 73) 58 (51 to 861 60 (51 to 751 
At 60 min 102 (81 to 1411 99 (73 to 1521 158 (105 to 1801 125 (85 to 1801 
At 90 min 112 (72 to 1651 126 (96 to 1801 180 (145 to 180) 163 (98 to 1801 
*For fibrinogen and iibrin(ogen) degradation products, the number of patients with assessable blood samples 
before infusion, at 60 min and at 90 min, respectively, was 198.212 and 210; for activated partial thromboplastin time, 
199, 212, 208. Continuous variables are given as median with the 1st and 3rd quartile in parentheses. rt-PA = 
recombinant tissue-type plasminogen activator. 
quently, bleeding and patency rates were determined in each 
subgroup. The subgroup with low serum levels of fibrin-
( ogen) degradation products was chosen as the reference 
group. The second and third subgroups were compared with 
the reference group with use of rate ratios (that is, the rate in 
the second or third group divided by the rate in reference 
group); 95% confidence intervals for rate ratios were deter-
mined according to the method of Katz et al. (12). 
Distortion in the relation between serum levels of fibrin or 
fibrinogen degradation products and bleeding or patency 
(confounding) caused by unequal distributions of other 
known determinants of bleeding or patency among these 
subgroups was simultaneously eliminated by multivariate 
logistic regression analysis. The following determinants of 
bleeding were considered: I) trial in which the patient 
participated, 2) age, 3) gender, 4) pulmonary rales before 
allocation, 5) thrombocyte count before rt-PA infusion, 6) 
fibrinogen after rt-PA, 7) activated partial thromboplastin 
time after rt-PA, reflecting mainly the degree of hepariniza-
tion, 8) streptokinase given after rt-PA, and 9) second 
infusion of rt-PA in the third trial (10). Similarly, for coro-
nary patency, the determinants considered were: I) trial in 
which the patient participated, 2) age, 3) gender, 4) use of 
intravenous nitrates, which has been reported to be benefi-
cial for coronary patency in the setting of thrombolytic 
therapy (13,14), and 5) activated partial thromboplastin time, 
prolonged mainly by heparinization, which possibly im-
proves thrombolytic efficacy (15,16). A detailed description 
of the design of the multivariate logistic regression models 
and methodology to obtain adjusted rate ratios and 95% 
confidence intervals is given in the Appendix. 
Results 
Clinical features. The median age of the 242 patients was 
56 years (range 31 to 70); 223 were male (84%). The median 
delay from the onset of symptoms to the start of rt-PA 
infusion was 2.8 h (range 0.9 to 5.8). A median dose of 40 mg 
(range 35 to 60) of rt-PA was administered over 90 min. Ten 
patients (4.1%) died during the hospital stay, 2 on the lst day 
and 8 after the 4th day_ No death was related to a bleeding 
complication. Cardiogenic shock was the cause of death in 
five patients, thromboembolism in 2, cardiac tamponade in 2 
and electromechanical dissociation during late angiography 
in I. 
Hemostasis variables before, during and after rt-PA (Ta-
ble 1). A moderate decrease in fibrinogen and a moderate 
increase in serum level of fibrin or fibrinogen degradation 
products were observed during rt-PA infusion. Before treat-
ment, I% of the patients (2 of 198 with analyzable blood 
samples) had a fibrinogen level <I g/liter and at 90 min 22% 
(46 of 210 with analyzable blood samples). At 90 min, a 
serum level of fibrin( ogen) degradation products 2:22 mg/ 
liter was found in 67% of the patients (141 of 210 with 
assessable blood samples). The activated partial thrombo-
plastin time was increasingly prolonged during rt-PA infu-
sion, a finding that reflects the heparin administration and to 
a minute extent the formation of fibrin( ogen) degradation 
products. 
In the first two trials, the rt-PA dosage was higher than 
that in the third trial (Table 1). This is reflected in a trend 
toward a lesser decrease in fibrinogen and lower serum 
levels of fibrin( ogen) degradation products at 90 min after 
start of rt-PA infusion in the third trial (10). Nevertheless, 
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Table 2. Survey of the 62 Bleeding Events in All 242 Patients and 
the Time That the Bleeding Was First Noticed 
Within 24 to After 
No. of Patients With 24 h 48 h 48 h Total 
Retroperitoneal bleeding 
Hematemesis 
Hematuria 
Hematuria + gum bleeding 
Gum bleeding 
Hematuria + prolonged bleeding 
Hematoma and/or prolonged bleeding 
Blood transfusion given 6 
No blood transfusion given 33 43 
Unexplained anemia 
Total 45 10 62 
No. of patients with blood lO 
transfusion 
the activated partial thromboplastin time was more pro-
longed than that in the other trials, probably by more rigid 
heparinization in the third trial. 
Bleeding events (Table 2). In seven patients, two bleeding 
events were reported; the bleeding rate was 26% (62 of 242 
patients). Most bleeding complications occurred within the 
1st 24 h (73%) and consisted of hematoma or prolonged 
bleeding, or both, at a puncture site (84%). Two patients had 
hematemesis; one was treated with cimetidine, the other did 
not receive special therapy. Retroperitoneal bleeding was 
suspected in another patient with epigastric pain and de-
crease in hemoglobin from 14.7 to 10.2 g/dl; no special 
treatment was given and the patient was discharged on the 
Table 3. Increasing Serum Levels of Fibrin(ogen) Degradation 
Products (mg/liter at 90 min) in Relation to Bleeding and Coronary 
Patency Rate 
Fibrin(ogen) Degradation 
Products at 90 min Crude Rate Adjusted Rate 
(mg/liter) Ratio Ratio 
Bleeding Rate 
<22 16% (ll/69) Reference Reference 
22 to 85 29% (20/69) 1.82 (0.94 to 3.50) 1.40 (0.73 to 2.651 
;;,85 38% (27/72) 2.35 (1.27 to 4.37) 2.12 (1.01 to 4.431 
Missing 13% (4/32) 0.78 (0.27 to 2.28) 0.83 (0.27 to 2.551 
Patency Rate 
<22 70% (48/69) Reference Reference 
22 to 85 58% (40/69) 0.83 (0.65 to 1.081 0.75 (0.57 to 0.991 
;;,85 64% (46/72) 0.92 (0.73 to 1.16) 0.87 (0.67 to I. 131 
Missing 75% (24/32) 1.08 (0.84 to 1.39) 1.13 (0.82 to !.56) 
Crude and adjusted rate ratio, respectively. before and after elimination of 
distortion of the relation between serum levels of fibrin(ogen} degradation 
products and bleeding or coronary patency caused by unequal distribution of 
other determirtants of bleeding or coronary patency over the various catego-
ries of serum levels of fibtin(ogen) degradation product (see Methods): 95% 
confidence intervals are presented in parentheses. 
lith day. No intracranial bleeding occurred. Blood transfu-
sion was given to I 0 (16%) of 62 patients with a bleeding 
event: for hematoma in 7 patients, a combination of he-
matoma and prolonged bleeding in 2 and unexplained anemia 
in I patient. No patient classified as a nonbleeder received 
blood transfusion. 
Fibrinogen degradation products and bleeding (Table 3). 
The bleeding rate was higher among patients with higher 
serum levels of fibrin(ogen) degradation products. Patients 
with a serum level of >85 mg/liter had a bleeding complica-
tion approximately twice as often as did those with a serum 
level <22 mg/liter. This relation was maintained after adjust-
ment by multivariate logistic regression analysis. The varia-
bles that were used for this adjustment are listed in the 
Appendix. The other variables mentioned in the Methods 
section did not influence the relation between serum levels of 
fibrin( ogen) degradation products and bleeding. Figure I 
depicts the relation between serum levels of fibrinogen 
degradation products and bleeding, adjusted for the varia-
bles listed in the Appendix, together with its 95% confidence 
range. 
Coronary patency. At 90 min after the start of rt-PA 
infusion, the infarct-related vessel was found patent in 159 of 
the 242 patients (patency rate 65%, 95% confidence interval 
59 to 71). The patency rate was similar in the three trials: 
61% (95% confidence interval48 to 73) in the first trial, 69% 
(95% confidence interval 56 to 80) in the second trial and 66% 
(95% confidence interval 56 to 74) in the third trial. 
Fibrin or fibrinogen degradation prodncts and patency 
(Table 3). A trend of decreasing coronary patency was 
observed with increasing serum levels of fibrinogen degra-
dation products before and after correction by logistic anal-
ysis. The variables used in the logistic regression model are 
given in the Appendix. The other determinants of coronary 
patency mentioned in the Methods section did not distort the 
relation between fibrin(ogen) degradation products and cor-
onary patency. Figure 2 illustrates the absence of higher 
patency rates with increasing serum levels of fibrinogen 
degradation products. 
Discussion 
Recombinant tissue-type plasminogen activator (rt-PA) is 
an effective thrombolytic agent with limited systemic fibrino-
genolysis in the vast majority of patients, when compared 
with intravenous streptokinase. However, bleeding has re-
mained a frequent side effect in the clinical trials so far 
(I ,2,3,6). This analysis reveals that increasing serum levels 
of fibrinogen degradation products are related to more 
frequent bleeding complications, but not to greater coronary 
patency at 90 min after the start of rt-PA infusion. 
Fibrinogen degradation products and bleeding. The rela-
tion between fibrin( ogen) degradation products and bleeding 
might be explained by the fact that fibrinogen degradation 
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Figure 1. Bleeding rate as a function of increasing serum levels of 
fibrin(ogen) degradation products (as continuous variable, logarith-
mic scale) at 90 min after start of rt-PA infusion. Confounding by 
other determinants of bleeding was eliminated by multiple logistic 
regression analysis. The dotted lines represent 95% confidence 
limits. rt-PA ~ recombinant tissue-type plasminogen activator. 
products act as antithrombins, fragment Y being the most 
active (18). There is evidence that fibrinogen degradation 
after rt-PA results in relatively large amounts of early 
degradation products belonging to the fragment X and Y 
groups (11). In addition, fibrinogen degradation products 
inhibit fibrin polymerization, resulting in a defective fibrin 
structure, and impair platelet function (18). Also, the TIMI 
study group reported a relation between serum levels of 
fibrinogen degradation products and bleeding after adminis-
tration of double and single chain rt-PA (6). However, in that 
report no adjustment for confounding variables was made by 
multivariate regression analysis. 
The adjusted rate ratios of 1.40 and 2.12 for bleeding at 
increasing levels of fibrinogen degradation products are 
probably an underestimation of the strength of the relation 
Figure 2. Coronary patency rate as a function of increasing serum 
levels of fibrinogen degradation products (as continuous variable, 
logarithmic scale) at 90 min after infusion ofrt-PA. Confounding by 
other determinants of coronary patency was eliminated by multiple 
logistic regression analysis. The dotted lines represent 95% confi-
dence limits. rt-PA ~ recombinant tissue-type plasminogen 
activator. 
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because they are conditional on the prolongation of activated 
partial thromboplastin time, which is partly caused by fibrin-
ogen degradation products. 
Fibrinogen degradation products and patency. Increasing 
serum levels of fibrin( ogen) degradation products were not 
related to better coronary patency at 90 min, but tended to 
be inversely related to coronary patency. The TIMI study 
group (19) also reported an inverse relation between sys-
temic fibrinogenolysis and recanaliza~ion at 90 min for 
double chain rt-PA; patients with recanalization had 31% 
decline in fibrinogen versus 41% in those patients without 
recanalization (95% confidence interval for this 10% differ-
ence: 8% to 12%). The possibility of an inverse relation is 
worth further investigation, both in vitro and in animal and 
clinical studies. An explanation could be that systemic 
fibrinogenolysis counteracts the fibrinolytic efficacy ofrt-PA 
through negative feedback (inactivation of t-PA by fibrin-
ogen degradation products?). 
In patients treated with streptokinase or urokinase, reca-
nalization occurs more frequently with increasing serum 
levels of fibrinogen degradation products (7,8). This finding 
is in agreement with the fact that streptokinase and uroki-
nase are not fibrin specific and result in conversion of 
plasminogen to plasmin in the free circulation, producing 
breakdown of fibrinogen and clotting factors V and VIII (18). 
It could be argued that prolongation of activated partial 
thromplastin time might not be a determinant of coronary 
patency, because the Thrombolysis and Angioplasty in Myo-
cardial Infarction (TAM!) study group (20) recently reported 
that patients given heparin concomitant with rt-PA did not 
have a higher coronary patency rate than did patients given 
rt-PA alone. Also, it has been suggested (21) that heparin 
might reduce plasmin formation by t-PA at the site of the 
thrombus. Therefore, the multivariate logistic regression 
analysis in this analysis was repeated without activated 
partial thromboplastin time. The same trend was found for 
the relation between serum levels of fibrinogen degradation 
products and coronary patency, although less pronounced 
(rate ratio and 95% confidence interval for serum level of 
fibrinogen degradation products from 22 to 85 mg/liter, 0.82; 
0.63 to 1.06; for serum level of fibrinogen degradation 
products 2:85 mg/liter, 0.92, 0.72 to 1.18). 
Limitations of the analysis. The test developed by Mers-
key that we used in these studies does not differentiate 
between fibrin degradation and fibrinogen degradation prod-
ucts. However, this lack does not invalidate our analysis 
because the degradation products after thrombolysis with 
rt-PA for acute myocardial infarction consist primarily of 
fibrinogen degradation products (22). Similarly, in pulmo-
nary embolism where fibrin mass is much larger than that in 
coronary thrombosis, predominantly fibrinogen degradation 
products were found (23). Therefore, in the present analysis 
the degradation products observed most likely reflect fibrin-
ogen degradation and not fibrin degradation. 
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Another concern could be that in vitro degradation of 
fibrinogen might have occurred between blood collection 
and deep-freezing, which is not completely eliminated by 
aprotinin. If indeed fibrinogen degradation products in the 
present analysis originated mainly from in vitro degradation, 
the serum level of such products reflects lytic activity in 
serum rather than in vivo fibrinogen breakdown. Greater 
lytic activity in serum would then be associated with in-
creased bleeding rate, but not with higher coronary patency. 
One should be cautious in extrapolating the relation 
between fibrinogen degradation products and bleeding 
events that was observed in the present analysis to other 
forms of bleeding (e.g., intracranial bleeding). In this inves-
tigation, the incidence of serious bleeding events was too 
low to allow separate analyses of various types of bleeding. 
Finally, it should be appreciated that in all patients in these 
trials acute angiography was performed to assess coronary 
patency. One would expect less frequent bleeding if acute 
catheterization is not performed. However, in patients 
treated with rt-PA without acute angiography, similar inci-
dence rates ranging from 23% to 29% and similar types of 
bleeding have been reported (3,24). 
Implications of the present analysis. Increasing serum 
levels or fibrinogen degradation products were related to 
more frequent bleeding, but not to better coronary patency. 
The observation that thrombolytic effect and systemic fibrin-
ogenolysis were completely uncoupled confirms the fibrin 
specificity of double chain rt-PA in patients. These findings 
probably hold also for single chain rt-PA because fibrin 
specificity of single chain rt-PA is at least similar to fibrin 
specificity of double chain rt-PA. Although single chain 
rt-PA needs to be administered at higher doses than does 
double chain rt-PA. because of its shorter plasma half-life, it 
resulted in less fibrinogen breakdown at equipotent doses in 
terms of coronary recanalization (6). 
These considerations suggest that there may be an opti-
mal dose of rt-PA for every individual with maximal throm-
bolytic effect and without fibrinogen breakdown, whereas at 
higher doses, systemic fibrinogenolysis is induced with an 
increased risk for bleeding but without better thrombolytic 
effect. Determination of fibrinogen degradation product lev-
els during rt-PA infusion might help to identify this optimal 
dose for an individual patient. Rapid tests for quantitative or 
semiquantitative determination of levels of fibrinogen degra-
dation products, preferrably in whole blood and specifically 
measuring fibrinogen degradation products, should be devel-
oped. These tests might enable the clinician to titrate the 
rt-PA dosage, in a manner similarly to the titration of insulin 
dosage on the basis of blood sugar levels. This approach, 
which is restricted to fibrin-specific thrombolytic agents, 
might be even more relevant for possible indications as 
pulmonary lung embolism, artificial heart valve thrombosis 
and venous thrombosis, where time is less crucial than that 
in acute myocardial infarction. In addition, prolonged rt-PA 
infusion for prevention of coronary reocclusion after throm-
bolysis for acute myocardial infarction might be individual-
ized in this manner. 
Appendix 
Multivariate logistic regression analysis. Multiple logistic regres-
sion analysis was performed with the BMDP statistical package 
(program LR). The relation between serum levels of fibrinogen 
degradation products and bleeding or patency was expressed in a 
multivariate logistic regression model. A set of reported variables 
that were known to be predictors of bleeding or patency was 
selected. These variables were forced in a model, one at a time, 
together with the various categories of serum levels of fibrin(ogen) 
degradation products. Only those variables affecting the relation 
Table 4. Multivariate Logistic Regression Model for the 
Assessment of the Relation Between Serum Levels of 
Fibrin(ogen) Degradation Products and Bleeding 
Variable (Xi) Bleeding Rate Coefficient (b;) Standard Error 
Fibrinlogen) Degradation Products lmg/liter) at 90 min 
<22 16% (ll/69) Reference 
22 to 85 29% 120/69) 0.47 0.46 
;;,85 38% 127(/2) 1.10 0.55 
Missing 13% (4/32) -0.25 0.77 
Pulmonary Rales Before Allocation 
No 22% 143/194) Reference 
Yes 40% (19/48) 0.90 0.39 
Thrombocytes Before Infusion (109/liter) 
<220 39% 126/74) 1.13 0.45 
220 to 280 23% (15/7!) 0.31 0.47 
~280 19% (1!17!) Reference 
Missing 39% (10/26) 1.35 0.57 
Fibrinogen at 90 min (g/liter) 
<!.21 31% 122/70) -0.40 0.56 
!.21 to !.91 24% (18/74) -0.35 0.44 
;;,!.91 27% (18/66) Reference 
Missing 13% 14/32) -0.25 0.77 
aPTT at 90 min Is) 
<95 16% (8/49) Reference 
95 to 180 24% (15/63) 0.41 0.52 
2o180 37% (35/96) 0.77 0.49 
Missing 12% 14/34) -0.25 0.77 
Second Infusion of 30 mg rt-PA (3rd trial) 
No 24% 147/200) Reference 
Yes 36% (15/42) 0.54 0.42 
Intercept -2.74 0.61 
aPTT = activated partial thromboplastin time (s); rt-PA = recombinant 
tissue-type plasminogen activator. 
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Table 5. Multivariate Logistic Regression Model for Assessment 
of the Relation Between Serum Levels of Fibrin(ogen) 
Degradation Products and Coronary Patency 
Variable (X;) Patency Rate Coefficient (b1) Standard Error 
Fibrin(ogen) Degradation Products {mg/liter) at 90 min 
<22 70% (48/69) Reference 
22 to 85 58% (40/69) -0.76 0.38 
2o85 64% (46/72) -0.39 0.37 
Missing 75% (24/32) 0.39 0.54 
Nitroglycerin iv 
No 62% (106/170) Reference 
Yes 72% (52/72) 0.58 0.32 
aPTT at 90 min (s) 
<95 59% (29/49) Reference 
95 to !80 56% (35/63) -0.24 0.39 
2ol80 71% (68/96) 0.62 0.38 
Missing 77% (26/34) 0.39 0.54 
Intercept 0.59 0.35 
iv = intravenous: other abbreviations as in Table 4. 
between the various categories of these serum levels and bleeding or 
patency were combined in a final model. Adjusted rate ratios and 
95% confidence intervals for the various categories of serum levels 
of fibrinogen degradation products were obtained according to the 
method of Miettinen (17) by the following formula, in which the 
mean was entered for all variables (X;) other than the category of 
serum levels of fibrinogen degradation products for which the 
adjusted rate ratio was determined; one for the category of serum 
level of fibrinogen degradation products under study (variable X) in 
the numerator and 0 in the denominator: 
Rate ratio = [I+exp(-(intercept+ 2-;b;X;+bi*l)Jr 1 
[I +exp(-(intercept+ 2-;b;X;+b;*O)Jr 1 
95% confidence interval: rate ratio0 ·1.96fchi-O>, rate ratio0 +1.961chHn; 
where chi-0 is the ratio of the fitted coefficient for the category of 
serum level of fibrinogen degradation products of which the confi-
dence interval has to be determined, to the standard error (SE) of 
this coefficient. Coefficients (b;. b;) and standard errors for all 
variables in the final model are listed in Tables 4 and 5. 
We gratefully acknowledge the methodological advice of Jan G. P. Tijssen, 
PhD of the Clinical Epidemiology Unit of the Thoraxcenter and Patrick 
Bossuyt, MSC of the Center for Clinical Decision Analysis of the Erasmus 
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Intravenous tissue pla~minogen activator and size of infarct, left 
ventricular function, and survival in acute myocardial infarction 
Frans Van de Werf, Alfred E R Arnold 
For the European Cooperative Study Group for recombinant tissue type plasminogen activator 
Abstract 
Study objective-To assess effect of intravenous 
recombinant tissue type plasminogen activator on 
size of infarct, left ventricular function, and survival 
in acute myocardial infarction. 
Design-Double blind, randomised, placebo con-
trolled prospective trial of patients with acute myo~ 
cardia! infarction within five hours after onset of 
symptoms. 
Setting-Twenty six referral centres participating 
in European cooperative study for recombinant 
tissue type plasminogen activator. 
Patients-Treatment group of 355 patients with 
acute myocardial infarction allocated to receive 
intravenous recombinant plasminogen activator. 
Controls comprised 366 similar patients allocated to 
receive placebo. 
Intervenzion-All patients were given aspirin 
250 mg and bolus injection of 5000 IU heparin 
immediately before start of triaL Patients in treat-
ment group were given 100 mg recombinant tissue 
plasminogen activator over three hours (10 mg 
intravenous bolus, 50 mg during one hour, and 40 mg 
during next two hours) by infusion. Controls were 
given placebo by same method. Full anticoagulation 
treatment and aspirin were given to both groups until 
angiography (10-22 days after admission). ~Blockers 
were given at discharge. 
End point-Left ventricular function at 10-22 
days, enzymatic infarct size, clinical course, and 
survival to three month follow up. 
Measurements and main results-Mortality was 
reduced by 51% (95% confidence interval -76 to 1) in 
treated patients at 14 days after start of treatment 
and by 36% ( -63 to 13) at three months. For 
treatment within three hours after myocardial in-
farction mortality was reduced by 82% (-95 to -31) 
at 14 days and by 59% ( -83 to - 2) at three months. 
During 14 days in hospital incidence of cardiac 
complications was lower in treated patients than 
controls ( cardiogenic shock, 2 ·5% v 6·0%; ventricular 
fibrillation, 3·4% v 6·3%; and pericarditis, 6·2% v 
11·0% respectively), but that of angioplasty or artety 
bypass, or both was higher (15·8% v 9-6%) during the 
first three months. Bleeding complications were 
commoner in treated than untreated patients. Most 
were minor, but 1·4% of treated patients had intra-
cranial haemorrhage within three days after start of 
infusion. 
Enzymatic size of infarct, determined by a hy-
droxybutyrate dehydrogenase concentrations, was 
less (20%, 2p=0-0018) in treated patients than in 
controls. Left ventricular ejection fraction was 2-2% 
higher (0·3 to 4·0) and end diastolic and end systolic 
volumes smaller by 6·0 ml ( -0·2 to -11·9) and 5-8 ml 
( -0·9 to -10·6), respectively, in treated patients. 
Conclusion-Recombinant tissue type plasmino-
gen activator with heparin and aspirin reduces size 
of infarct, preserves left ventricular function, and 
redUces complications and death from cardiac causes 
but at increased risk of bleeding complications. 
Introduction 
Intravenous thrombolysis is becoming widely 
accepted as a standard treatment for acute myocardial 
infarction. Nevertheless, the effects on early and late 
survival, site of infarct, and left ventricular function 
are variable and not always consistent. J.t5 Further-
more, in most trials thrombolytic treatment has been 
associated with an increased risk of bleeding. 
Newer thrombolytic agents are being evaluated for 
intravenous use in the acute stage of myocardial 
infarction. 11}-1H Among these, recombinant tissue plas-
minogen activator has a considerably higher specificity 
for fibrin and a greater thrombolytic efficacy than 
streptokinase.17 lR To study the effect of intravenous 
recombinant tissue plasminogen activator on size of 
infarct, left ventricular function, and follow up a large 
prospective, placebo controlled, double blind, multi-
centre trial was launched by the European Co-operative 
Study Group for recombinant tissue plasminogen 
activator in May 1986; the main results are presented 
here. 
Patients and methods 
Patients between 21 and 71 years old who had chest 
pain typical of myocardial ischaemia for ar least 30 
minutes were digible for the trial, provided that 
experimental treatment could be staned within five 
hours after the onset of symptoms. ST segment 
elevation of at least 2 mm (measured 60 milliseconds 
after the J point) in two or more limb leads or leads V5 
. and V6 had to be present or an elevation of3 mm in two 
or more precordial leads. Patients with ST segment 
depression of 2 rom or more in two precordial leads 
together with ST segment elevation of a least 1 mm in 
two limb leads or leads VS and V6, indicating infarction 
of the posterior wall, were also included. 
Exclusion criteria were: oral anticoagulation treat-
ment, recent major trauma, prolonged or traumatic 
heart massage, artificial respiration, transmural myo-
cardial infarction during the preceding two weeks, 
previous myocardial infarction at the same site or 
previous coronary artery bypass surgery, history of 
cerebrovascular accident or gastrointestinal bleeding 
during the previous three months, major hepatic or 
renal disease, known proliferative di<1betic retinopathy, 
bleeding disorders and other diseases with an expected 
survival of less than two years, and expected problems 
with catheterisation of the heart or with follow up. 
Consenting patients were registered with a central 
telephone allocation service. Allocation to receive 
either recombinant tissue plasminogen activator or 
placebo was made double blind during the same 
telephone call by opening a sealed envelope containing 
the treatment number corresponding to a treatment 
package at the clinic. Randomisation was in blocks of 
four patients and was balanced for each of the 26 
participating hospitals (see appendix). 
TREATMENT 
All patients received 250 mg aspirin and a bolus 
injection of 5000 IU heparin immediately before the 
start of the trial treatment. Patients in the treatment 
group were given 10 mg intravenous bolus of pre-
dominantly single chain recombinant tissue plas-
minogen activator (G-11044, Genentech supplied by 
Boehringer Ingelheim International) followed by 50 
mg during one hour and 40 mg during the next two 
hours given with an infusion pump; in the other group 
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(controls) placebo was given in exactly the same way. 
After the start of infusion all patients were treated 
with intravenous heparin 1000 IU/hour and aspirin 
75-125 mg orally every other day until angiography. 
After three days heparin could be replaced by oral anti-
coagulants. Any other treatment was given only if 
clinically indicated. At discharge patients were given a 
~blocker, unless this was contraindicated. 
LABORATORY ANALYSES 
Samples of blood for assessment of the activities of 
cardiac enzymes locally and of plasma u. hydroxy-
butyrate dehydrogenase centrally were collected before 
the stan of the trial treatment and after 12, 24, 36, 48, 
72, and 96 hours. Cumulative release of plasma a 
hydroxybutyrate dehydrogenase was calculated in the 
core ln. bora tory for enzyme determinations as described 
before1"~0 and expressed in U/1 of plasma. The value at 
72 hours was used as an estimate of the size of infarct. 
In patients in whom data was incomplete this value was 
estimated by extrapolation of the data at 48 or 36 hours, 
or from a single value of the activity determined after 
at least 24 hours, or from serum aspartate amino~ 
transferase activity, which was detennined locally. In a 
predetermined subset of patients samples of blood for 
assays of coagulation and fibrinolysis were obtained 
before the start of infusion and at two and 24 hours 
afterwards. The concentrations of fibrinogen and 
fibrin(ogen) degradation products were estimated 
centrally. 1 ~ 
CARDIAC CATHETERISATION 
Coronary arteriography and left ventriculography 
were done 10-22 days after the acute event with either 
the Sones or the Judkins technique and recorded on 35 
mm xray film. Each hospital chose a time interval of 4 
days in which angiography had to be performed, at I 0-
14, 12-16, 14-18, 16-20, or 18-22 days after the 
allocation of patients. All films were examined centrally 
by the angiography assessment group, which identified 
the infarcted vessel with the help of the electro-
cardiogram, assessed its patency according to the 
thrombolysis in myocardial infarction study, 17 and 
confirmed that the technical quality of the left ven-
tricular angiograms was adequate for quantitative 
measurements. Left ventricular end systolic and end 
diastolic volumes and ejection fraction were measured 
by the central core laboratory from the 30o right 
anterior oblique projection of the angiogram by the 
area-length method. Internal calibration was provided 
by a cast of known volume filmed at the time of the 
angiogram. 
STATISTICAL ANALYSES 
Calculation of the size of the trial was based on the 
left ventricular ejection fraction at 10-22 days: to detect 
a relative 5% difference in ejection fraction between the 
two treatment groups with 80% power at a 0·05 level 
of significance 300 patients whose angiograms were 
analysable were needed in each group. Assuming that 
missing and non-analysable angiograms might be 
predicted in 15% of the patients, we calculated that 700 
patients would be needed. 
Collection and analysis of data were performed by an 
autonomous data centre, which was·independent of the 
investigators and the sponsor. All registered patients 
were included in the analysis even if the experimental 
treatment had not been started. All assessments 
were performed without knowledge of the treatment 
allocation. Continuous variables are reported as median 
and 90% range values. When the distribution of a 
variable permitted, the difference between means and 
95% confidence intervals were calculated. !t Results 
for release of myocardial a hydroxy butyrate dehydro-
genase at 72 hours were analysed by the Mann-
Whitney rank sum test. The ratio of proportions (rate 
ratio) and its 95% confidence interval were calculated 
according to Miettinen and N urminen, 22 in addition to 
the X2 test. 
Results 
Between May 1986andNovemberl987, 721 patients 
were randomised in the 26 participating hospitals: 366 
were allocated to receive placebo and 355 to receive 
plasminogen activator. In eight patients the trial 
treatment was not given. Three patients violated the 
protocol: one in each group refused consent after being 
allocated and one control was given streptokinase 
instead of the trial treatment. In five patients the 
trial treatment was not given for clinical reasons: 
normalisation of ST-T changes in two controls and 
cardiac arrest and death, diabetic retinopathy, and a 
severe haematoma due to arterial puncture in three 
patients allocated to receive plasminogen activator. 
The eight patients were included in the analysis 
according to their allocation to treatment. Two patients 
in the placebo group were allocated, although coronary 
artery bypass had been performed previously. Baseline 
characteristics on admission were similar in the two 
groups (table I). 
TABLE I-Baseline characteristics at admission 
Median (range)• age (vcars) 
No(%}men · 
No(%}with: 
History of angina 
History of prcviou~ infan:tinn 
Anterior infarction 
Electrocardiogram missing 
Median (range]•: 
Heart rate (beats/min} 
Systolic blood pressure (mm Hgl 
Diastolic blood pre~sure (mm Hg) 
No(%]with: 
Mild heart failure ( Killip class II) 
Oven heart failure or shock (Ki11ip 
clas\III,IVJ 
Ventricular fibrillation 
Third dL-gree atrioventncu!ar block 
Median (range)* delay frnm onset of 
i.ymptoms to treatment {hours) 
*901'·oRange. 
CLINICAL COURSE 
Placebo 
(n=-366) 
)~ {43-69] 
304(83) 
176(48) 
26(7) 
130(36) 
12(3} 
72 (49-102) 
130(90-170} 
80(60-110) 
78{11} 
17(5) 
12{3) 
11(3) 
H\iH-4·5) 
Recombmant 
p!a~~inogen 
acuvator 
(n='355] 
58(41-69) 
313(88) 
168(471 
27(8) 
145(41) 
13(4} 
72 (50-104) 
130(90-180} 
80(60-109) 
71(20) 
11131 
8{2} 
11(3) 
2·9(1·4-4·6) 
Tables II and III summarise the clinical course 
during the stay in hospital and the three month follow 
up. During the first 14 days after allocation 21 out of 
the 366 controls (5·7%) died. The cause of death was 
cardiogenic shock (12), documented tamponade (six), 
sudden death (two), refractory ventricular fibrillation 
(one). After three months' follow up eight additional 
patients had died. Among the 355 patients allocated to 
receive plasminogen activator 10 (2·8%) died during 
the first two weeks, of whom one developed a third 
degree atrioventricular block and asystole and died 
before the infusion could be started. Another patient 
had intracranial bleeding and died in cardiogenic 
shock a few hours after the interruption of the heparin 
infusion and administration of tranexamic acid and 
plasma. Further causes of death were: cardiogenic 
shock (five patients) and ventricular fibrillation, 
el~ctromechanical dissociation, and asystole (three). 
Eight additional patients died during the three month 
follow up, one of whom died from intracranial bleeding 
12 hours af~er angioplasty and intravenous strepto-
kinase. The reduction in mortality in the patients 
treated with plasminogen activator was 51% (95% 
confidence interval -76 to I) at 14 days and 36% ( -63 
to 13) at three months (figure). In patients in whom the 
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TABLE n-Clinical events during hospital stay in patients allocated to receive placebo or recombinant 
plam:irwgen activator. Figures are numbers (percentages) of patients 
experimental infusion was staned within three hours 
after the onset of symptoms (207 controls and 179 
allocated to receive plasminogen activator) the re-
duction in mortality was 82% ( -95 to - 31) at 14 days 
and 59% ( -83to -2)at three months. 
Recombinant 
plasminogen. 
Placebo activator 
95% 
Rate Confidence 
(n=366) (n=355) ratio interv:~l 
Bleeding complications and stroke 27(7·4) 104(29·3) (2·69to5·9l) 
Documented haemorrhagic stroke 6(1·7) 
Documented non-haemorrhagic stroke I (0·3) 
Non-documented stroke 2(0•6) 
Gastrointestinal b1eeding 4(!-1) 
Retroperitoneal bleeding 1(0·3) 
Macroscopic haematuria 4CHJ 
H:~emoptysis 2(0·6) 
Epistaxis 1(0·3) 
Oropharyngeal bleeding 
Pericardi:~l bleeding 6{1·6) 
Genital bleeding 
Local haematomll 9(2·5) 
Prolonged bleeding 2(0·6) 
Unexplained anaemia 3(0·8) 
Blood transfusion 7(1·9) 
Cllrdiac complications: 
Shock 22(6·0) 
Pulmonary oedema 24(6·6) 
Pericarditis 4{)(11) 
Ventricular fibrill:~tion 23(6·3) 
Third degree atrioventricular block 18(5·0) 
Supraventricular tachyarrhythmia 38(10·4) 
$(o.Uat 14days 
DCllths: 
All patients 21(5•7) 
Pmients trellted <3 hours ufter onset of 
symptoms"' 13(6·3) 
Angiopl:lSty 9(2·5) 
Bypass surgery 1(0·3} 
Angioplasty and bypass surgery I (0•3) 
Reinfarction 15(4·1) 
5(1-4) 
2(0·G) 
16(4-5) 
4(1·1) 
4(1·1) 
7(2•0) 
2(0·6) 
68(19) 
15(4•2) 
13(3·7) 1·92 
9(2·5) 0·37 
22(6·3) 0·95 
22(6·2) 0·57 
12(3·4) 0·54 
ll(3·1) 0·63 
27(7•6) 0·73 
10(2·8) 0·49 
2(1·1) 0·18 
9(2·5) 1·03 
10(2·8) 7·22 
1(0·3) 1·03 
14(3·9) 0·% 
(0·80to4·62) 
(0·17to0·83) 
(0·54to 1·64) 
{0•35 to0·93) 
(0·28to 1·05) 
(0·31 to 1·29) 
(0·4610 1·17) 
(0·24to 1·01) 
(0·05to0·69) 
(0·43to2·50) 
(1·17 to4·09) 
{0·11 to9·86) 
(0·48to 1·94} 
'• ---, _______ ,_ __ _ 
340 337 
90 o'---'="'--=-------'3"'::'------":'3~~ 
Survival to 90 da_vs after allocation to receive recombinant tissut' 
plasminogen acrivator(n=355) or placebo (n=366l 
"'207 Patients allocated to receive plllcebo, 179 patients allocated to receive recombinant plasminogen activator. 
Cardiovascular complications occurred less com-
monly in the treatment group. In particular the 
incidence of shock, ventricular fibrillation, and peri-
carditis was lower in this group than in the controls. 
Angioplasty or coronary artery bypass, or both~ were 
performed in a higher percentage of patients in the 
thrombolysis group during the three month follow 
up. 
On the other hand, complications of bleeding were 
more common with plasminogen activator. Most were 
of little importance. In five patients (1·4%), however, 
intracranial bleeding occurred within three days after 
the infusion of plasminogen activator; one died whereas 
two recovered without neurological deficit. Table IY 
summarises all cases of intracranial events. In one 
patient receiving plasminogen activator (case 6) intra-
cranial haemorrhage and death occurred on the 15th 
day, 12 hours after treatment of reocclusion with 
angioplasty and intravenous streptokinase. Three 
additional strokes occurred, one documented cerebral 
infarct in the treatment group (case 7) and two in 
the placebo group (cases 8 and 9), in which computed 
tomography had not been performed. Gastrointestinal 
bleeding was fairly uncommon in both groups. 
TABLE III-Clinical events during three rrwnth follow up in patients allocated to receive placebo or 
plam:irwgen activators. Figures are cumulative numbers (percentages) of patients 
Recombinant 
plasminogen 95% 
Placebo activator Ra« Confidence 
(n-=366) (n=355)"' ntio interval 
Deaths: 
All patients 29(7·9) 18(5·1) 0·64 (0•37tol•l3) 
Patients trCllted <3 hours lifter onset of 
symptomst 17(8·2) 6(3·4) 0·41 (0·17to0·98) 
Reinfarction 23(6·2) 21 (5·9) 0·94 (0·53to 1·66) 
Angioplasty 16(4·4) 22(6·2) 1·42 (0·77 to 2·64) 
Bypass surgery 17(4•6) 32(9·0) 1·94 (I· II to3·41) 
Angioplasty and bypass surgery 2(0·5) 2(0·6) 1-03 (0·18to5·84) 
t207 Patients allocated to receive placebo, 179 patients allocated to receive recombinant plasminogen activator. 
TABLE rv-Details of clinical course and outcome in cases of cerebrovascular accident during treatment U'ith recombmant p/asminogm acriz'ator 
or placebo 
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C= Age and Time after 
No :illocation 
56M 2Days 
55M 2-3Days 
64M l2Hours 
64M 2Days 
67 M 16Hours 
67F 15Days 
53M 4Dllys 
70M lODays 
65M !?Hours 
"'Hypertension nod diabetes. 
tconfinncd by computed tomography. 
Syndrome and diagnosis Outcome 
Trtatmntt group 
Hemiparesis due to Complete recovery 
subdural bleedingt after operation 
Hemianopsia due to Completerecovel}' 
intracerebral bleedingt 
Diplopia and ataxia due to Partial recovery 
intracerebral bleedingt 
Hemiplegill due to Partial recovery 
intracerebral bleedingt 
Cerebellar syndrome due Reocclusion 23 hours 
to intracerebral b!eedin&t due later,cardiogenic 
to unrecognised syncope and shock, and dCllth 
hClld trauma before allocation 
Probable intracerebrlll bleeding Coma and death 
after streptokinase for 
reocdusion before 
angiography 
Hemiplegia one hour after Partial recovery 
angioplasty due to cerebral 
infarctt 
Controls 
Paresis of left ann after P:11 ,ial recovery 
prolonged hypotension, 
diagnosis uncertain 
Insult and cerebral deterioration Death 
during cardiogenic shock 
F1bnnuE:en (g.'l1 
Risk Before After After 
factors'" treatment :?:hour; 24hours 
3·7 3·) 3-Q 
Hypertension 4·0 4·0 3·9 
Hypertension 
Hypertension, H 2·2 .?·_1 
diabetes 
1·9 1·S Hl 
Hypertension 
45 
46 SIZE OF INFARCT Cumulative release of a hydroxybutyrate dehydro-
genase into plasma up to 72 hours could be determined 
from complete data in 618 patients. In 37 this value was 
extrapolated from data at 48 and 36 hours,..;md in 43 it 
was estimated from a single measurement of plasma a 
hydroxybutyrate dehydrogenase activity. The values 
of aspartate aminotransferase activity were used to 
estimate relt~ase of a hydroxybutyrate dehydrogenase 
up to 72 hours in four patients. Thus for 702 patients a 
value for release of the enzyme at 72 hours could be 
calculated. Median (90% range) values in the controls 
and treated patients were 867 (123-2143) Ulland 697 
(119-1889) Ull respectively. The figures indicate a 
significant reduction in the size of infarct of 20% (2p= 
0·0018) with plasminogen activator. 
ANG~OGRAPHIC FINDINGS 
Angiography could not be performed in 22 patients 
(6%) allocated to receive plasminogen activator and in 
30 (8%) controls, including 10 treated patients and 20 
controls who died before catheterisation. Other reasons 
for not performing the procedure were: cardiovascular 
complications (four in rre:Hment group and two con-
trols), patient refusal (shin treatment group and seven 
controls), non-cardiovascular complications (one in 
treatment group), or organisational and technical 
problems (one in both groups). In 14 patients (4%) 
allocated to receive recombinant tissue plasminogen 
activator and in 17 controls (5%) angiography was 
performed outside the chosen time interval because of 
cardiovascular complications (five patients in treat-
ment group and four controls), non-cardiovascular 
clinical reasons (three patients in treatment group and 
one control), or organisational problems (sbc patients 
in treatment group and 12 controls). 
Table V shows the patency of the affected vessel 
10-22 days after the experimental treatment. A high 
TABLE v-Angiographic findings in patients allocated co receive 
placebo or plasminogen activator I 0-22 days afrer admission 
Patency of affected vessel* 
GradeD 
Gmdel 
Gradel 
Gradc3 
Undetermined 
Mean (SD) ejection fraction(%) 
Mean (SD) left ventncular volumes (ml) 
End diastolic 
End systolic 
Placebo 
(n=366) 
(n=336) 
58(17·3) 
17 (5·1) 
38(11-3) 
221 (65-8) 
2 (0·6) 
(n=288) 
48·5(11·3) 
(n=283) 
124·2(34·6) 
65·6(29·7) 
Recombinant 
plasminogen 
activator 
(n=355) 
(n=333) 
37(11·1) 
19 (5·7) 
28 (8•4) 
247(74·2) 
2 (0•6) 
(n=289) 
50·7(10·9) 
(n=282) 
118·2(35·2) 
59·8(28·1) 
*According to grades of perfusion in the thrombolysis in myocardial 
infarction trial: O==non-perfusion; 1 =penetration with minimal perfusion 
(contrast fulls to opacify entire coronary bed distal to the stenosis for the 
duration of filming); 2=partial perfusion (contrast opacifies the entire 
coronary bed distal to the stenosis; the rate of entry or clearance or both, is, 
however, slower in coronary bed distal to the obstruction than in comparable 
areas not perfused by the affected vessel); 3=completc perfusion (filling and 
clearance of contrast as rapid in coronary bed distal to stenosis as in other 
coronary beds). 
percentage of patent (grades of perfusion 2 and 3 
according to the criteria of the thrombolysis in myo-
cardial infarction trial) coronary arteries was found in 
both groups: 77% in the controls and 83% in the 
thrombolysis group. The vessel could not be identified 
in 26 treated patients and in ll control patients, in 
whom angiography was performed. 
Left ventricular angiograms that were suitable for 
quantitative ana.lysis were obtained in 577 (80%) of 
the recruited patients. The ejection fraction was 
significantly greater by 2·2% (95% confidence interval 
0· 3 to 4·0), in the treated group than the controls 
(50·7% v 48·5%). The end diastolic volume was 6·0 ml 
( -0·2 to -11·9) smaller and the end systolic volume 
5·8 ml ( -0·9 to -10·6) smaller in the thrombolysis 
group than in the control (table V). 
COAGULATION TESTS 
In a· subset of 140 patients allocated to receive 
plasminogen activator the median (90% range) value 
for circulating fibrinogen at the start of infusion was 
2·4(1·5-4·3) gil, after 120minures 1·9 (0·6-3·3) gil, and 
after 24 hours 2 · 2 (0·9-3·5) gil. The corresponding 
values for 143 controls were 2·5 (1·1-4·0) gil, 2·5 
(1·3-3·9) g/1, and 3·1 (1·3-4·6) g/1. Fibrin(ogen) 
degradation products rose from I (1-17) [lg/ml before 
infusion to 16 (2-145) [!g/ml after 120 minutes and to 6 
(1-64) [!g/ml after 24 hours in the treated group and 
from 2 (1-24) [!g/ml to 2 (1-39) [!g/ml after 120 minutes 
and to 2 (1-36) [lglml after 24 hours in the controls. 
Discussion 
In this randomised, double blind, placebo controlled 
trial intravenous administration of recombinant 
plasminogen activator within five hours after the onset 
of symptoms was associated with limitation of the size 
of infarct, preservation ofleft ventricular function, and 
lower morrality. The limitation of the size of infarct 
measured from myocardial release of a hydroxy-
butyrate dehydrogenase was 20%. Smaller infarcts 
were also shown after intravenous2 10 and intracoronary 
streptokinase.23 The limitation of enzymatic infarct 
size in this trial was associated with preserved left 
ventricular function as measured by a higher angie-
graphic ejection fraction of 2·2% and by smaller left 
ventricular end diastolic and end systolic volumes. 
Several studies have reponed a 2·9-6% higher ejection 
fraction after intravenous streptokinase.2•7 Further-
more, a significant improvement in ejection fraction 
has also been shown in patients with a first myocardial 
infarction and in those with anterior infarction in two 
placebo controlled trials of anisoylated plasminogen 
streptokinase activator complex. 10 11 Three placebo 
controlled trials with much smaller numbers of patients 
have shown a 6-7% higher ejection fraction in patients 
treated with intravenous plasminogen activator. The 
exclusion of patients with a previous infarction together 
with the earlier administration of activator (less than 
2Y2 hours) after the onset of symptoms in one trial, 14 
and the possible interaction of reperfusion and angio-
plasty!' and a larger proportion of patients with 
anterior infarction assigned to active treatment15 in 
the other, might explain the greater difference~'in 
ventricular function in these trials. As in two other 
studies with streptokinase"' the end diastolic and 
end systolic volumes were significantly smaller in 
patients allocated to receive plasminogen activator. 
These findings suggest that early reperfusion not only 
improves contractile function but also prevents or at 
least limits expansion of the infarct and cardiac 
dilatation. Limitation of e.xpansion of the infarct and 
cardiac dilatation may be even more important as 
ventricular volumes have a greater predictive value for 
survival after infarction than ejection fraction. 25 
Although this trial was not designed as a study of 
mortality, the administration of plasminogen activator 
was associated with improved short term survival. 
Despite low mortality in the controls mortality was 
reduced in patients treated with plasminogen activator 
from 5·7% to2·8%at 14daysandfrom 7·9% to 5·1% at 
three month follow up. In patients treated within three 
hours after the onset of symptoms mortality decreased 
from 6-3% to 1·1% at 14 days and from 8·2% to 3·4% 
after three months. Mortality after treatment with 
plasminogen activator in this trial is close to that 
recently reported by us for patients similarly selected 
and treated"h and is the lowest reported so far in large 
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thrombolysis trials. Mortality in the controls was low 
when compared with other studies of thrombolytic 
treatment (13·0% at 21 days in the Gruppo Italiano per 
lo Studio della Streptochinasi nell' Infarto Miocardico 
triaP, 12·0% at five weeks in the second international 
study of infarct survival," and 12·2o/; at 30 days in the 
anistreptase intervention mortality study9). This is 
unlikely to have been caused by selection of low risk 
patients as the electrocardiographic entry criteria were 
more stringent than in the other studies1" and patients 
with cardiogenic shock were not excluded. All patients 
in our study were treated with low dose aspirin and 
heparin, which may have contributed to the low 
mortality in the controls. a The reduction in mortality 
despite the low monality in the controls supports the 
efficacy of treaunem with plasminogen activator. 
In addition to reduced mortality, the incidence of 
cardiovascular complications such as shock, ventricular 
fibrillation, and pericarditis was considerably lower 
in the treated patients. The reduced cardiovascular 
morbidity and mortality in conjunction with the 
reduction in the size of infarct, the smaller cardiac 
volumes, and the preservation of contractile function 
suggest a substantial saving of ischaernic myocardium 
as a result of the early administration of plasminogen 
activator. 
Despite a moderate decrease in fibrinogen con-
centration five out of the 355 patients given plasminogen 
activator had an intracranial haemorrhage after the 
infusion (table IV). This incidence of intracranial 
bleeding ofl·4% (95% confidence interval 0· 2 to 2·7) in 
the present study is higher than the 0· 3% incidence 
(one patient out of 367 treated with plasminogen 
activator) reported in a trial by the European Study 
Group."b In this twin study the entry criteria; treatment 
regimens with plasminogen activator, heparin, and 
aspirin; and the registration of events were identical. 
When the data of these two trials are combined the total 
incidence of intracranial bleeding is si.x patients out of 
722 (0·8% (0·2 to 1·5)). Out of 3768 patients treated 
with 80-120 mg single chain recombinant plasminogen 
activator from the same source as ours up to summer 
1987, intracranial bleeding occurred in 0·4% (0· 2% to 
0·6%).27 The number of patients with gastrointestinal 
or other serious bleeding and the number of blood 
transfusions given were small. Whether the con-
comitant administration of heparin and aspirin is 
partly responsible for the bleeding complications in 
patients treated with plasminogen activator is un-
known and will be the subject of a future trial of our 
study group. 
In conclusion, the intravenous infusion of plas-
minogen activator over three hours in addition to 
heparin and aspirin~ within five hours after the onset of 
an acute myocardial infarction, has a beneficial effect 
on the size of infarct, left ventricular function, early 
survival, and cardiovascular morbidity, but at a cost of 
an increased risk of bleeding. 
We thank Dr W Feuerer and the staff of Dr Karl Thomae 
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Summary A randomised trial of 367 patients with 
acute myocardial infarction was performed 
to determine whether an invasive strategy combining 
thrombolysis with recombinant tissue-type plasminogen 
activator (rTP A), heparin, and acetylsalicylic acid, and 
immediate percutaneous transluminal coronary angioplasty 
(PTCA) would be superior to a noninvasive strategy with 
the same medical treatment but without immediate 
angiography and PTCA. Intravenous infusion of 100 mg 
rTP A was started within 5 h after onset of symptoms 
(median 156 min). Angiography was performed 6-165 min 
later in 180 out of 183 patients allocated to the invasive 
strategy; 184 patients were allocated to the non-invasive 
strategy. Immediate PTCA reduced the percentage stenosis 
of the infarct -related segment, but this was offset by a high 
rate of transient (16%) and sustained (7%) reocclusion 
during the procedure and recurrent ischaemia during the 
first 24 h (17%). The clinical course was more favourable 
after non-invasive therapy, with a lower incidence of 
recurrent ischaemia within 24 h (3%), bleeding 
complications, hypotension, and ventricular fibrillation. 
Mortality at 14 days was lower in patients allocated to 
non-invasive treatment (3%) than in the group allocated to 
invasive treatment (7%). No difference between the 
treatment groups was observed in infarct size estimated 
from myocardial release of alpha-hydroxybutyrate 
dehydrogenase or in left ventricular ejection fraction after 
10-22 days. Since immediate PTCA does not provide 
additional benefit there seems to be no need for immediate 
angiography and PTCA in patients with acute myocardial 
infarction treated with rTPA. 
Introduction 
RANDOMISED trials of thrombolytic therapy with 
intracoronary streptokinase' or intravenous streptokinase2 
have demonstrated improved survival as well as limitation of 
infarct size3 and preservation of left ventricular function• in 
patients treated within 4-6 h after onset of symptoms of 
acute myocardial infarction. Several groups have proposed 
immediate percutaneous transluminal coronary angioplasty 
(PTCA) for reperfusion of the ischaemic myocardium in 
addition to5 or without" thrombolytic therapy. Immediate 
PTCA may open vessels that remain occluded despite 
thrombolytic therapy and reduce the residual coronary 
stenosis after thrombolytic therapy. The improved 
bloodflow might further reduce infarct size and preserve left 
ventricular function. 7 Finally, PTCA might reduce the 
incidence of post-infarction angina, reocclusion, and 
reinfarction after thrombolytic therapy.8 ·9 
The European Cooperative Study Group for 
Recombinant Tissue-type Plasminogen Activator (rTPA) 
has conducted a randomised trial to determine whether an 
invasive strategy, combining thrombolysis with rTPA, 
heparin, acetylsalicylic acid, and immediate PTCA, would 
be superior to a non-invasive strategy of treatment with 
intravenous rTPA, heparin, and acetylsalicylic acid alone. 
The end-points were enzymatic infarct size, global left 
ventricular function, and fmdings on clinical follow-up. 
Patient enrolment started in May, 1986. The tri<ll was 
prematurely terminated in June, 1987, on the advice of the 
data monitoring and ethical committee. This report presents 
the main results of the trial. 
Patients and Methods 
Ten hospitals with extensive PTCA experience in six European 
countries participated in the trial. Patients were adrnitted with a 
diagnosis of suspected myocardial infarction, characterised by chest 
pain of at least 30 min duration and typical changes in the 
electrocardiogram: ST-segment elevation of0·3 mV or greater in 
two or more chest leads (V,-V4 ) and/or greater than 0·2 m V in leads 
I, II, III, aVL, aVF, V,, or V6 • In addition, patients were included 
with at least 0·1 mV ST-segrnent elevation in two leads (II, III, 
aVF, V,, V J and at least 0·2 mV ST-segment depression in two 
chest leads V1-V4 • 
Patients younger than 71 years in whom treatment could be 
started within 5 h after the onset of symptoms were included. The 
usual contraindications for thrombolytic therapy were applied.'" In 
addition, patients with a previous myocardial infarction at the same 
site or with previous coronary artery bypass surgery were excluded. 
Patients with heart failur~ or shock were not excluded. 
When informed consent had been obtained, intravenous 
administration of rTPA was started without delay. After a 10 mg 
bolus injection, 50 mg was given in the first hour, followed by 40 mg 
in the next 2 h. Thus, in total 100 mg was administered in 3 h. 
Single-chain rTPA (Genentech Inc, G-ll044) was supplied by 
Boehringer Ingelheim International GmbH. In addition to rTPA, 
250 mg acetylsalicylic acid was given intravenously, plus heparin 
5000 IU followed by a continuous infusion of I 000 IU /h. Patients 
were allocated by telephone to either the non-invasive strategy of 
treatment with intravenous rTP A, acetylsalicylic acid, and heparin 
or to the invasive strategy with the same medical treatment 
combined with immediate PTCA. At first a lower dose of 75-125 
mg acetylsalicylic acid was given as initial' treatment. As the PTCA 
procedure was complicated .by reocclusion in about 5 out of 7 
patients allocated to invasive strategy, the initial dose of 
acetylsalicylic acid was increased to 250 mg. 
The protocol specified that coronary angiography was to be 
performed as soon as the catheterisation laboratory was available. 
Mechanical recanalisation should be attempted if the infarct -related 
segment of the coronary artery appeared occluded. PTCA should 
be attempted in all patients, unless the diameter stenosis of the 
lesion was judged to be less than 60%. Until hospital discharge all 
patients were anticoagulated with heparin, which could be replaced 
by warfarin after 3 days, provided that full anticoagulation was 
maintained. In addition, 75-125 mg acetylsalicylic acid was given 
every other day. Beta-blockers, calcium antagonists, and nitrates 
could be prescribed when indicated but were to be withdrawn the 
night before late angiography. 
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Infarct size was estimated from serial alpha-hydroxybutyrate 
dehydrogenase (HBDH) determinations by the core laboratory for 
enzyme determination.11•12 Blood samples were taken at admission 
and at 12, 24, 36, 48, 72, and 96 h. Enzymatic infarct size was 
estimated by the cumulative quantity of HBDH released by the 
heart per litre plasma in 72 h (Q72). 
Coronary arteriography and ven.triculography were performed 
before hospital discharge. To ensure comparability, each hospital 
chose a time window in which late angiography was scheduled: 
10-14, 12-16, 14-18, 16-20, or 18-22 days after admission. Left 
ventricular ejection fraction was computed by the core laboratory 
for quantitative angiography. In addition to local assessment of the 
coronary angiograms, both acute and late angiograms were centrally 
assessed by members of the angiography assessment group. In 
patients who underwent immediate PTCA, all intracoronary 
manipulations, including further dilatations with a larger size 
balloon in case of reocclusion, were considered to be part of the same 
PTCA procedure until the guiding catheter was withdrawn. 
Further procedures that were performed after withdrawal of the 
guiding catheter are reported as new interventions (re-PTCA). 
Two methods of grading of coronary angiograms were applied--the 
grades of diameter stenosis as previously used by the European 
Cooperative Study Group10 and the TIM! perfusion score:" 
Grades of Srenosis 
5 = 100% diameter stenosis 
4 = 91-99% diameter stenosis, no complete filling within 3 cycles 
3 = 91-99% diameter stenosis, complete filling within 3 cycles 
2 = 50-90% diameter stenosis 
1 =less than 50% diameter stenosis 
O=normal 
Grades of Perfusion 
0 =non-perfusion 
1 = penetration with minimal perfusion (contrast fails to opacify 
entire coronary bed distal to the stenosis for the duration of the 
cine run) 
2 = pa.rtial perfusion (contrast opacities the entire coronary bed 
distal to the stenosis. However, the rate of entry and/or 
clearance is slower in coronary bed distal to the obstruction 
than in comparable areas not perfused by the infarct related 
vessel) 
3 =complete perfusion (filling and clearance of contrast as rapid 
in coronary bed distal to stenosis as in other coronary beds) 
Both the core laboratory for enzyme determination and the core 
laboratory for quantitative angiography were unaware of the 
treatment allocation. 
Results 
367 patients were evaluated. The median number of 
patients per hospital was 34, ranging from 13 to 78 patients. 
184 patients were allocated to non-invasive treatment and 
183 to rTP A followed by immediate angiography and 
PTCA. 1 additional patient had been allocated to non-
invasive therapy but has been excluded from analysis 
because treatment allocation as given by telephone was not 
correctly interpreted by the local investigator and immediate 
ITCA was performed. This patient had an uneventful 
follow-up. Baseline characteristics were similar in the two 
treatment groups, except that the non-invasive group had 1 
patient with severe cardiac failure on admission and the 
invasive group 7 patients, and mild heart failure on 
admission was more frequent in the non-invasive group 
(table I). Imn1ediate angiography was performed in 180 
patients (fig 1 ). Angiography was not performed in 1 patient 
who died from shock, in 1 patient because of withdrawal of 
consent, and in 1 patient for technical reasons. The delay 
between onset of symptoms and rTP A infusion ranged from 
30 to 294 min, median 156 min, and the delay between 
TABLE I-BASELINE CHARACTERISTICS 
No of patients 
Age (yr) 
Male 
History of angina 
Previous infarction 
Anterior infarction 
Heart rate (/min) 
Systolic blood pressure (mrn Hg) 
Diastolic blood pressure (mrn Hg) 
Mild heart failure 
Overt heart failure/shock 
Immediate angiography 
Infarct-related vessel 
Left main stem 
Anterior descending artery 
Left circumflex artery 
Right coronary artery 
Normal coronary arteries 
Non-invasive 
strategy 
I84 
54 (37-67) 
164 (89) 
133 (72) 
12 (7) 
82 (45) 
76 (52-100) 
130 (100-160) 
80 (~100) 
46 (25) 
1 (1) 
Invasive 
strategy 
183 
58 (38-68) 
161 (88) 
136 (74) 
13 (7) 
83 (45) 
76 (55--100) 
130 (95--160) 
80 (~100) 
36 (20) 
7 (4) 
180 (98) 
1 
80 
28 
69 
2 
Actual number of patients are shown. Continuous variables are presented as 
median and 90% range. Percentages of patients in each treatment group or 
ranges are shown in parentheses. 
180 
0 • 
108 72 
I 
NO PTCA PTCA PTCA 
12 96 72 
0 0 • ? 0 • ? 
12 92 3 57 14 
Fig !-Results of angiography and PTCA in 180 patients allocated to 
invasive treatment who underwent immediate angiography. 
Vessels were classified as patent ( 0 =stenosis grades 0-3) or occluded ( e =stenosis grades 4-5). In 2 patients no angiogram was available after 
attempted PTCA. 
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infusion and angiography ranged from 6 to 165 min, median 
42min. 
Immediate Angiography 
In patients allocated to invasive therapy, patency ( defmed 
as stenosis grades 0-3) was related to the delay between onset 
of rTP A infusion and angiography as shown in fig 2. 
Complete occlusion (grade 5) was observed in 42 patients 
and subtotal occlusion without complete filling of the distal 
vessel (grade 4) in 30 patients (fig 3a). PTCA was anempted 
in 168 patients. No immediate PTCA was done in 8 patients 
who did not have significant lumen narrowing, in 3 patients 
in whom the anatomy was judged unsuitable for ITCA (1 
. left main equivalent, 1 severe 3-vessel disease, and 1 old 
occlusion in the anterior descending artery with retrograde 
filling by the right coronary artery), and in 1 patient in whom 
the infarct-related vessel could not be identified (fig 1). 
Immediate ITCA in this smdy appeared to be more 
troublesome than elective ITCA. The number of balloon 
inflations ranged from 1 to 15, median 4, with a total 
inflation time between 30 and 885 s, median 180. In 5 
patients the lesion could not be crossed with guidewire or 
balloon. In 32 patients more than one stenosis was dilated. 
At the end of intervention, central angiographic assessment 
revealed an occluded vessel (grades 4 and 5) in 17 patients 
and less than 50% stenosis (grades 0 and 1) of the 
infarct-related segment in 103 patients (fig 3). Before the 
initial acetylsalicylic acid dose was increased to 250 mg 
100 
~ 80 
> 
0 
z 
w 60 1-
< 
0.. 
> a: 40 < 
z 
0 
a: 
0 20 0 
44 0 81 37 14 
0 30 60 GO 120 
INTERVAL (MIN) 
Fig 2---Patency of infarct related vessel {stenosis grades 0-3) in 
relation to interval between start of rTP A infusion and 
angiography. 
The four large dots indicate percentage of patients with a patent vessel 
when angiography was performed within 30, 30-00, 6o-90, and later than 90 
min after start of infusion. A logistic regression model was used to estimate the 
relation between the duration of rTP A infusion and patency. The result of 
this analysis is presented by the closed line, and its 95% confidence intervals 
by the· dotted lines. Estimated patency at 90 min was 89%. In 4 patients the 
exact delay was uncertain. In the four groups patency was 15/44,51/81,25/37, 
and 14/14. 
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Fig 3--Grades of stenosis (a) and perfusion (b) of infarct-related 
vessel before and after PTCA and after 10-22 days in patients 
allocated to invasive (IN) and non-invasive (non-IN) therapy. 
Unknown=patients in whom the infarct-related segment (a) or artery (b) 
could not be identified in the angiogram. The number of patients with 
angiography is given under each bar: numbers next to the bars represent the 
number of patients in that particular subgroup. 
intravenously, transient reocclusion during intervention 
occurred in 4 out of7 patients and permanent reocclusion in 
1. After increasing the acetylsalicylic acid dose, transient 
reocclusion during intervention occurred in 22 and per-
manent reocclusion in 12 patients in whom PTCA was 
attempted. Additional intracoronary streptokinase was 
given in 2 patients with transient reocclusion and in 1 patient 
because of re=rent stenosis. In 2 patients an initially patent 
infarct-related segment was found to be occluded after 
completion of the PTCA procedure. In 1 other patient 
reocclusion occurred during coronary angiography before 
PTCA. Subsequent PTCA was not successful. 
Clinical Course 
The clinical course is summarised in table II. Overall, the 
outcome was more favourable in patients with non-invasive 
therapy. Differences betWeen the treatment groups were 
equally distributed over the participating clinics, and not 
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TABLE II-CLINICAL COURSE AND FOLLOW UP 
Non-invasive Invasive 
strategy strategy 
(n=l84) (n=l83) 
Recurrent ischaemia within 24 h 6 (3) 31 (17) 
Hypotension (less than 90 mm Hg) 17 (9) 57 (31) 
Shock 6 (3) 11 (6) 
Pulmonary oedema 8 (4) 9 (5) 
3rd degree A-V block 7 (4) 11 (6) 
Ventricular fibrillation 6 (3) 21 (11) 
Ventricular tachycardia 51 (28) 54 (30) 
Pericarditis 12 (7) 11 (6) 
Bleeding complications: 43 (23) 75 (41) 
Local haematoma 30 55 
Prolonged bleeding 11 22 
Intracranial bleeding/CV A 1* 1 
Haemoptysis 1 
Epistaxis 1 1 
Gingival bleeding 3 9 
Haematemesis 5 
Melaena 1 
Rectal bleeding 2 
Macroscopic haematuria 4 5 
Retroperitoneal haematoma 1 3 
Haemopericardium 1 2 
Blood transfusion 7 (4) 18 (10) 
Surgical correction at bleeding site (1) 2 (1) 
Status at 14 days 
Mortality 5 (3) 12 (7) 
Recurrent ischaemia after 24 h 21 (11) 23 (13) 
Reinfarcrion 12 (7) 8 (4) 
(re-)PTCA 11 (6) 8 (3) 
CABG 3 (2) 
(re-)PTCA + CABG (1) 
Status at 3-month follow-up: 
Mortality 6 (3) 15 (8) 
Recurrent ischaemia after 24 h 55 (30) 52 (28) 
Reinfarction 18 (10) 12 (7) 
(re-)PTCA 23 (13) 11 (6) 
CABG 7 (4) 9 (5) 
(re-)PCTA + CABG 3 (2) 
Actual number of patients with an event after allocation are presented; 
percentages of patients in each treatment group are shown in parentheses. 
Recurrent ischaemia after 24 h represents patients without reinfarction. 
Numbers given for status at 3-month follow-up are cumulative. *CT scan: no 
bleeding. 
dependent on infarct location at admission. Mortality at 14 
days and at three months was low (3%) in patients allocated 
to non-invasive strategy. 1 patient in this group was 
resuscitated during rTPA infusion (table III). He had 
intraperitoneal bleeding from a liver ha=atoma on day 2 
and died on day 3 after reinfarction and shock. In patients 
allocated to invasive therapy, 14 day mortality was 7%.4 of 
the 7 patients in this gro1,1p admitted with severe heart failure 
or shock died. Two deaths after immediate PTCA were 
associated with bleeding complications, one of them in a 
patient who died from intraperitoneal bleeding, probably 
caused by trauma before hospital admission. 
TABLE III-EARLY AND LATE MORTALITY 
Stenosis 
grades/ Cause of death and 
Sex Age Site IRV intervention Time details of intervention 
Non-im;asive strategy 
M 59 I - - 8h Shock, cardiac arrest 
M 55 I - - 3d Intraperitoneal bleeding after resuscitation, 
reinfarction 
M 58 A - - 3d Shock 
M 59 A LAD - 7d Shock after reinfarction 
PTCA not successful 
M 62 A - - !3d At LV -angie possibly 
dissection aorta, shock 
M 67 A - - 22 d Low output after aneurysmectomy 
broasive strateg)' 
M 64 I RCA 2-PTCA-2 2h Shock after PTCA, VF 
M 58 I* - - 2h Shock, no angiography 
F 64 I RCA 5-PTCA-5 4h Cardiac arrest, VF 
M 62 A LAD 2-PTCA-1 15h Cerebral bleeding 
F 67 I RCA 4-PTCA-1 15 h Intraperitoneal bleeding 
M 61 A* LAD 5-PTCA-1 17 h Mainstem lesion, shock, 
death during CAGB 
M 45 I LCX 3-5 2d Occlusion during angio, 
PTCA attempt failed, shock 
F 69 I RCA 3-PTCA-3 3d Reinfarction 
F 62 I LCX 2 3d No PTCA (3 vessel), asystole 
after delayed PTCA for angina 
M 53 A LAD 5-PTCA-2 3d Reinfarction, shock 
F 66 A* LAD 3-PTCA-2 7d Reocclusion, shock 
M 67 A* LAD 3-PTCA-2 14 d Shock 
M 56 I RCA 3-PTCA-1 47 d Late VF,.coma 
M 60 I RCA 3-3 48 d Failure to cross lesion, 
old anterior MI, sudden death 
M 47 A LAD 3-PTCA-4 66 d Sudden death 
Baseline data, results of angiography and PTCA, when performed, as well as time and cause of death are given. Stenosis grades before and after PTCAas centrally 
assessed are presented. IRV=infarct-related vessel; A=anterior, !=inferior; *=shock at admission; LAD=Ieft anterior descending artery; RCA= right 
coronary artery; LCX =left circumflex artery; VF =ventricular fibrillation; CABG =coronary artery bypass grafting; h =hours after allocation; d =days after 
allocation. 
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Recurrent isc:haemia within 24 h was observed in 17% of 
patients with immediate PTCA and in 3% of patients 
allocated to non-invasive therapy. In the latter group 
exacerbation or recurrence of chest pain was recorded in 1 
patient, chest pain with ST -segment elevation in 4 patients, 
and ST -elevation without chest pain in 1 patient. After 
PTCA these figures were 4, 19, and 8, respectively. 
Episodes of hypotension and ventricular fibrillation were 
more frequent after PTCA. 
Bleeding complications were more prominent after 
immediate PTCA, mostly as a result of arterial puncture and 
the catheterisation procedure. 1 patient in the PTCA group 
underwent surgery for a retroperitoneal haematoma 
after angiography, and 2 patients survived after 
pericardiocentesis for cardiac tamponade. In 1 patient this 
was· related to perforation by a pacemaker electrode, in the 
other there was no apparent trauma. In the group allocated 
to non-invasive treaunent, 1 patient survived after 
pericardiocentesis for cardiac tamponade. The greater 
incidence of bleeding complications after attempted PTCA 
is also apparent from the greater drop in haematocrit in these 
patients (44 SD 4% at admission and 37 SD 5% after 72 h) 
in comparison with those treated non-invasively ( 44 SD 4% 
and 40 SD 5%, respectively), and from the greater need for 
blood transfusions. 
Enzymatic Infarct Size 
Complete blood sample series for determination of 
enzymatic infarct size by the core laboratory were obtained 
in 309 patients (84%). HBDH -Q72 could be estimated from 
series ofHBDH measurements obtained up to 36 or 48 h in 
18 patients, and from a single HBDH plasma level between 
24 and 96 h after onset of symptoms in 25 patients. Local 
determinations of aspartate aminotransferase (ASAT) or 
HBDH could be employed to estimate HBDH-Q72 in 7 
patients. Thus, enzymatic infarct size could be assessed in 
359 patients (98%). In 7 patients HBDH data were not 
available because of early death and in 1 patient because of 
early bypass surgery. Enzymatic infarct size did not differ 
between the non-invasive group (median 665 U /1, 90% 
range 32-2022 U /1) and the invasive group (median 706 U /1, 
90% range 115-1914 U/1). Similar results were obtained 
when only complete sample series from 309 patients were 
used. 
Lare Angiography 
The effect of immediate PTCA on the status of the 
infarct-related segment after 10-22 days is best described by 
the grade of residual stenosis (fig 3a). An occluded vessel 
(grades 4 and 5) was observed in 20 patients without PTCA 
and in 23 patients with immediate PTCA. On the other 
hand, stenoses of less than 50% diameter were observed 
more frequently in patients allocated to invasive therapy 
(n = 106) than in the other group (n = 25). These differences 
were not apparent if the TIMI perfusion score was applied, 
as shown in fig 3b. Complete perfusion (TIMI grade 3) was 
observed in 138 pati<>.nts after non-invasive initial therapy 
and in 130 patients after immediate PTCA. 
Left ventricular angiography was performed in 333 
patients between days 10 and 22. Missing angiograms were 
due to patient death (n = 17), patient refusal (n = 6), 
coronary bypass surgery (n = 3), very poor ventricular 
function (n = 2), ventricular tachycardia (n = 1), and re-
infarction (n = 1 ), and in 4 cases to clinical, non-cardiac 
reasons. Quantitative anaiysis was performed in 291 
angiograms of adequate quality. There were no differences 
in left ventricular ejection fraction between patients 
allocated to non-invasive therapy and those allocated to 
invasive therapy (median 51%, 90% range 29-65%, versus 
median 51%, 90% range 31-66%). 
Discussion 
Contrary to what was expected when the study was 
designed, thrombolytic therapy combined with immediate 
PTCA did not appear to be superior to early non--invasive 
treatment with intravenous rTPA, heparin, and acetyl-
salicylic acid in acute myocardial infarction. Immediate 
PTCA was effective in increasing the number of patients 
with a patent infarct-related vessel and improved perfusion 
as visualised during angiography (fig 3). However, in the 
setting in which it was studied, PTCA was associated with a 
high rate of· early reocclusion and/or early recurrent 
ischaemia. Also, immediate PTCA did not further reduce 
enzymatic infarct size or improve global left ventricular 
function when compared with non-invasive treatment. 
Finally, a complicated clinical course oc=red more 
frequently after PTCA and 3-month mortality was higher 
than after non-invasive therapy. 
The present study was planned to include a total of 400 
patients. However, when the data monitoring and ethical 
committee reviewed the data in June 1987, it became 
apparent that immediate PTCA in this setting was not 
beneficial and might even be detrimental in some cases. At 
that time monality was 6 out of 171 patients allocated to 
non-invasive therapy and 11 out of 173 patients allocated to 
invasive therapy, while cardiovascular and bleeding 
complications were also more frequent in the latter group. 
Enzymatic infarct size had been determined in 165 patients 
and left ventricular ejection fraction in 110 patients. Median 
values in the non-invasive and invasive group were 730 U /1 
versus 911 U /1 for HBD H -Q72 and 53% versus 4 7% for left 
ventricular ejection fraction. Therefore, patient intake was 
terminated by the steering committee as of June 27, 1987. 
In patients allocated to invasive strategy who underwent 
angiography 42 min after the stan of rTPA infusion 
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(median), the infarct-related segment was patent (stenosis 
grades 0-3) in 59%. It should be appreciated that in most 
other studies8 ·10·13·14 patency rates were reported after 90 
minutes' infusion of rTPA. Fig 2 shows that patency is 
achieved gradually during rTPA administration and ranges 
from 34% in patients studied within 30 min to 100% in 
patients studied between 90 and 165 min from the start of 
infusion. Patency at 90 min, estimated by a logistic 
regression model, was 89%. 
Recurrent ischaemia and/or reinfarction within 14 days 
was observed in 15% of patients after non-invasive therapy. 
Similar results were obtained in the TAMI Study, where 
recurrent ischaemia and/or reinfarction was observed in 
17% of patients with a patent vessel without immediate 
PTCA.'4 It should be appreciated that the clinical observa-
tion of recurrent ischaemia or reinfarction does not neces-
sarily coincide with angiographic reocclusion. For example, 
in the T AMI study reocclusion was observed in only 6 out of 
17 patients who underwent angiography for recurrent 
ischaemia. 14 These observations confirm the results from an 
earlier study by the European Cooperative Study Group in 
which reocclusion occurred in 7% of73 patients 6-24 h after 
double-chain rTPAY Thus reocclusion after thrombolysis 
with rTPA occurs less frequently than indicated by earlier 
studies in a small number of patients treated with a relatively 
low dose of double-chain rTP A. 16 
Immediate PTCA in patients with acute myocardial 
infarction was introduced as an extension of intracoronary 
thrombolytic therapy with streptokinase. 5 In selected 
patients, PTCA after intracoronary streptokinase has been 
reported to reduce the risk of reocclusion and mortality. 5 ·6 In 
a randomised trial, Erbel et al'7 compared treatment with 
intracoronary streptokinase with and without immediate 
PTCA in 162 patients. These workers report that PTCA 
reduced the reocclusion rate at 4 weeks from 14 out of 71 
patients with a patent vessel without PTCA (20%) to 10 out 
of 71 patients (14%) after PTCA, while a trend towards 
lower mortality in patients with immediate PTCA was also 
observed.17· 19 Thus, the question arises whether the 
response to angioplasty in patients treated with 
streptokinase differs from that in patients treated with 
rTP A. The higher tendency to reocclude in the latter group 
might be related in part to the "thrombus specificity" of 
rTP A. Remnants of thrombus material, together with the 
endothelial trauma caused by PTCA and subintimal 
bleeding/021 can then be held responsible for the tendency 
to thrombosis in patients treated with rTPA, despite 
concomitant treatment with acetylsalicylic acid and heparin, 
while early rethrombosis after PTCA in patients treated 
with streptokinase may be prevented by the depletion of 
fibrinogen and other coagulation factors due to 
streptokinase. On the other hand, it is possible that 
differences between studies of PTCA in combination with 
streptokinase or rTP A are merely due to patient selection 
and small sample sizes. 
The clinical course in the present study was less 
favourable in patients allocated to immediate PTCA. The 
higher mortality in the invasive group may be due in part to 
the greater number of patients with severe heart failure or 
shock at admission, of whom 4 died, and to the high 
incidence of reocclusion during or after immediate PTCA. 
The latter factor can also explain the higher incidence of 
hypotension and ventricular fibrillation. The higher inci-
dence of bleeding complications was related to arterial 
puncture for angiography and PTCA. The observations in 
the present trial are similar to those reported from the 
T AMI'4 trial which likewise showed a trend towards higher 
mortality without improvement in global or regional 
ejection fraction. It should be noted, however, that the 
design of these two studies was different. In T AMI all 
patients underwent acute angiography and only those with a 
patent vessel, suitable for PTCA, were randomised ( 197 out 
of386 patients). In the present study acute angiography was 
performed only in patients randomised to invasive strategy 
and PTCA was attempted in 92% of these. T AMI 
answered the question wl1ether PTCA would be beneficial 
in a selected subgroup of patients who underwent angiogra-
phy during thrombolytic therapy with intravenous rTPA. 
The European Cooperative Study Group investigated 
whether an invasive strategy, including angiography and 
immediate PTCA, would be superior to non-invasive 
intravenous thrombolytic therapy with rTPA. These 
differences notwithstanding, both studies indicate that 
immediate PTCA after intravenous rTPA in combination 
with acetylsalicylic acid and heparin should be avoided. 
The present study was not designed to demonstrate the 
effect of thrombolysis with intravenous rTPA per se. The 
value of thrombolytic therapy in selected patients with acute 
myocardial infarction has been shown by randomised trials 
with intracoronary and/ or intravenous streptokinase. 14 
Patient selection criteria in the present trial were similar to 
those of the trial conducted by the Interuniversity Cardio-
logy Institute in the Netherlands.' Hospital mortality in 
conventionally treated patients in that study was 10%, and 
6% in patients allocated to intracoronary streptokinase. In 
the present trial 14-day mortality in patients treated 
non-invasively was even lower-3%. Were these fmdings to 
be confirmed by ongoing trials comparing the effect of 
intravenous rTP A and placebo on enzymatic infarct size, 
left ventricular function, and mortality, treatment with 
rTP A should certainly be recommended in selected 
patients. An invasive strategy of treatment with rTPA, 
acetylsalicylic acid, and heparin, in combination with 
immediate angiography and PTCA has no additional 
benefit. Delayed angiography, PTCA, or bypass surgery 
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might be offered to patients with new episodes of myocardial 
ischaemia. 
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CHAPTER 5 
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IN ACUTE MYOCARDIAL INFARCTION MIGHT 
BE BENEFICIAL IF REOCCLUSION AND 
REINFARCTION ARE PREVENTED 
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ABSTRACT 
Regional ventricular wall motion analysis utilizing three different methods was 
performed on pre-discharge left ventriculograms from 291 of 367 patients enroled in a 
randomized trial of single chain recombinant tissue type plasminogen activator (rt-PA), 
aspirin and heparin with and without immediate angioplasty in patients with acute 
myocardial infarction. 
With univariate analysis no difference in parameters of regional wall motion 
between the 2 treatment groups was observed. However, with individual baseline risk 
assessment by multivariate linear regression analysis using baseline characteristics 
known to be related to left ventricular function after thrombolytic therapy and/or 
outcome of coronary angioplasty, an excess of high risk patients in the invasive 
treatment group was detected. To adjust for this unequal distribution of baseline risk, 
multivariate linear regression analysis was performed. No benefit of immediate coronary 
angioplasty was observed after adjustment. 
Reocclusion and/or reinfarction occurred more frequent in the invasive than in 
the non-invasive group (18% versus 13%). Among patients with a patent infarct related 
vessel at 10-22 days angiography and without reinfarction prior to angiography, there 
was a trend towards benefit of the invasive strategy, indicating that reocclusion and 
reinfarction might be responsible for the lack of benefit of the invasive strategy. This 
implies that immediate coronary angioplasty may be beneficial in selected patients, 
provided that these complications can be prevented. 
INTRODUCTION 
In 1988 the European Cooperative Study Group published the results of a trial 
comparing an invasive strategy, combining thrombolysis with recombinant tissue-type 
plasminogen activator (rt-PA), heparin, aspirin and immediate coronary angioplasty, to 
a non-invasive strategy of intravenous rt-PA, heparin and aspirin in patients with acute 
myocardial infarction [1]. Contrary to the expectations when the trial was initiated, the 
invasive treatment strategy did not result in smaller enzymatic infarct size, better global 
left ventricular function, and lower mortality. In fact, complications were more frequent 
and mortality was higher after the invasive strategy [1]. 
Additional analyses were performed to evaluate whether: (1) a true benefit of 
immediate angioplasty was not detected because of an excess of high risk patients in the 
invasive treatment group, despite randomization; (2) a true benefit in one subgroup was 
obscured by an adverse effect in another. This would have important implications if 
these subgroups could be identified on admission or if they would be characterized by 
an untoward effect like reocclusion or reinfarction, which may be prevented by new 
treatment strategies; (3) preservation of function in the infarct territory was missed by 
using global function because of compensatory hyperkinesia of the contralateral wall [2]. 
The results of these investigations are presented in this report. Multivariate 
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analysis was used to adjust for unequal baseline risk and to assess treatment effects in 
subgroups. Regional left ventricular wall motion analysis in the infarct territory was 
performed to evaluate the role of compensatory hyperkinesia of tbe non-infarcted area. 
PATIENTS AND METHODS 
Of 367 patients less than 71 years of age with at least 30 minutes of chest pain 
and electrocardiographic evidence of extensive transmural myocardial ischaemia, 184 
were allocated to non-invasive treatment and 183 to immediate angiography and 
coronary angioplasty, provided that thrombolytic therapy could be started within 5 hours 
after onset of symptoms. Patients with a previous myocardial infarction at the same site 
or with previous coronary artery bypass surgery were excluded, but patients with heart 
failure or shock were not. Further details of patient selection have been published 
elsewhere [1]. 
Left ventricular angiography of adequate quality for analysis was available in 291 
patients (table I). These patients form the study population of the present analysis. 
TABLE I - Reasons for missing 10-22 days regional wall motion. 
10 to 22 days angiography Non-1 Invasive 
N=184 N=183 
not performed due to: 
death 5 12 
cardiac reason 1 3 
non-cardiac reason 1 2 
refused 3 4 
other 1 2 
performed 173 160 
not analyzable due to: 
extrasystole 15 15 
inadequate filling 4 1 
ventricle outside screen 2 1 
other 2 1 
available and analyzable 149 142 
Non-1: non-invasive treatment strategy. 
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Patient management 
After informed consent, patients were treated with 5000 IU heparin bolus 
followed by 1000 IU/hour intravenously, 250 mg aspirin and 100 mg single chain rt-PA 
(alteplase) over 3 hours. Coronary angiography was performed as soon as possible in all 
patients who had been randomized to the invasive strategy. Angioplasty was to be 
attempted, provided that there was a luminal diameter stenosis of 60% or more in the 
infarct related coronary artery. In case of complete occlusion mechanical perforation had 
to be performed. 
Aspirin (7 5-125 mg) was continued on alternate days until hospital discharge. 
Heparin could be replaced by oral anticoagulants after three days, provided that full 
anticoagulation was maintained until cardiac catheterization. 
Electrocardiographic analysis 
Infarct localization was determined from the admission electrocardiogram by the 
Core Laboratory. It was judged anterior if ST-segment elevation was present in leads V1 
-V4 and inferior if ST-segment elevation occurred in leads II, III and aVF. In case of 
ST-segment elevation in leads I, aVL, V5 and V6, infarct localization was deemed 
anterior unless ST -segment elevation was also present in II, III or a VF, or ST -depression 
was present in leads V1 to V4 , in which cases the localization was inferior. ST-segment 
shift was measured at J-point. 
Coronary angiography and ventriculography 
Coronary angiography and left ventriculography were performed 10 to 22 days 
after treatment allocation. In order to enhance comparability between the 2 groups, each 
clinic was required to perform angiography within a preselected time window of 10-14, 
12-16, 14-18, 16-20, or 18-22 days after allocation. Beta-blockers, calcium antagonists 
and nitrates were stopped the night before angiography. All angiograms were assessed 
by members of the Angiography Assessment Group. Perfusion of the infarct related 
vessel was assessed using the TIMI perfusion score [3-5]. 
Left ventriculography was performed with a 0.5-1 ml/kg non-ionic contrast 
injection at a flow of 6-20 ml/sec in the 30 degrees right anterior oblique projection. 
End-systolic and end-diastolic contours were digitized. Left ventricular volumes in right 
anterior oblique projection were calculated according to Simpson's rule after calibration 
with a phantom of known volume filmed after ventriculography, and were indexed for 
body surface area. No corrections for trabeculae and papillary muscles were applied. All 
analyzes were performed at the Core Laboratory for Quantitative Angiography without 
knowledge of treatment allocation. 
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Regional left ventricular wall motion analysis 
Regional wall motion was analyzed according to the "Regional contribution to 
ejection fraction"-method, which assesses wall motion along experimentally determined 
and validated vectors [2,6], and can detect small differences in regional wall motion [2], 
the "Centerline-method" [7-9], which assesses fractional shortening in 100 chords 
perpendicular to a centerline between the end-diastolic and end-systolic contours, and 
the "Radial-axes-method" which assesses fractional shortening in 300 radii from the 
center of mass of the end-diastolic contour [10]. In none of the methods translational or 
rotational corrections were made. A description of each model is given in figure 1. 
The extent of hypokinesia (wall motion in the infarct territory) can be assessed 
by quantitative regional wall motion with all three models. In the "Regional contribution 
to ejection fraction"-method as the number of segments with abnormal regional 
contribution to ejection fraction (below lOth percentile of a population of 31 normal 
individuals) per patient. In the "Centerline-method" as the number of contiguous chords 
of which the shortening fraction differed more than 1 standard deviations from the mean 
shortening fraction in a group of normals (so called circumferential extent of wall 
motion abnormality). In the "Radial-axes-method" as percentage of radii of which the 
shortening fraction differed more than 2 SD from the mean normal shortening fraction 
in a group of normal individuals (so called hypokinetic circumference). 
The severity of hypokinesia was assessed with the "Regional contribution to 
ejection fraction"-method as the mean regional contribution to ejection fraction per 
abnormal segment(%) and was calculated by dividing the sum of regional contributions 
below lOth percentile of normal by the number of abnormal regions [11]. 
In the "Centerline-method" the severity of the hypokinesia was defined as maximally 
abnormally contracting 50% (expressed in standard deviation/chord) and is computed as 
follows. The difference between shortening fraction of each chord and mean shortening 
fraction of the corresponding chord in a group of normals was divided by 1 standard 
deviation of normal for each chord in the hypokinetic area. This difference divided by 
1 standard deviation of normal is called "standardized motion" of a chord. The 
hypokinetic area was defined as a set of contiguous chords, chosen in such way that half 
the number of chords in the infarct territory are included and that the mean "standard-
ized motion" in that set of chords is most abnormal. This mean "standardized motion" 
in the hypokinetic area is called maximally abnormally contracting 50% [7-9]. 
In the "Radial-axes-method" the severity of hypokinesia was given by the 
contribution to the global ejection fraction by the sector of radii with wall motion 
abnormality exceeding 2 SD of normal wall motion (called regional ejection fraction in 
the infarct territory. 
Similarly, the extent and severity of hyperkinesia (wall motion abnormality in 
the contralateral area) were determined with the "Regional contribution to ejection 
fraction"-method as the number of segments with abnormal regional contribution to 
ejection fraction and the mean regional contribution to ejection fraction per abnormal 
segment (% ). Abnormal segments were defined as regional contributions exceeding the 
90th percentile of normal. For the Centerline-method only the severity of hyperkinesia 
was calculated [7] as maximally abnormally contracting 50% (standard deviation/chord). 
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Figure la. "Regional contribution to ejection fraction "-method of regional wall motion 
analysis. A. End-diastolic left ventricular endocardial contour in 30 degree right anterior 
oblique left ventriculogram. The 20 coordinates along which left ventricular wall motion 
occurs are superimposed. B. The volume of each slice in the end-diastolic volume is 
calculated from the radius of the slice (R) and 1/20th of the left ventricular long axis 
length (L): Vi = 1/20 x 1t x Ri2 x L. 
The slices or segments are numbered from 1 to 10 for the anterior wall and from 11 to 
20 for the infero-posterior wall. C. Similarly, the volume of each slice in the 
end-diastolic volume is calculated. The regional contribution to global ejection fraction 
is determined as: 
(end-diastolic - end-systolic) slice volume 
xlOO% 
global end-diastolic volume 
D. An example of a plot of regional contribution to ejection fraction, in which the 
values for regional contribution to ejection fraction (x-axis) for all20 segments (y-axis) 
are given. The shaded zones represent the lOth and 90th percentiles of the regional 
contribution to ejection fraction for each segment in 31 normal individuals. (Reproduced 
from reference 2 with permission of the author and the Journal of the American College 
of Cardiology). 
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Figure lb. "Centerline"-method of regional wall motion analysis. A. End-diastolic and 
end-systolic left ventricular endocardial contours with the computer-constructed 
centerline in between. B. Motion is measured along 100 chords constructed perpendicu-
lar to the centerline. C. Motion at each chord divided by the end-diastolic perimeter 
yields a shortening fraction. Motion along each chord is plotted for the patient. In 
addition, the mean motion ( + 1 standard deviation) in the group of normal individuals 
(for RAO projection 31) is plotted for comparison. D. Standardized motion. The 
difference between the shortening fraction of a chord and the mean shortening fraction 
of that chord number in a group of normal individuals was divided by the standard 
deviation of the mean shortening fraction of that chord number in the group of normal 
individuals. (Reproduced from reference 9 with permission of the author and 
Circulation). 
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Figure lc. "Radial axes"-method. The central axis (0-180 degrees) are determined by 
the center of mass of the end-diastolic contour and the junction of the mitral and aortic 
valve. The percentage radiant shortening of approximately 300 radii is calculated as: 
(end-diastolic radius - end-systolic radius) 
end-diastolic radius 
and plotted together with the mean(+ 2 standard deviations) of a group of 31 normals. 
The sector in which radiant shortening was less than the mean normal radiant shortening 
minus 2 standard deviations is called the hypokinetic region (in this example from 85 
to 233 degrees). 
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Localization of infarct- and non-infarct territories in the "Centerline-method", are 
defined by the angiographically assessed infarct related vessel and the number of 
diseased coronary arteries [7-9]. In the "Regional contribution to ejection fraction"-
method and the "Radial-axes-method" regions of hypokinesia are not defined by 
coronary anatomy, but considered in all segments, except for the latter method if 2 
hypokinetic regions separated by at least 25 radii were found. In that case selection of 
the appropriate region was made on the basis of infarct localization on the qualifying 
electrocardiogram. 
Enzymatic infarct size 
Cumulative release of plasma a-hydroxybutyrate dehydrogenase was determined 
centrally in the core laboratory for enzyme determinations from serial plasma samples 
at 12, 24, 36, 48 and 72 hours after start of treatment onset. Details have been published 
elsewhere [1,12]. 
DATA ANALYSIS 
Baseline risk assessment 
Since more patients in the invasive treatment group did not undergo cardiac 
catheterization because of death or cardiac contraindications than in the non-invasive 
group (see table 1), unequal distribution of high risk patients over the 2 treatment groups 
in the present analysis was likely to influence the measured treatment effect of the 
invasive strategy. Therefore individual baseline risk was assessed. 
Baseline risk assessment consisted of three steps. Firstly, the relation between 
baseline characteristics and the number of segments with regional contribution to 
ejection fraction below the lOth percentile of normal was assessed with multivariate 
linear regression analysis. Only baseline characteristics known to be related to left 
ventricular function [13] and/or outcome of coronary angioplasty [14] were considered: 
(1) age, (2) gender, (3) history of previous infarction, (4) history of angina exceeding 
4 weeks, (5) sum of ST-segment elevation on electrocardiogram, (6) infarct localization, 
(7) hemodynamic status before thrombolytic treatment and (8) delay from symptom 
onset to start of rt-PA. Details of the multivariate linear regression analysis are given 
in the Appendix. Secondly, the number of segments with regional contribution to 
ejection fraction below the lOth percentile of normal was calculated from this 
multivariate model in each individual patient by setting the indicator variable for 
treatment allocation to values indicating non-invasive treatment. Finally, patients were 
subdivided in three equally sized groups of low, medium and high baseline risk. 
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Figure 2. Mean regional contribution to global ejection fraction in 20 segments of the 
left ventriculography in patients with anterior (upper plot) and diaphragmatic (lower 
plot) infarct localization. The hatched area represents the normallO to 90 percent range. 
Patients allocated to the non-invasive strategy are represented by the dotted line; patients 
allocated to invasive treatment by the solid line. 
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Subgroup analysis 
The number of segments with regional contribution to ejection 
fraction below the lOth percentile of normal was assessed in both treatment groups 
stratified according variables available before treatment allocation. 
The "Regional contribution to ejection fraction"-method was chosen a priori for the 
baseline risk assessment and subgroup analysis, because this method has the advantage 
that it is applicable without knowledge of the infarct related vesseL The method is 
therefore available in a higher proportion of patients. Furthermore, the method is 
validated in both animal experimental and patient studies [2,6]. The multivariate 
methodology is described in the Appendix. 
Adjustment for imbalances of baseline risk 
Differences between both treatment groups for all parameters of regional wall 
motion were adjusted for imbalances in baseline risk by multivariate linear regression 
analysis. With this technique the treatment effect of immediate coronary angioplasty, 
adjusted for other determinants of the outcome parameter is provided by the coefficient 
of the indicator variable for treatment allocation (see Appendix) [15]. 
RESULTS 
The "Regional contribution to ejection fraction"-model could be assessed in all 
291 patients with analyzable left ventriculography at 10 to 22 days. Determination of the 
maximally abnormally contracting 50% ("Centerline-method") was not possible in 28 
patients in the non-invasive and 9 patients in the invasive treatment group, due to 
uncertainty about which vessel was infarct related. 
Baseline characteristics 
Baseline characteristics related to regional left ventricular wall motion are 
presented in table II. Anterior infarct localization and previous myocardial infarction 
were strong predictors of regional left ventricular function. Other contributors to reduced 
wall motion were the sum of ST-segment elevation and delay to start of rt-PA. Linear 
regression coefficients, listed in table III, indicate the independent contribution of each 
determinant of baseline risk. Intercept and coefficients as observed in this trial were very 
similar to those in 577 other patients entered in the rt-PA/placebo trial, which is 
conducted by the same study group using similar methodology in 23 other hospitals 
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[12]. This supports the validity of the baseline risk model used in the present analysis. 
Baseline risk assessment successfully separated high risk patients from low risk 
patients. The number of segments with abnormal regional contribution to ejection 
fraction in the non-invasive treatment group was twice as high in the high risk group 
than in the low risk group (table II). There was an excess of high risk patients with 
assessable left ventriculography in the invasive treatment group (40.8% versus 34.2%) 
(table II). As a consequence, any true difference in regional wall motion between 
treatment groups cannot be assessed without adjustment for this unequal distribution of 
baseline risk. 
Left ventricular function 
Left ventricular function after adjustment for unbalanced distribution of baseline 
risk was similar in the 2 treatment groups, both for global and regional wall motion 
(table IV). Confidence intervals for the differences were nearly symmetrically around 
zero, indicating that no real difference in treatment effect between the two treatment 
strategies was present. In figure 2 the CREF-plots are shown for bot treatment groups. 
Subgroup analysis 
None of the patient subsets defined by the baseline characteristics mentioned in 
the Methods section benefited from immediate angioplasty, neither with univariate (table 
II), nor with multivariate analysis. 
Occlusion of infarct related vessel and reinfarction 
Patency of the infarct related vessel could not be assessed in 4 out of 149 
patients in the non-invasive group and in 1 out of 142 patients in the invasive group 
with analyzable left ventriculography. An occluded infarct related vessel at 10 to 22 
days angiography and/or reinfarction occurred more often in the invasive group (25 out 
of 141 patients) than in the non-invasive group (19 out of 145 patients). 
In patients with a patent infarct related vessel at 10-22 days angiography and 
without reinfarction, global left ventricular ejection fraction was 1.9 points better in the 
invasive strategy group (table V). This was merely due to a smaller area of hypokinesia 
(see figure 3). Severity of hypokinesia and hyperkinesia were similar in both treatment 
groups. Findings for all three models of regional wall motion analysis were consistent. 
In this subset of patients, enzymatic infarct size was similar in both treatment groups 
(median a-hydroxybutyrate dehydrogenase plasma activity 615 U/1 with 90% range 46 
to 1882 U/1 in 126 patients in the non-invasive group and 660 U/1 with 90% range 115 
to 1576 U/1 in 116 patients in the invasive group). The same was found after adjustment 
for unequal baseline risk (infarct localization, time to rt-PA, and ST-segment elevation) 
with linear regression analysis. 
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TABLE II - Baseline characteristics related to left ventricular ejection function at 
hospital discharge. The simultaneous impact of all baseline characteristics in an 
individual patient is summarized in the baseline risk score. 
Patients with Number of abnormal 
characteristic CREF's (mean and SD) 
Non-I Invasive Non-I Invasive 
N=149 N=142 N=l49 N=l42 
History of infarction 
no 138 134 8.6(4.2) 8.6(3.7) 
yes 11 8 10.3(5.7) 12.1(5.1) 
Sum ST (mV) 
<2 115 105 8.3(4.4) 8.3(3.7) 
:;:::2 34 36 9.9(4.1) 10.6(3.7) 
mis 1 
Anterior infarct localization 
no 86 78 7.0(3.2) 7.2(2.9) 
yes 63 64 11.0(4.6) 10.8(4.0) 
Delay to rt-PA (hrs) 
<2 42 30 7.4(3.7) 8.3(3.8) 
2-3 53 46 8.5(4.4) 8.4(3.8) 
:;:::} 54 66 9.8(4.5) 9.4(3.9) 
Allocation to invasive strategy 
no 149 8.7(4.3) 
yes 142 8.8(3.9) 
Baseline risk score 
low 43 35 6.2(2.8) 6.6(2.3) 
medium 55 49 7.7(3.7) 7.8(3.2) 
high 51 58 11.8(4.3) 11.1(4.0) 
Number of abnormal CREF's: number of segments with regional contribution to ejection fraction below 
lOth percentile of normal. Baseline risk score: predicted number of abnormal CREF's with linear 
regression analysis from above baseline characteristics (see methods). 
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TABLE III - Prediction of the number of segments with abnormal regional contribution 
to ejection fraction. A similar multivariate model was developed in an independent 
group of 577 patients with left ventriculograms from the rt-PNplacebo trial [12]. 
Model All Patent IRV/ rt-P A/placebo 
patients no reinfarction trial 
N=291 N=242 N=577 
Intercept 5.6 5.8 6.5 
History of infarction 
no 
yes 2.5(0.8) 2.6(0.9) 2.4(0.6) 
Sum ST (mV) 
<2 
~2 1.8(0.5) 1.7(0.5) 1.6(0.3) 
Anterior infarct localisation 
no 
yes 3.7(0.4) 3.6(0.4) 3.1(0.3) 
Delay to rt-PA (hrs) 
<2 
2-3 1.0(0.5) 1.1(0.6) 0.6(0.4) 
~3 1.5(0.5) 1.3(0.6) 1.1(0.4) 
Allocation to invasive strategy 
no 
yes -0.1(0.4) -0.4(0.4) 
Allocation to rt-PA 
no 
yes -0.5(0.3) 
IRV:infarct related vessel. The number of abnormal segments in an individual patient may be determined 
by adding up intercept and all relevant coefficients. For example, a patient without previous infarction, 
more than 2mV ST elevation, inferior infarction, Killip 1, treated with rt-PA within two hours and 
allocated to invasive strategy has 5.6 + 1.8 - 0.1 = 7.3 segments with abnormal contribution to ejection 
fraction. The same patient after non-invasive therapy has 7.4 abnormal segments. 
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TABLE IV - Treatment effect of immediate PTCA before and after adjustment for 
unequal baseline risk in all 291 patients. 
Mean (SD) Difference (Invasive - Non-invasive) 
Non-I Invasive Crude Adjusted 95% Confidence 
N=149 N=142 
Global left ventricular function 
LVEF(%) 49.7(11.4) 49.7(10.8) 0.0 0.7 -1.6 to 2.9 
Extent of hypokinesia 
CREF 8.7(4.3) 8.8(3.9) 0.2 -0.1 -0.8 to 0.7 
Centerline 32.4(21.4) 33.2(20.9) 0.8 -0.1 -4.3 to 4.1 
Radial axes 44.7(21.0) 43.8(20.1) -0.9 -1.5 -6.1 to 3.0 
Severity of hypokinesia 
CREF 1.4(0.7) 1.5(0.7) 0.1 0.1 -0.1 to 0.2 
Centerline -2.8(1.6) -2.7(1.6) 0.1 0.1 -0.3 to 0.5 
Radial-axes 0.6(0.8) 0.7(0.9) 0.1 0.1 -0.0 to 0.3 
Extent of hyperkinesia 
CREF 2.1(2.3) 2.0(2.2) -0.1 0.0 -0.5 to 0.5 
Severity of hyperkinesia 
CREF 4.3(2.2) 4.2(2.1) -0.1 -0.3 -0.8 to 0.3 
Centerline 0.2(1.2) 0.1(1.3) -0.0 -0.1 -0.4 to 0.2 
L VEF: left ventricular ejection fraction(%) (N=291). CREF: "Regional contribution to ejection fraction"-
method. The definitions of the measurements have been presented in the methods section. Extent of 
hypokinesia was assessed with the CREF, Centerline and Radial-axes method in respectively 291, 289 
and 291 patients. Severity of hypokinesia in 289, 255 and 285 patients respectively. Extent of 
hyperkinesia was assessed in 291 patients. Severity of hyperkinesia in 189 patients (in 102 patients no 
hyperkinesia was present according to the CREF-method) and in 255 patients with the "Centerline"-
method. 
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DISCUSSION 
In spite of thrombolytic therapy with rt-PA, the infarct related vessel remains 
occluded in approximately 25% of patients [1,4,16]. Furthermore part of the patients 
have a hemodynamically significant stenosis after thrombolysis. Immediate coronary 
angioplasty has been proposed to recanalize the remaining occluded vessels and to 
improve blood flow in patients with a severe residual stenosis. 
Recovery of left ventricular function and the incidence of reocclusion were 
reported to be related to the degree of residual stenosis after thrombolysis [17-19] and 
small randomized trials, assessing immediate angioplasty with and without intracoronary 
streptokinase, suggested that recovery of left ventricular function might be improved by 
angioplasty [20,21]. However, the present larger randomized trial of the European 
Cooperative Study Group failed to confirm this. Other investigators also reported lack 
of benefit of immediate [4,16] or delayed (18-48 hours) angioplasty [5] in patients 
treated with rt-PA. 
Baseline comparability 
There was an excess in baseline risk in the invasive treatment group in the 
present analysis. This could not be explained by the fact 
that patients without predischarge left ventriculography were excluded for the present 
analysis, since missing left ventriculography was related to poor left ventricular function 
and more patients in the invasive treatment group had no left ventriculography (table 1). 
The explanation is that randomization did not yield groups of identical baseline risk. 
Although randomization is the best way of achieving patient groups with identical 
baseline risk, it is not always successful, especially in small and medium sized trials 
[22]. 
Multivariate linear regression analysis provides an estimation of relative efficacy 
of treatment strategies, independent of imbalances in baseline risk. After adjustment, no 
benefit of immediate angioplasty was found. 
Occlusion of infarct related vessel and reinfarction 
In the present trial, immediate angioplasty was associated with more frequently 
an occluded infarct related vessel and reinfarction during stay in the hospital, which 
might have abolished a benefit of immediate angioplasty. In fact, a trend towards 
improved regional wall motion, was observed in those patients with a patent infarct 
related vessel and without recurrent infarction at the time of hospital discharge. The 
magnitude of treatment effect of immediate angioplasty in these patients was of the same 
order of magnitude as found for thrombolytic therapy with rt-PA in comparison to 
placebo (table III). This suggests that immediate angioplasty may be beneficial if the 
complications of angioplasty, i.e. reocclusion and reinfarction can be prevented. 
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Figure 3. Mean regional contribution to global ejection fraction in 20 segments of the 
left ventriculography in patients with a patent infarct related vessel at 10-22 days 
angiography (TIMI perfusion grade 2 or 3) and without reinfarction prior to angiography 
for anterior (upper plot) and diaphragmatic infarct localization (lower plot). The hatched 
area represents the normallO to 90 percent range. Patients allocated to the non-invasive 
strategy are represented by the dotted line; patients allocated to invasive treatment by 
the solid line. 
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TABLE V - Treatment effect of immediate PTCA before and after adjustment for 
unequal baseline risk in 242 patients with a patent infarct related vessel at 10-22 days 
angiography (TIMI perfusion grade 2 or 3) and without reinfarction prior to angiography 
only. 
Mean (SD) Difference (Invasive - Non-invasive) 
Non-1 Invasive Crude Adjusted 95% Confidence 
N=126 N=116 
Global left ventricular function 
LVEF(%) 49.0(11.5) 50.8(9.9) 1.9 1.9 -0.5 to 4.4 
Extent of hypokinesia 
CREF 9.1(4.3) 8.6(3.7) -0.5 -0.5 -1.3 to 0.4 
Centerline 34.5(22.1) 32.1(19.5) -2.4 -2.1 -6.7 to 2.5 
Radial-axes 46.3(20.5) 42.4(19.3) -3.9 -3.9 -8.7 to 0.9 
Severity of hypokinesia 
CREF 1.4(0.6) 1.6(0.7) 0.1 0.1 -0.0 to 0.3 
Centerline -2.9(1.6) -2.6(1.5) 0.3 0.2 -0.2 to 0.6 
Radial-axes 0.6(0.7) 0.8(0.9) 0.2 0.2 -0.0 to 0.4 
Extent of hyperkinesia 
CREF 1.9(2.1) 1.8(2.0) -0.1 -0.1 -0.6 to 0.4 
Severity of hyperkinesia 
CREF 4.3(2.3) 4.2(2.2) -0.1 -0.3 -0.9 to 0.3 
Centerline 0.1(1.2) 0.2(1.3) 0.1 0.1 -0.3 to 0.4 
See legend of table IV. Extent of hypokinesia was assessed with the CREF, Centerline and Radial-axes 
method in respectively in 242, 239 and 242 patients. Severity of hypokinesia in 242, 215 and 237 patients 
respectively. Extent of hyperkinesia in 242 patients. Severity of hyperkinesia was assessed with the 
CREF-method in 152 pts, in the remaining 90 patients no hyperkinesia was present; with the "Centerline"-
method in 214 patients. 
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Better left ventricular function after immediate coronary angioplasty in patients 
without reocclusion and/or reinfarction may be explained by further limitation of infarct 
size, and by enhancement or acceleration of left ventricular recovery. The fact that 
enzymatic infarct size was not reduced, favours the latter explanation. In addition, this 
is in agreement with the observation that recovery of left ventricular function is related 
to residual stenosis after thrombolytic therapy [17]. 
One might argue that excluding the patients in whom infarct related vessel 
patency could not be assessed might have influenced the effect of immediate angioplasty 
in patients with a patent infarct related vessel and without reinfarction. However, the 
same results were obtained if these patients were included in the analysis. 
The lack of benefit of the invasive strategy in the present trial may also be due 
in part to sudden and complete reperfusion during angioplasty. There is evidence from 
animal experiments that recovery of left ventricular function is accelerated after gradual 
(in 2 hours time) in comparison to recovery after sudden reperfusion. The underlying 
mechanism is unknown, but the no-reflow phenomenon and increased calcium influx 
with contraction band necrosis may contribute [23]. Thus a certain degree of residual 
stenosis after thrombolysis may help protect myocardium against reperfusion damage. 
This would favour an approach of immediate thrombolytic recanalization or mechanical 
recanalization with a guidewire, followed by coronary angioplasty after a few hours. 
This regimen requires further study. 
Patient selection 
In the present trial no patient subset benefited from coronary angioplasty. In the 
present trial angioplasty was attempted in most patients (92%), including patients with 
an occluded infarct related vessel. Initial experience with immediate coronary 
angioplasty in patients with an occluded infarct related vessel at 90 min after start of 
thrombolysis with rt-PA ("rescue angioplasty") was not favourable [16], but promising 
results were obtained when rt-PA was combined with urokinase [24]. The concept of 
"rescue" angioplasty deserves further study in connection with treatment regimen for the 
prevention of reocclusion or reinfarction, especially if patients with persistent occlusion 
(failed thrombolysis) can be recognized non-invasively. In the mean time, angioplasty 
and coronary bypass surgery should be reserved for treatment of recurrent ischemia not 
responding to medical treatment. The role of thallium myocardial perfusion scintigraphy 
in the selection of patients for revascularization procedures is unknown sofar. 
Conclusion 
No benefit of an invasive strategy of immediate coronary angioplasty in addition 
to rt-PA, heparin and aspirin, could be documented when compared to a non-invasive 
strategy with rt-PA, heparin and aspirin alone. Nevertheless, a trend towards benefit of 
immediate angioplasty was found in selected patients with a patent predischarge infarct 
related vessel and without reinfarction. This suggest that reocclusion and reinfarction are 
responsible for the lack of benefit of immediate coronary angioplasty after thrombolytic 
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therapy for acute myocardial infarction. At present, an invasive strategy with immediate 
angiography and angioplasty cannot be recommended, but angioplasty in selected 
patients (e.g. with failed thrombolysis) warrants further investigation, provided that 
reocclusion and reinfarction can be prevented. 
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APPENDIX 
Linear regression analysis 
Linear regression analysis was performed (BMDP statistical package, program 
lR and 2R) to assess the relation between the variables mentioned in the "Methods" 
section (independent variables = X) and each parameter of left ventricular function 
(dependent variable= Y): Y =A+ Li Bi Xi 
Independent and dependent variables 
Indicator variables were defined by assigning zero to patients in whom an event 
or characteristic was absent and one in case of presence. Continuous variables were not 
used directly. For these variables patients were categorized in three equally sized 
subgroups according to patients value for that variable. The category with the lowest 
value for the parameter of wall motion under study was chosen as reference group. For 
the second and third subgroups indicator variables were designed: one in case a patient 
belonged to that subgroup, zero if not. Thus, patients in the reference group were 
characterized by zero's for the design variable for the second and third subgroup. 
Design of the linear regression models 
For the baseline risk model, all indicator variables representing the baseline 
87 
characteristics mentioned in the "Methods-section" were simultaneously entered in the 
model. Only indicator variables with coefficients with P :::;; 0.10 were retained in 
subsequent models, unless a product term of that term with another term had to be 
included in the model. In that case, the indicator variable was forced into the model. The 
same applied for the indicator variable of treatment allocation. 
For each parameter of regional wall motion, the same independent variables as 
used for the baseline risk assessment, were entered in a model in order to adjust for 
unbalanced baseline risk of regional wall motion. 
To assess the contributions of the various determinants in both treatment groups 
separately, "product terms" (indicator variable for determinant under study multiplied by 
the indicator variable of treatment allocation) were tested in the model [25]. 
Interpretation of results of linear regression model 
Since all independent variables are zero/one variables, the coefficients (B) reflect 
the difference (DIF) in the number of segments with regional contribution to ejection 
fraction below lOth percentile of normal between a patient with characteristic Xi and a 
patient without that characteristic, all other determinants of regional wall motion being 
equal. 95% confidence limits for this difference may be calculated from the standard 
error (SE) of the coefficient [26]: DIFi ± 1.96 x (SEJ 
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ONE YEAR FOLLOW-UP 
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ABSTRACT 
The European Cooperative Study Group conducted 2 randomized trials in patients 
with suspected myocardial infarction to assess the effect of single chain recombinant 
tissue plasminogen activator (rt-PA, alteplase) on enzymatic infarct size, left ventricular 
function, morbidity and mortality relative to placebo (rt-PA/placebo trial) and to assess 
the effect of immediate coronary angioplasty in addition to rt-PA (rt-PA!PTCA trial). 
In the rt-PA/placebo trial 721 patients with chest pain of less than 5 hours and extensive 
ST-segment elevation were entered and in the rt-PA/PTCA trial 367 similar patients. In 
the former trial patients were allocated at random to 100 mg rt-PA or placebo (double 
blind) over 3 hours. In the rt-PA/PTCA trial all patients received rt-PA and were 
subsequently allocated at random to immediate coronary angiography and angioplasty 
of the infarct related vessel or controL All patients in both trials received aspirin and 
intravenous heparin, started with a 5000 U bolus and followed by 1000 U per hour. 
In the rt-PA/placebo trial, mortality during the first year was reduced by 36% 
with rt-PA, from 9.3% to 5.6%. Late revascularization was performed more frequently 
after rt-PA (in 66 versus 57 patients) and more patients were in New-York Heart 
Classification class I or II (86.7% versus 81.4%) in the rt-PA group. Non-fatal 
reinfarction was more common after rt-PA than after placebo (6.8% versus 4.4%). In the 
rt-PA/PTCA trial, after immediate coronary angioplasty, non-fatal reinfarction was less 
common (4.9% versus 9.3%) and revascularization procedures less frequent (16.4% 
versus 25.0%). However, this was offset by a high rate of immediate reocclusion and 
early recurrent ischaemia and higher mortality at 1 year (9.3% versus 5.5%) in the 
invasive group, also after adjustment for unequal baseline risk. Benefit of rt-PA tended 
to be greater in patients treated early. In a multivariate analysis of 1043 hospital 
survivors, late mortality was related to coronary anatomy, left ventricular function, age 
and previous infarction, but not to initial treatment allocation. Reinfarction after hospital 
discharge was more common after rt-PA and tended to be related to coronary anatomy. 
INTRODUCTION 
In 1988 the European Cooperative Study Group reported two randomized clinical 
trials with single chain recombinant tissue type plasminogen activator (rt-PA, alteplase). 
In the rt-PA/placebo trial, 721 patients were allocated at random to rt-PA or placebo [1]. 
All patients received intravenous heparin and aspirin. Mean left ventricular ejection 
fraction was higher and enzymatic infarct size was 20% smaller after treatment with rt-
PA. Mortality was reduced by 51% at 2 weeks and by 36% at 3 months. In the rt-
p A/PTCA trial, 367 patients were allocated at random to a non-invasive strategy of rt-
PA, heparin and aspirin or to an invasive strategy ofrt-PA, heparin and aspirin followed 
be immediate coronary angiography and PTCA [2]. No additional benefit of immediate 
coronary angioplasty was found; left ventricular function and enzymatic infarct size were 
similar in both treatment groups and mortality at 3 months was higher in the invasive 
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treatment group. 
All patients in both trials were followed during one year in order to answer the 
following questions: (1) Is the reduction of mortality by rt-PA maintained during follow-
up; (2) are clinical course and functional class influenced by rt-PA and immediate 
angioplasty; (3) which are the predictors of mortality and reinfarction after hospital 
discharge. 
PATIENTS AND METHODS 
Patients with electrocardiographic evidence of extensive myocardial infarction 
were enroled in two different trials, provided that thrombolytic therapy could be started 
within 5 hours after the onset of symptoms. Details of trial size determination, patient 
selection and baseline characteristics have been previously published [1,2]. All patients 
entered in both trials had given their informed consent and the committee on human 
research in every participating center had approved the study protocol. In the rt-
PA/placebo trial, patients were randomized to either rt-PA or placebo. All patients 
received a bolus of 5000 IU hep?.rin followed by an infusion of 1000 IU/hour and 250 
mg aspirin intravenously. Rt-PA was given as a 10 mg bolus injection followed by 50 
mg in one hour and 40 mg in the subsequent 2 hours. In the rt-PA/PTCA trial patients 
were allocated to a non-invasive strategy ofrt-PA, heparin and aspirin, or to an invasive 
strategy of rt-PA, heparin, and aspirin followed by immediate angiography and PTCA. 
In both trials aspirin (75 to 120 mg on alternating days) as well as anticoagulation with 
heparin and/or coumarin were continued until pre-discharge angiography which was 
required in all patients between 10 and 22 days after admission. After discharge long 
term treatment with beta blockers was recommended (metropolol100 mg twice a day). 
In case of recurrent ischaemia resistant to medical treatment, coronary angioplasty or 
coronary bypass surgery should be performed. In the rt-PNplacebo trial, investigators 
remained unaware of the treatment allocation. Left ventricular ejection fraction and 
coronary anatomy were assessed centrally by the Core Laboratory and the Angiographic 
Assessment Group. Residual stenosis in the infarct related vessel at 10 to 22 days was 
assessed visually. Left ventricular ejection fraction was determined from contrast left 
ventricular angiography in left anterior oblique projection [1]. 
Follow-up information was obtained by the investigators at each participating 
center, during a visit of the patient to the outpatient clinic some weeks later than 3 
months and 1 year after myocardial infarction. Data on survival, date and cause of death, 
dates and duration of any hospital admission, reinfarction, coronary angioplasty and 
bypass surgery, functional class (New-York Heart Association classification) and use of 
medication were obtained. If a patient could not visit the outpatient clinic, information 
was gathered by telephone contact or via the general physician. 
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Data analysis 
Survival and survival without reinfarction were determined according to Kaplan-
Meier [3]. Relative risk in one patient group compared to a reference group is reported 
as hazard ratio, obtained with Cox regression analysis [4]. Baseline risk was assessed 
in each individual patient by calculating a baseline risk score based on the independent 
contribution of multiple determinants of mortality available before treatment allocation. 
The independent contribution was assessed by Cox multivariate regression analysis (see 
Appendix) in the rt-PNplacebo trial. The obtained risk prediction model was 
subsequently applied in the rt-PNPTCA trial. Similarly, determinants of death after 
hospital discharge were identified with Cox multivariate regression analysis [4] (see 
Appendix). 
To assess the relation between residual stenosis in the infarct related vessel and 
reinfarction during the first year after hospital discharge, a multivariate logistic 
regression model was designed. Adjusted rate ratios were calculated from this logistic 
model according to Miettinen [5]. 
RESULTS 
Mortality 
Mortality at one year follow-up was 9.3% in the placebo group and 5.6% in the 
rt-PA group (table I and figure 1). Mortality reduction was 36% (Cox regression 
analysis, 95% confidence interval from -62% to +8%). Most benefit was found for 
patients treated within 3 hours after onset of symptoms; mortality was 9.7% (20/207 
patients) in the placebo group and 3.9% (7/180) in the rt-PA group. In the rt-PA/PTCA 
trial mortality appeared higher after invasive therapy, both at 14 days and at one year 
follow-up. In both trials, heart failure was the most common cause of death (36 
patients). Other common causes of death were ventricular arrhythmia (9 patients), 
sudden death (8 patients), tamponade (7 placebo treated patients) and bleeding (in 6 
patients). 
Reinfarction 
Reinfarction within one year was reported for 8% of patients, of which more than 
half occurred within 14 days (table I and figure 2). Reinfarction was diagnosed on the 
basis of a combination of enzyme elevation and electrocardiographic pattern (in 57% of 
cases) or on the basis of one of these criteria (31% ). In the remaining patients, 
diagnosis was made on clinical pattern or at autopsy. Reinfarction occurred in 78% of 
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TABLE I - Mortality, reinfarction and revascularization procedures within first year. 
rt-PA/placebo trial rt-P A/PTCA trial 
Placebo rt-PA rt-PA Invasive 
N=366 N=355 N=184 N=183 
Events: (%) patients with®: 
Death 14 days 5.7 2.8 2.7 6.6 
1 year 9.3 5.6 5.4 9.3 
Reinfarction 14 days 4.1 3.9 6.0 4.4 
1 year 6.8 8.2 11.4 6.6 
PTCA 14 days 2.5 2.5 6.0 4.9 
1 year 7.7 7.3 16.3 7.7 
CABG 14 days 0.3 2.3 0.0 2.2 
1 year 7.4 10.1 7.6 8.2 
PTCA+CABG 14 days 0.3 0.3 0.5 0.0 
1 year 0.5 1.1 1.6 0.5 
Patient status at 14 days (% )#: 
Survival 94.3 97.2 97.3 93.4 
Survival without reinfarct 91.3 93.8 92.9 90.7 
Survival without reinfarct, 
PTCA orCABG 89.3 90.4 90.2 86.9 
Patient status at 1 year (% )#: 
Survival 90.7 94.4 94.5 90.7 
Survival without reinfarct 86.3 87.6 85.2 85.8 
Survival without reinfarct 
PTCA or CABG 72.7 72.4 67.1 73.1 
@: Number of patients with event divided by total number of patients allocated in each treatment group. 
In the rt-P Nplacebo trial 1.4% of patients in the placebo group and 1.1% in the rt-PA group could not 
be followed until365 days. In the rt-PA/PTCA trial this occurred in 2.7 and 3.8% of patients in the rt-PA 
and invasive treatment group respectively. However, 3 month follow up was available for all but I patient 
and most events occurred within 3 months.#: Patient status at 14 days and one year were determined by 
Kaplan-Meier survival analysis. PTCA: percutaneous transluminal coronary angioplasty. CABG: coronary 
artery bypass grafting. 
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cases at the same site as the index infarct, but in 10 patients at a distant site. In 6 cases 
the localization of reinfarction could not be determined and for 2 patients data were 
missing. Reinfarction was slightly more common among rt-PA allocated patients with 
8.2% versus 6.8% among controls (table I). In the invasive group reinfarction was less 
frequent than in the non-invasive group: 6.6% versus 11.4%. However, recurrent 
ischaemia during the flrst 24 hours after allocation was more frequent in the invasive 
group, 17% versus 3% [2]. 
Revascularization and medication 
As reported in table I, surgical revascularization was performed more frequently 
after rt-P A than in the placebo group (table I and II). Most interventions were done after 
the first two weeks. Overall, interventions were more frequent in the rt-PA/PTCA trial 
than in the rt-PA/placebo trial. In the invasive group, coronary angioplasty was less 
frequently performed than in the non-invasive group, while the number of patients 
undergoing bypass operations was similar in both groups. At one year approximately 
72% of patients in both studies were alive, without reinfarction or additional revasculari-
zation procedures. About two third of patients were treated with anticoagulant or 
antiplatelet drugs. In the rt-PNplacebo trial, the most commonly prescribed antithrom-
botic medication at hospital discharge were coumarins, while antiplatelet drugs were 
more commonly used in the rt-PA/PTCA trial. This difference disappeared at one year 
follow-up, when antiplatelet drugs were used by half of the patients in both trials. 
Betablockade was more commonly used in the rt-PNplacebo trial than in the rt-
p A/PTCA trial. Calcium antagonists and nitrates were more frequently prescribed in the 
rt-PA/PTCA trial than in the rt-PNplacebo trial. Medications such as digitalis, diuretics 
or anti-arrhythmics were scarcely used in both trials. 
Functional class 
In the rt-PA/placebo trial, more patients were in functional class I or II in 
patients treated with rt-PA than among those allocated to placebo (table III). Functional 
impairment at 1 year was primarily due to angina pectoris (in 44% of cases in the rt-PA 
group and in 49% among controls) symptoms of congestive heart failure (18% versus 
17%) or both (2% and 1% respectively). Other reasons included lung disease (8 patients 
in rt-PA group and 7 control cases), undetermined dyspnea (8 versus 6), fatigue or 
psychological reasons (7 versus 9) and arthropathy (3 rt-PA cases versus 2 controls). 
Among patients allocated to invasive strategy functional class seemed worse compared 
to the non-invasive strategy throughout the follow-up period. Reasons for functional 
impairment were angina pectoris and/or congestive heart failure in 88% and 81% in the 
non-invasive and invasive group respectively. In both trials functional class tended to 
worsen during follow-up. Functional class at 3 month follow-up was intermediate 
between hospital discharge and one year follow-up for all treatment groups. 
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TABLE IT - Proportion of patients (%) with medication at hospital discharge, three 
month and 1 year follow-up for patients alive and with information available. 
rt-PA/placebo trial rt-PA/PTCA trial 
Placebo rt-PA rt-PA Invasive 
N=366 N=355 N=l84 N=l83 
Coumarins 
discharge 59 55 20 17 
3 month 55 54 27 20 
1 year 21 24 14 15 
Anti platelet 
discharge 35 35 59 50 
3 month 41 43 55 52 
1 year 50 43 54 54 
None of these 
discharge 22 24 25 36 
3 month 16 13 22 30 
1 year 30 35 33 33 
Betablockers 
discharge 56 51 39 37 
3 month 59 59 42 48 
1 year 59 54 45 42 
Calcium antagonists 
discharge 16 17 39 38 
3 month 20 20 44 38 
1 year 26 25 42 42 
Nitrates 
discharge 12 8 35 31 
3 month 16 13 57 54 
1 year 18 17 45 44 
Patients using combinations of medication are counted in each group. 
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Hospital stay 
In the rt-PA/placebo trial duration of the initial hospitalization was 14 days in 
both treatment groups (median, 90% range 9 to 28 in the placebo; 9 to 23 among 
controls). Readmissions contributed only 3 days to the total duration of hospitalization 
during the first year. Thus, the total duration of hospitalization during the first year was 
17 days in both treatment groups (median, 90% range 10 to 47 in the rt-PA group and 
10 to 43 among controls). In the rt-PA/PTCA trial initial hospitalization was longer, 20 
days in each treatment group (median, 90% range 11 to 36 in the invasive group; 11 to 
37 among controls). Including readmissions, patients of both treatment groups remained 
22 days in the hospital during the first year (90% range 12 to 65 in the invasive, 12 to 
58 in the non-invasive group). 
Determinants of death and reinfarction after discharge 
In order to identify determinants of mortality and reinfarction after hospital 
discharge, data were analyzed from 1043 hospital survivors. Mortality in the first year 
after discharge was low (3.4%) and appeared related to coronary anatomy, left 
ventricular function and to a lesser extent to age and a history of previous infarction 
(table IV and V). It should be noted that the initial treatment allocation did not affect 
mortality after hospital discharge. Similarly, for the combined endpoint death or 
reinfarction left ventricular function and extent of coronary artery disease were 
predictors. Reinfarction within the first year after hospital discharge occurred in only 39 
out of 1043 patients (3.7%). Reinfarction tended to occur 2.4 times more frequently 
among patients with a patent infarct related vessel with a diameter stenosis between 50 
to 99%. This could not be explained by different revascularization approach in this 
categories of residual stenosis, since entry of indicator variables for bypass surgery and 
angioplasty in the logistic regression model did not affect this relation. Reinfarction after 
discharge occurred twice as common in patients treated with rt-PA than among patients 
allocated to placebo. No other parameters available before hospital discharge appeared 
related to reinfarction. 
DISCUSSION 
The reduction in mortality by rt-PA noted during the first 3 months [1] was still 
present at one year. Other investigators have also reported that the initial benefits of 
thrombolytic therapy are maintained at 7 months [6], 1 year [7-9] and even at 5 years 
[10]. In both the rt-PNp1acebo and rt-PA/PTCA trial patients with extensive ST-segment 
elevation were entered. Cardiogenic shock was not an exclusion criterion. Nevertheless, 
mortality was very low in both trials and among the lowest published to date in any trial 
with similar inclusion criteria. This is probably due to the combination of effective early 
thrombolytic therapy and antithrombotic therapy with aspirin [11] and heparin [12]. 
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TABLE ill- Functional class according to New-York Heart Association classification 
at hospital discharge and 1 year follow-up. 
At hospital discharge 
rt-PA/placebo trial 
Placebo 
N=366 
rt-PA 
N=355 
Median number of days to follow up (90% range) 
14(10-29) 14(10-23) 
Dead 6.6 3.1 
Alive 
Canadian Functional Class 
I 73.2 78.6 
II 14.5 12.4 
III 4.1 3.9 
IV 1.4 0.8 
Unknown 0.3 1.1 
At 1 year follow-up 
Median number of days to follow up (90% range) 
No follow up 
Dead 
Alive 
399(365-643) 399(365-615) 
0.5 0.6 
9.8 6.5 
Canadian Functional Class 
I 60.1 63.9 
II 21.3 22.8 
III 7.4 4.5 
IV 0.5 1.1 
Unknown 0.3 0.6 
Proportions of patients are given as percentages. 
rt-PA!PTCA trial 
rt-PA 
N=184 
20(11-40) 
3.3 
77.2 
13.0 
6.5 
Invasive 
N=183 
20(11-39) 
7.1 
69.9 
16.4 
5.5 
1.1 
404(366-599) 412(365-663) 
1.6 1.6 
6.0 9.3 
60.9 51.9 
22.3 25.1 
7.6 9.8 
1.1 1.6 
0.5 0.5 
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TABLE IV - Determinants of mortality within frrst year after hospital discharge in 1043 
hospital survivors in order of decreasing importance. 
Determinant Mortality 
within 
first year 
(%) 
Relative risk 
N= 
Crude Adjusted (95% Cl) 
Nr of coronary vessels with ~50% diameter stenosis 
<2 623 1.6 
~2 378 5.8 4.55 3.17 (1.49 to 6.75) 
missing 42 11.9 
Left ventricular ejection fraction (%) 
2::40 710 1.8 
<40 158 8.2 4.14 3.13 (1.49 to 6.57) 
missing 175 5.7 
Residual diameter stenosis in infarct related vessel (%) 
<90 635 2.2 
~90 331 5.2 2.31 1.94 (0.99 to 3.79) 
missing 77 6.5 
Age (y) 
<60 
2::60 
652 
391 
Previous infarction 
no 972 
yes 71 
Treatment allocation 
no 345 
rt-PA 346 
rt-PA 180 
invasive 172 
2.3 
5.4 
2.9 
11.3 
3.8 
3.2 
3.4 
3.5 
2.23 
3.92 
0.92 
0.88 
0.80 
1.78 (0.95 to 3.33) 
2.03 (0.94 to 4.40) 
0.97 (0.47 to 2.02) 
1.13 (0.45 to 2.85) 
0.98 (0.36 to 2.69) 
Proportions of patients are given as percentages and were obtained by Kaplan Meier survival analysis. The 
crude relative risk is determined by univariate Cox regression analysis; adjusted relative risk by 
multivariate Cox regression analysis. CI: confidence interval. Indicator variables for treatment allocation 
were forced into the model. 
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TABLE V - Reinfarction within the first year after hospital discharge in various 
categories of residual stenosis in the infarct related coronary artery in 1043 hospital 
survivors. 
Determinant 
N= 
Reinfarction Relative risk 
within 
first year 
(%) Crude Adjusted (95% Cl) 
Diameter stenosis in infarct related vessel (%) 
::;so 193 2.1 
50 to 99 585 5.0 2.39 2.38 (0.76 to 7.59) 
(sub)total 188 2.7 1.28 1.30 (0.39 to 4.32) 
missing 77 1.3 
Treatment allocation 
placebo 345 2.6 
rt-PA 346 4.9 1.88 1.95 (0.88 to 4.34) 
rt-PA 180 5.0 1.92 2.06 (0.82 to 5.17) 
invasive 172 2.3 0.89 1.43 (0.39 to 5.23) 
Patients with reinfarction within the first year after hospital discharge divided by total number of patients 
in that category of residual stenosis at the time of hospital discharge, given as percentage. The crude 
relative risk in this table is a rate ratio. Adjusted rate ratio is obtained by multivariate logistic regression 
analysis according to Miettinen (see Appendix). CI: confidence interval. 
As in other studies [ 6, 10] revascularization procedures were more common after 
thrombolytic therapy. This may be explained by a smaller infarct size and thus more 
myocardium susceptible for ischaemia in the territory of the infarct related vessel. 
Patient selection criteria, thrombolytic therapy regimen, therapy with aspirin and 
heparin and guidelines for further therapy were identical in both trials. Indeed, one year 
survival was strikingly similar in patients treated with rt-PA but without coronary 
angioplasty in both trials (94%). Some differences were apparent in patient management 
between both trials. In the non-invasive group of the rt-PA/PTCA trial PTCA was 
performed more often than in the corresponding group in the rt-PA/placebo trial. This 
might be related to an excess of patients with a history of angina before the myocardial 
infarction in the rt-PA/PTCA trial (70% versus 48% in the rt-PA/placebo trial). 
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Furthermore the initial hospital stay was longer, coumarins and beta-blockers were 
prescribed less frequently and calcium antagonists more frequently in the rt-PA/PTCA 
trial. These differences may reflect differences in medical culture between university 
hospitals in Germany, France, Belgium, the Netherlands and Spain participating in the 
rt-PA/PTCA trial on one hand and large district hospitals in Belgium, United Kingdom, 
the Netherlands, Spain and Switzerland co-operating in the rt-PNplacebo trial [2] on the 
other hand. However, these differences in medical culture had no major impact on 
patient outcome at one year, since mortality and functional state at one year were similar 
in patients treated with rt-PA in the rt-PA/placebo trial and patients in the non-invasive 
group of the rt-PA/PTCA trial. 
Reinfarction 
Reinfarction was slightly more common after treatment with rt-PA. Again, a 
smaller infarct size after thrombolytic therapy and thus more viable myocardium in the 
territory of the infarct related vessel after thrombolysis is the most likely explanation. 
In most other trials a higher incidence of reinfarction was reported after thrombolytic 
therapy than among controls [6,10,13,14], except in one trial [15]. In another trial [16] 
reinfarction rate after rt-PA was higher than in the present trials. In that trial aspirin was 
started after 8 to 10 days after myocardial infarction, while reinfarctions tend to occur 
earlier (figure 2). The low incidence of reinfarction after invasive treatment in the rt-
p A/PTCA trial is probably misleading, since recurrent ischaemia during the first 24 
hours was much more common in the invasive group [2]. Reinfarctions among patients 
with early recurrent ischaemia are difficult to diagnose, because the electrocardiographic 
and enzymatic patterns of the evolving initial myocardial infarction are blurring the 
diagnosis of reinfarction. 
Functional class 
Functional class in patients initially treated with rt-PA, heparin and aspirin, was 
superior to that among patients treated with heparin, aspirin and placebo. Thus, 
thrombolytic therapy improves survival after myocardial infarction, without negatively 
influencing quality of life. More than half of the patients treated with rt-PA were 
asymptomatic at one year follow-up. This is similar to earlier observations after 
intracoronary streptokinase [13]. Only a few patients were treated for heart failure 
(vasodilators, digitalis and diuretics), which corresponds with the small number class III 
and IV patients during follow-up. 
Immediate angioplasty 
Immediate angioplasty was not beneficial, neither in the early phase, nor in the 
first year after infarction. Similar conclusions were drawn by other investigators [17,18]. 
Since routine coronary angioplasty later during hospitalization also proved to be not 
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beneficial [19], we recommend that coronary angioplasty should be restricted to patients 
with recurrent ischaemia during follow-up. It has been suggested that the lack of benefit 
of immediate angioplasty was due to the difference in baseline characteristics since overt 
heart failure and shock were observed more often in the invasive group (7 patients) than 
in the non-invasive group (1 patient). However correction for difference in baseline risk 
did not alter the trial outcome. Mortality was 1.6 times higher after invasive therapy. 
This increased risk remained 1.46 after adjustment for unequal baseline risk by Cox 
regression analysis (see Appendix). 
Mortality after hospital discharge 
Mortality after hospital discharge was mainly determined by left ventricular 
function and coronary anatomy. Predictors of mortality were identical as reported in an 
intracoronary streptokinase trial with similar patient selection [10]. Many studies have 
stressed the predictive value of left ventricular function, determined on admission [20] 
or before hospital discharge [21-23]. In addition, the importance of coronary patency for 
mortality have been described [20,23]. Initial treatment, although an important 
determinant of mortality during hospital stay (table I), did not influence mortality after 
hospital discharge, independently from coronary anatomy and left ventricular function. 
Sophisticated analyses in other trials suggested that the same is true for intracoronary 
streptokinase [10,20]. To evaluate whether the relation between residual stenosis in the 
infarct related vessel and mortality after discharge was different after angioplasty than 
after non-invasive treatment, the multivariate analysis was repeated after exclusion of 
patients in the invasive treatment group. Results were similar to those in the combined 
group. 
The prognostic implication of the extent of coronary artery disease and the degree of 
residual stenosis of the infarct related vessel after myocardial infarction have received 
little attention sofar. The rt-PA/PTCA trial was designed because earlier reports 
suggested that reduction in residual stenosis would be beneficial [24,25]. Therefore, the 
impact of the degree of residual stenosis in the infarct related vessel was assessed 
separately in this analysis. Severity of residual stenosis in the infarct related vessel 
appeared related to mortality and reinfarction. This suggest that routine revascularization 
may turn out to be beneficial, provided that patients are properly selected and 
reocclusion and restenosis are sufficiently prevented. 
Conclusion 
Treatment with rt-PA, heparin and aspirin results in limitation of mortality and 
better functional class during the first year after myocardial infarction. Reinfarction is 
not frequent and only slightly more common than after heparin and aspirin without 
thrombolytic therapy. Immediate coronary angioplasty does not result in a further 
benefit. Prognosis after hospital discharge is determined by coronary anatomy and left 
ventricular function but not by the initial treatment. 
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APPENDIX 
Baseline risk was assessed in three steps. First, a Cox multivariate prediction 
model describing the relation between baseline characteristics and mortality was assessed 
in the rt-PNplacebo trial. Only baseline characteristics known to be related to mortality 
after myocardial infarction were considered: (1) age, (2) gender, (3) history of previous 
infarction, (5) sum of ST-segment elevation (6) infarct localization, (7) haemodynarnic 
status before thrombolytic treatment and (8) delay from symptom onset to start of 
treatment [26]. In a stepwise manner (BMDP statistical software, program 2L - MPLR), 
determinants of which the coefficient had a P-value of less than 0.10 for entry in the 
model were included. Indicator variables for treatment allocation were forced into the 
model, as was the case with indicator variables for missing values. Determinants 
included in the final model are listed in table VI. Second, the probability of dying within 
the first year was calculated from this multivariate model for each individual patient as: 
1 _ 0.979exp(ax\ +bxX
2 
+ .... ) 
The number 0.979 is the estimated survival at one year for a patient without any risk 
factor ~; a, b, ... represent the Cox regression coefficients of the indicator variables 
listed in table V and X 1, X 2, ••• zero/one depending on absence or presence of each risk 
factor for each patient For this calculation, the indicator variable for treatment allocation 
was set to zero (indicating placebo treatment). Finally, patients were subdivided in a 
low, medium and high baseline risk group, according to their predicted probability of 
death within the first year, using arbitrary cutoff values of 0.96 and 0.91 to obtain 
similarly sized subgroups. In the rt-PNplacebo trial proportions of patients in each 
baseline risk category were similar in both treatment groups. In the rt-PA/PTCA trial 
30.1% of invasively treated patients were in the high risk group, versus 22.3% in the 
non-invasive group. Mortality (Kaplan-Meier) of high risk patients was 7.4% and 20.0% 
in the non-invasive and invasive treatment group respectively, and 4.9% and 4.7% in the 
other categories combined in the non-invasive and invasive treatment group respectively. 
Relative risk for mortality in the rt-PA/PTCA trial, adjusted for imbalanced 
baseline risk in the two treatment groups, was obtained by designing a Cox model in 
which indicator variables for treatment allocation and high baseline risk were forced. 
Similarly as for baseline risk assessment, multivariate Cox models were designed 
for prediction of mortality and reinfarction after discharge. The Cox assumption of 
proportionality was checked in the data as described previously [27]. Ninety five percent 
confidence intervals for the relative risk of an indicator variable Xi was calculated as the 
natural antilogarithm of the Cox regression coefficient of Xi ± 1.96 x standard error of 
xi. 
TABLE VI - Determinants of one year mortality in the rt-P Nplacebo trial, that were 
used in the baseline risk assessment of both trials (see methods section and Appendix). 
Determinant Mortality Relative risk 
N= within 
first year 
(%) Crude 
History of previous myocardial infarction 
no 668 6.3 
yes 53 22.6 3.87 
Age (y) 
<60 
:?:60 
SumST 
<2.0 mV 
:?:2.0mV 
missing 
412 
309 
500 
189 
32 
3.9 
12.3 
5.8 
12.2 
6.3 
Anterior infarct localization 
no 446 5.8 
yes 275 10.2 
Gender 
male 
female 
617 
104 
Treatment allocation 
placebo 366 
rt-PA 355 
See legend of table IV. 
6.5 
13.5 
9.3 
5.6 
3.18 
1.97 
1.73 
2.10 
0.64 
REFERENCES 
Adjusted (95% CI) 
4.03 (2.16 to 7.52) 
3.26 (1.86 to 5.73) 
2.20 (1.28 to 3.78) 
1.87 (1.11 to 3.15) 
1.78 (0.98 to 3.23) 
0.64 (0.37 to 1.08) 
1. Van de Werf F, Arnold AER, for the European Cooperative Study Group: Intravenous tissue 
plasminogen activator and size of infarct, left ventricular function, and survival in acute 
myocardial infarction. Br Med J 1988,297,1374-1379. 
106 
2. Simoons ML, Arnold AER, Betriu A, et al: Thrombolysis with tissue plasminogen activator in 
acute myocardial infarction: no additional benefit from immediate percutaneous coronary 
angioplasty. Lancet 1988;1:197-203. 
3. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assos 
1958;53:457-481. 
4. Kalbfleisch JD, Prentice RL: The Statistical analysis of failure time data. New York: John Wiley 
& sons, 1980:32-33. 
5. Miettinen OS: Theoretical Epidemiology: Principles of Occurrence Research in Medicine. New 
York: John Wiley & Sons, 1985:235. 
6. SchrOder R, Neuhaus KL, Leizorovicz A, et al: A prospective placebo-controlled double-blind 
multicenter trial of intravenous streptokinase in acute myocardial infarction (IS AM): Long-term 
mortality and morbidity. JAm Coli Cardiol 1987;9:197-203. 
7. Gruppo Italiano per lo studio della streptochinasi nell'infarto miocardico (GISSI): Long-term 
effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI 
study. Lancet 1987;1:871-874. 
8. AlMS trial study group: Long-term effects of intravenous anistreplase in acute myocardial 
infarction: final report of the AlMS study. Lancet 1990; 335: 427-31. 
9. Wilcox RG, von der Lippe G, Olsson CG, et al: Effects of alteplase in acute myocardial 
infarction, 6 month results from the Asset study. Lancet 1990;335: 175-178. 
10. Simoons ML, Vos J, Tijssen JGP et al: Long term benefit of early thrombolytic therapy in 
patients with acute myocardial infarction. JAm Col Cardiol 1989;14:1609-1615. 
11. ISIS-2 Collaborative Group: Randomised trial of intravenous streptokinase, oral aspirin, both or 
neither among 17.187 cases of suspected acute myocardial infarction. Lancet 1988;ii:349-360. 
12. MacMahon S, Collins R, Knight C et al: Reduction in major morbidity and mortality by heparin 
in acute myocardial infarction. Circulation 1988; 78: II-98. 
13. Vermeer F, Simoons ML, Zwaan C de, et al: Cost benefit analysis of early thrombolytic 
treatment with intracoronary streptokinase. Twelve month follow up report of the randomised 
multicentre trial conducted by the Interuniversity Cardiology Institute of The Netherlands. Br 
Heart J 1988;59:527-534. 
14. Kennedy JW, Ritchie JL, Davis KB et al: The Western Washington randomized trial of 
intracoronary streptokinase in acute myocardial infarction: a 12 month follow-up report N Engl 
J Med 1985; 321:1073-1078. 
15. Wilcox RG, von der Lippe, Olsson CG, Jensen G, Skene AM, Hampton JR for the ASSET study 
group: Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction 
(ASSET). Lancet 1988;ii:525-530. 
16. Dalen JE, Gore JM, Braunwald E et al: Six and twelve month follow-up of the phase I 
thrombolysis in myocardial infarction (TIMI) trial Am J Cardiol 1988;62:179-185. 
17. Topol EJ, Califf RM, George BS, et al: and the TAMI Study Group. A randomized trial of 
immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in 
acute myocardial infarction. N Engl J Med 1987;317:581-588. 
18. The TIMI Research Group: Immediate vs delayed catheterization and angioplasty following 
thrombolytic therapy for acute myocardial infarction. JAMA 1988;260:2849-2858. 
19. The TIMI Research Group: Comparison of invasive and conservative strategies after treatment 
with intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 
1989;320:618-627. 
20. Stadius ML, Davis K, Maynard C: Risk stratification for 1 year survival based on characteristics 
identified in the early hours of acute myocardial infarction. Circulation 1986;74:703-711. 
21. Multicenter Postinfarction Research Group: Risk stratification after myocardial infarction. N Engl 
J Med 1983:50:266-272. 
107 
22. Fioretti P, Brower RW, Simoons ML, et al: Relative value of clinical variables, bicycle 
ergometry, reset radionuclide ventriculography and 24 hour ambulatory electrocardiographic 
monitoring at discharge to predict 1 year survival after myocardial infarction. J Am Coli Cardiol 
1986;8:40-49. 
23. Mathey DG, Schofer J, Sheehan FH, et al: Improved Survival up to four years after early 
coronary thrombolysis. Am J Cardiol 1988;61:524-529. 
24. Erbel R, Pop T, Henrichs K-J, et al: Percutaneous transluminal coronary angioplasty after 
thrombolytic therapy: A prospective controlled randomized trial. JAm Coli Cardioll986;8:485--
495. 
25. O'Neill WW, Timmis GC, Bourdillon PD, et al: A prospective randomized clinical trial of 
intracoronary streptokinase versus coronary angioplasty for acute myocardial infarction. N Engl 
J Med 1986;314:812-818. 
26. Vermeer F, Simoons ML, BarF, et al: Which patients benefit most from early thrombolytic 
therapy with intracoronary streptokinase. Cirulation 1986; 74:1379-1389. 
27. Christensen E: Multivariate survival analysis using Cox's regression model. Hepatology 
1987;7: 1346-1358. 

CHAPTER 7 
EXPECTED INFARCT SIZE WITHOUT THROMBOLYSIS 
A CONCEPT THAT HELPS TO SELECT PATIENTS WITH EVOLVING 
MYOCARDIAL INFARCTION FOR THROMBOLYTIC THERAPY 
Alfred E.R. Arnold, MD [* ,!], 
for the European Cooperative Study Group 
Peter De Jaegere, MD [!], 
Rolf Schroder, MD[&], Thomas Briiggemann, PhD[&], 
for the Intravenous Streptokinase in Acute Myocardial Infarction (ISAM) Study Group 
Maarten L. Simoons, MD, [!], 
for the Working Group in Thrombolytic Therapy in Acute Myocardial Infarction of the 
Interuniversity Cardiology Institute of the Netherlands 
Jacobus Lubsen, MD, [*,!]. 
From the Center of Clinical Decision Analysis [*] and Thoraxcenter [!], Erasmus 
University, Rotterdam, The Netherlands; from the Division of Cardiology [&], 
University of Berlin, West-Germany. 
110 
SUMMARY 
Benefits and risks of thrombolytic therapy should be carefully considered in each 
patient. Benefits of thrombolysis differ from patient to patient. Risk factors for intracran-
ial bleeding were recently reported. Benefits of thrombolysis might be best predicted by 
an estimate of infarct size if no thrombolytic therapy would have been given. This was 
studied in the present analysis. Enzymatic infarct size was predicted from the clinical 
state and the admission electrocardiogram in 1088 patients of the European Cooperative 
Study Group by multivariate regression analysis. This multivariate prediction function 
was used to predict the "expected infarct size without thrombolytic treatment" in 2274 
patients of the ISAM study and the Intracoronary Streptokinase trial of the 
Interuniversity Cardiology Institute of The Netherlands. This parameter was found to 
correlate well with the measured infarct size in these trials. Infarct size limitation by 
thrombolytic therapy was greater in patients with a large "expected infarct size without 
thrombolysis" and if treated early. Mortality in untreated patients with a small "expected 
infarct size without thrombolysis" was low (4.0%) at one year. Patients with a small 
"expected infarct size without thrombolysis" and with increased risk of intracranial 
bleeding such as patients using coumarins and with low body weight will not benefit of 
thrombolytic therapy. 
INTRODUCTION 
Limitation of infarct size, preservation of left ventricular function and reduction 
of mortality have been demonstrated for all currently available thrombolytic agents [1-6]. 
Benefits of thrombolytic therapy are greater in patients with extensive ST-segment 
elevation on admission and in patients with anterior infarction, if treated early after onset 
of symptoms [1,2,7]. On the other hand, risk of intracranial bleeding was reported to be 
related to advanced age, use of coumarin, and low body weight [8]. For each individual 
patient benefits and risks of thrombolytic therapy should be carefully considered. Most 
patients with evolving myocardial infarction will benefit from thrombolytic therapy, but 
in some subsets of patients with good infarct related prognosis, an increased risk of 
intracranial bleeding may exceed the benefits from thrombolytic therapy. It is therefore 
crucial to identify patient characteristics which determine the infarct related prognosis 
for an individual patient, the benefit of thrombolytic therapy and the risk of intracranial 
bleeding. 
In this analysis the concept of predicted infarct size in patients not treated with 
thrombolytic therapy (labelled "expected infarct size without thrombolysis") was used 
as a determinant of risk. Theoretically, this concept has the advantage to be directly 
related to the way by which thrombolysis improves clinical outcome, i.e. infarct size 
limitation. 
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The following questions were addressed: 
1. Is it possible to predict infarct size on hospital admission using simple demo-
graphic, historical, hemodynamic and electrocardiographic criteria? 
2. Is "expected infarct size without thrombolysis" a useful composite determinant 
of the risk profile in individual patients with acute myocardial infarction? 
3. Does the concept "expected infarct size without thrombolysis" integrates those 
determinants of prognosis that can be modified by thrombolytic therapy? 
4. Does "expected infarct size without thrombolysis" help to identify patients in 
whom the risk of intracranial bleeding outweigh the benefits of thrombolysis? 
DESIGN AND METHODS 
Data were analyzed of 3362 patients entered in the four major clinical trials 
which assessed enzymatic infarct size: the rt-PNplacebo and rt-PNPTCA trial of the 
European Cooperative Study Group (ECSG) [6,9], the Intracoronary Streptokinase Trial 
of the Interuniversity Cardiology Institute of the Netherlands (ICIN) [5,7,10] and the 
Intravenous Streptokinase in Acute Myocardial Infarction Trial (ISAM) [11,12]. 
Study design 
The essentials of trial design, patient selection, setting and main results 
are summarized in table I. Patients with chest pain suggesting myocardial ischemia were 
considered for inclusion when electrocardiographic ST-segment elevation was present 
on admission. Atrial fibrillation was an exclusion criterium in the ISAM trial, but not 
in the others. Previous infarction was no reason for exclusion in either trial, although in 
the trials of the European Cooperative Study Group patients with a previous myocardial 
infarction at the same site and patients with previous coronary artery bypass surgery 
were excluded. Patients with heart failure or shock were not excluded. In addition to 
thrombolytic therapy with streptokinase or rt-PA, patients received aspirin as well as 
heparin intravenously and/or coumarins until hospital discharge. The controls in the 
ICIN trial did not receive aspirin. More detailed descriptions of each trial have been 
published previously [5,6,7,9-12]. 
Electrocardiographic analysis 
Electrocardiograms obtained before start of trial medication were assessed. Infarct 
location was determined on the basis of the admission ECG by core laboratories for 
Central ECG reading. ST-segment was measured at J-point. QRS width was measured 
in all trials except in the ICIN trial. Further details of ECG readings are published 
elsewhere [7,13]. 
TABLE I- Study design and main results of the various ttials. 
...... 
...... 
N 
rt-PA/Placebo rt-PA/PTCA ICIN ISAM 
Plac rt-PA rt-PA PTCA Control SK-IC Plac SK-IV 
N=366 N=355 N=l84 N=183 N=264 N=269 N=882 N=859 
Entry criteria: 
age (yrs) <71 <71 <71 5:75 
ST-segment 60msec after J-point idem at J-point at J-point 
elevation ;:::2 x 0.2 mV in limb idem ;:::1 x 0.1 mV in limb ;:::0.1 mV in limb leads 
leads or V5-V6 ;::;I x 0.2 mV in Vl-V6 ;:::0.2 mV in Vl-V6 
;:::2 x 0.3 mV in Vl-V4 
depression ;:::2 x 0.2 mV in V-V4 ;::;I x 0.2 mV in Vl-V4 
+ ;:::2 x 0.1 m V ST- compatible with 
elevation in II, III, postedor infarction 
aVF, V5-V6 
treatment delay start of treatment start of treatment admitted to CCU <4 start of treatment 
<5 hrs after onset <5 hrs after onset hrs after onset <6 hrs after onset 
Setting: 26 European centers 10 European centers 5 centers in 38 West-German, Swiss, 
The Netherlands and Canadian centers 
Initial treatment: 
heparin bolus 5000U 5000U 5000U 5000U 5000U 5000U 5000U 5000U 
infusion 1000 U/hr 1000 U/hr 1000 U/hr 1000 U/hr aPTT2x aPTT2x aPTT 2-3x aPTT 2-3x 
aspirin 250mg 250mg 250mg 250mg 250mg 500mg 500mg 
thrombolytic agent placebo alteplase alteplase alteplase SK-IV# placebo SK-IV 
(dosage) (IOO mg) (100 mg) (100 mg) (0.5xi06IU) (1.5xl06 IU) 
+PTCA + SK-IC 
(0.25x106IU) 
Late treatment: 
coumarins until discharge until discharge until discharge until 3 weeks 
unless indicated unless indicated unless indicated unless indicated 
aspirin until discharge until discharge 
75 to 125 mg/2days 75 to I25 mg/2days 
Outcome: 
infarct size -20% 0% -30% -9% 
LVEF 49% 51% 51% 51% 47% 53% 54% 57% 
mortality at 1 year 9.3% 5.6% 5.4% 9.3% 16.3% 9.7% 11.2% Il.l% 
#: in the last 117 patients. Plac: placebo. SK-IC: intracoronary streptokinase LVEF: left ventricular ejection fraction. SK-IV:intravenous streptokinase. 
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Infarct size assessment 
Cumulative myocardial enzyme release served as a measure for infarct size. In 
the European Cooperative trials and the ICIN trial the cumulative release 
of alpha hydroxy butyric acid (HBDH) was assessed. In the ISAM trial enzymatic infarct 
size was assessed as cumulative release of creatine kinase (CK-MB fraction). Blood 
samples, taken at regular intervals (12 hours for HBDH, 4 hours for CK-MB), were sent 
to the core laboratories. Details of the methodology have been reported previously 
[5,6,14]. In patients for whom no infarct size determination was available (e.g. due to 
early death) the enzymatic infarct size was estimated by linear regression analysis as 
described below. HBDH plasma levels in the ICIN trial were divided by 1.34 in order 
to compensate for different assay conditions, compared with the European Cooperative 
trials [14]. 
DATA ANALYSIS 
Prediction of enzymatic infarct size 
For each trial separately, enzymatic infarct size was predicted by linear 
regression analysis using parameters available immediately after onset of symptoms and 
known to be related to infarct size or limitation of infarct size by thrombolytic therapy. 
The following parameters were considered: sum of ST-segment elevation and depression 
on the admission ECG [15], QRS width exceeding 0.12 sec [2], anterior infarct 
localization [1-4], clinical state before treatment [16,17], history of previous infarction 
[1-4], age [1-4], female gender [2] and delay from onset symptoms to treatment 
allocation [1-4]. Medians and 50% ranges of enzymatic infarct size were determined in 
various categories of above variables. Continuous variables were subdivided into three 
or four subgroups of approximately equal size. Subsequently, variables associated with 
enzymatic infarct size were entered in a multivariate linear regression model. For each 
category, except for the reference category, an indicator variable was used with value 
one in case the patient belonged to that category and zero if not. To assess the treatment 
effect in certain subsets of patients, interaction terms were constructed of the indicator 
variable for a certain characteristic and treatment strategy. Variables were entered in a 
stepwise regression model if the F statistic to enter was more than 4 and removed if the 
F to remove was less than 4. In the final model, optimized on the basis of medical 
plausibility, indicator variables for treatment strategy and missing data were forced to 
enter the model. Also, indicator variables for characteristics were forced into the model 
in case their interaction terms with treatment strategy was entered. 
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Calculation of "expected infarct size without thrombolysis" in individual patients 
The multivariate linear regression model for enzymatic infarct size developed in 
the trials of the European Cooperative Study Group (table II) was used to calculate 
"expected infarct size without thrombolysis" for every individual patient in all trials, by 
setting the indicator variables for treatment to values indicative for placebo infusion. For 
example the expected infarct size without thrombolysis for a patient with anterior infarct 
location, 12 mm ST-segment elevation (1.2 mV), narrow QRS complex, no signs of 
heart failure and 1 hour treatment delay is: 495 + 233 + 308 = 1036 U/1 (table II). 
Because QRS-complex width measurement was not available in the ICIN trial, the 
calculation of the "expected infarct size without thrombolysis" was performed using a 
slightly different model derived from the European Cooperative Studies, in whicl;l that 
measurement was omitted. 
Prognostic implications of "expected infarct size without thrombolysis" 
The value of this risk estimate to separate patients with small and large 
infarctions was assessed in the patient populations of the ICIN and !SAM trial by 
plotting the median and 50% range of measured enzymatic infarct size for various 
categories of "expected infarct size without thrombolysis" (figure 1). In addition, the 
prognostic implications of "expected infarct size without thrombolysis" for one year 
mortality were evaluated Cumulative one year mortality is reported for patients with 
small and extensive "expected infarct size without thrombolysis". To exclude 
confounding by treatment delay, patient subsets with early and late treatment are 
reported separately. Subsequently, a multivariate logistic regression model for the 
prediction of one year mortality was developed using similar methods as described for 
the prediction of enzymatic infarct size. Determinants of mortality were identified 
univariately by assessing one year mortality in subgroups of patients and subsequently 
by multivariate logistic regression analysis. In the stepwise regression analysis variables 
were entered when the p-value associated with entry of that variable was less than 0.10 
and removed if the p-value associated with removal was greater than 0.15. Adjusted rate 
ratios and 95% confidence intervals in table VI were obtained from the logistic 
regression equation according to Miettinen [18]. 
Probabilities of death during the first year for a range of values of "expected infarct size 
without thrombolysis" for a patient given a certain combination of other risk factors (Xi) 
were calculated from a logistic regression function, in which "expected infarct size 
without thrombolysis" was entered as continuous variable (figure 4): 
P=l/[1+exp-(a+bl X xl + bz X Xz ..... )]. 
The characters bi represent the logistic regression coefficients. In addition, 95% 
confidence intervals were calculated [19]. 
TABLE II- Determinants of enzymatic infarct size in 1088 patients of the rt-PA/placebo and rt-PA/PTCA trial. 
Number of pts Enzymatic infarct size (median, 50% range HBDH U/1)& Linear regression analysis@ 
Plac rt-PA rt-PA PTCA rt-P A/Placebo rt-PA/PTCA All pts Additional for: 
N= N= N= N= trial trial N=1061 rt-PA PTCA 
366 355 184 183 Plac rt-PA rt-PA PTCA 
Intercept 495 
SumST (mV) 
-207 (84) 1 (50) 
<0.6 32 31 19 21 569(244,1031) 527(272,801) 370(105,565) 413(305,654) 
0.6-1.2 110 105 62 56 727(458,968) 581(406,859) 451(205,784) 537 (256, 777) 140 ( 63) 
1.2-2.0 104 118 58 57 913(563,1229) 800(514,1164) 697(389,1005) 867(474,1256) 308 ( 63) 
-126 (78>* ;;::2,0 107 82 45 48 1215(845,1502) 940( 685' 1328) 1113(716,1690) 1132(753,1651) 618 ( 68) 
missing 13 19 1 
QRS exceeding 0.12 sec 
no 334 329 183 176 894(521,1243) 694( 455, 1077) 670(355,1062) 721(384,1145) 
yes 19 9 1 7 1312(627,2084) 1546(653,1849) 482 1126(620,2101) 273 ( 97) 
missing 13 17 
Anterior infarct localization 
no 236 210 101 98 841(503,1195) 664(439,948) 572(304,899) 591(364,888) 
yes 130 145 83 85 946(627,1395) 839(491,1343) 818(373, 1393) 1007(503,1450) 233 (35) 
Killip 3 or 4 
no 349 344 183 176 867(531,1262) 687(447,1074) 670(358,1062) 697(384,1134) 
yes 17 11 1 7 1262(765,1632) 1287(989,1598) 304 1374(1137,1891) 334 (103) 
Treatment delay (hrs)# 
966(511,1318) <2 69 61 51 43 661(367,1019) 451(161,677) 692(377' 1137) 
115 (91) * 2-3 139 121 68 56 790(499,1294) 751(468,1196) 801 (381' 1206) 621(444,1057) 47 (76) 
;;::3 158 173 65 84 900(583, 1242) 705(512,1017) 716(475,1149) 842(372, 1333) 
#:for 8 patients in the rt-PA/Placebo trial, who received no treatment, time of treatment was substituted by time to allocation.&: missing values 
were imputed by estimates obtained by linear regression analysis without product terms for treatment to avoid induction of differences in treatment 
effect in various strata;@: coefficients (standard error in parentheses) represent difference in enzymatic infarct size between patients with the 
characteristic and patients without, conditional on the other vriables in the model. Enzymatic infarct size for each patient is determined by adding up 
intercept and coefficients of all relevant indicator variables. *:additional treatment effect for patients with ;;::2.0 mV ST-elevation and/or 2 hrs ...... 
...... treatment delay U1 
TABLE III- Determinants of enzymatic infarct size in 533 patients of the ICIN trial. 
Number Enzymatic infarct size Linear regression analysis 
ofpts (median, 50% range HBDH U/l) 
Control SK-IC Control SK-IC All pts Additonal for 
N=264 N=269 N=448 SK-IC 
Intercept 552 -348 (102) 
SumST (mV) 
<0.6 28 23 567 (413, 831) 380 (187, 512) 
0.6-1.2 68 93 647 (378, 959) 455 (290, 724) 91 ( 85) 
1.2-2.0 84 79 891 (643,1237) 654 (390, 813) 300 ( 85) 
~2.0 63 50 1264 (870, 1501) 910 (540,1271) 627 (105) -190 (116) 
missing 21 24 
Anterior infarct localization 
no 148 139 724 (432,1170) 497 (334,791) 
yes 116 130 954 (641,1271) 617 (466,993) 158 (49) 
Killip 3 or 4 
no 253 257 806 ( 497,1202) 590 (372, 861) 
yes 11 12 1287 (1129,1745) 1075 (577,1318) 511 (142) 
Treatment delay (hrs)& 
<2 73 64 853 (584,1199) 445 (207,660) 
2-3 110 99 804 (476,1202) 599 (369,907) -24 (77) 240 (113) 
~3 81 106 815 (522,1279) 690 (456,962) 
See legend of table II.&: Treatment delay is time to admission on the coronary care unit (zero for in-hospital patients) 
plus 1 hour, since intracoronary streptokinase started 60 minutes later. 
....... 
....... 
0'1 
TABLE IV- Determinants of enzymatic infarct size in 1741 patients of the ISAM trial. 
Number Enzymatic infarct size Linear regression analysis 
of patients (median, SO% range CK-MB U/1) 
Placebo SK-IV Placebo SK-IV All pts Additonal 
N=882 N=859 N=1434 for SK-IV 
Intercept 1222 -484 (150) 
Sum ST (mV) 
<0.6 222 194 990 ( 452,1416) 1033 ( 492,1343) 
0.6-1.2 277 285 1543 ( 996,2104) 1394 ( 700,1948) 505 ( 83) 
1.2-2.0 179 190 2014 (1238,2749) 1842 (1213,2481) 1045 (116) -118 (135) 
:2::2.0 119 117 2199 (1612,2732) 2062 (1242,2793) 1230 (126) 
BBB 47 42 2920 (1859,3230) 2701 (1330,4334) 1673 (159) 
missing 38 31 
Anterior infarct localization 
no 448 465 1337 ( 785,2052) 1316 ( 715,2018) 
yes 434 394 1917 (1029,2560) 1664 ( 855,2370) 
Heart failure 
no 692 676 1495 ( 843,2204) 1390 ( 745,2117) 
yes 190 183 2023 (1300,2972) 1673 ( 840,2514) 307 ( 79) 
Treatment delay (hrs) 
<2 166 163 1967 ( 831,2714) 1242 ( 434,1957) 
2-3 245 260 1619 ( 891,2402) 1400 ( 770,2297) -214 (131) 357 (182) 
:2::3 458 419 1495 ( 870,2145) 1538 ( 897,2238) -249 (120) 563 (168) 
missing 13 17 
....... 
....... 
See legend of table II. BBB: Bundle branch block. -.J 
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Figure 1. Median and 50% range of enzymatic infarct size in various categories of 
"expected infarct size without thrombolysis" in the rt-PNplacebo trial of the European 
Cooperative Study Group, in the ICIN and in the ISAM trial, for the thrombolysis and 
control groups separately. 
"Expected infarct size without thrombolysis" and limitation of infarct size by 
thrombolytic therapy 
Benefit of thrombolytic therapy was assessed in terms of enzymatic infarct size 
in various categories of "expected infarct size without thrombolysis". Median and 50% 
range of actually measured enzymatic enzyme release were compared in patients treated 
with thrombolysis and controls in various categories of "expected infarct size without 
thrombolysis" (figure 1). 
"Expected infarct size without thrombolysis" and limitation of mortality by 
thrombolytic therapy 
One year mortality in patient subsets in the control groups was plotted in a 
scattergram against one year mortality of patients treated with thrombolytic therapy, 
stratified for the "expected infarct size without thrombolysis" and treatment delay (figure 
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2). A linear regression line, weighed for subgroup size [20], was drawn to relate 
"expected infarct size without thrombolysis" to the limitation of mortality with 
thrombolytic therapy within 3 hours and after 3 hours after onset of symptoms. Kaplan 
Meier survival plots were used to study survival of patients in different categories of 
"expected infarct size without thrombolysis" in time [21] (figure 3). 
RESULTS 
Prediction of enzymatic infarct size in each trial 
The sum of ST-segment elevation, Killip class and QRS width were strongly 
related to enzymatic infarct size in all trials (tables II to IV). In the European 
Cooperative trials and the ICIN study anterior infarct location was associated with larger 
enzymatic infarct size than inferior infarct location, irrespective of the amount of 
ST -segment elevation. The contributions of each determinant of enzymatic infarct size 
were very similar in the trials assessing enzymatic infarct size with HBDH (table II and 
Im. In the ISAM trial the contributions of the predictors of enzymatic infarct size 
cannot be compared directly to those in the other trials since enzymatic infarct size was 
assessed with cumulative CK-MB release. Nevertheless, the relative contribution of each 
determinant of infarct size was similar to those in the other trials. 
Calculation of "expected infarct size without thrombolysis" in individual patients 
In figure 1 the medians and 50% ranges of the actually measured enzymatic 
infarct size are depicted for various categories of "expected infarct size without 
thrombolysis". The enzymatic infarct size prediction model developed in the trials of the 
European Cooperative Study Group was successful in separating patients with small 
infarctions from those with large infarctions in the ICIN and ISAM trials. 
Prognostic value of "expected infarct size without thrombolysis" 
"Expected infarct size without thrombolysis" as predicted with the linear 
regression model obtained in the European Cooperative trials from the admission 
electrocardiogram and clinical status was highly predictive for mortality (table V). As 
is apparent from figure 2, patients with a small "expected infarct size without 
thrombolysis" (open symbols) are in the low mortality range and had about 5% one year 
mortality without thrombolytic therapy in the rt-PNplacebo trial and ISAM trial and 
approximately 10% in the ICIN trial. Patients with a large "expected infarct without 
thrombolysis" (closed symbols) had high mortality without thrombolytic therapy. In 
figure 3 survival during the first 2 years of follow up is depicted for patients below 60 
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years and 60 years and older, stratified for "expected infarct size without thrombolysis". 
In the elderly group overall mortality was higher than in among young patients. 
Thrombolytic therapy yielded little benefit, if any, in patients with small "expected 
infarct size without thrombolysis". 
The results of the multivariate analysis are presented in table VI. As expected, age and 
previous infarction were important other determinants of mortality. Female gender was 
also associated with higher risk. Infarct localization was not predictive for one year 
mortality, when "expected infarct size without thrombolysis" was included in the model. 
In figure 4 the probabilities of one year mortality are given for a range of values of 
"expected infarct size without thrombolysis" for a young male patient without risk any 
other risk factor, for an similar elderly male and for an elderly male patient with all risk 
factors. 
The observed mortality among patients with a "expected infarct size without 
thrombolytic therapy" below 800 U/1 and without any risk factor (table VI) and not 
treated with thrombolytic therapy was 6 out 247 at 5 weeks (2.4%, 95% confidence 
interval 0.5 to 4.3) and 4.0% (95% confidence interval 1.6 to 6.5) at one year. 
"Expected infarct size without thrombolysis" and limitation of infarct size by 
thrombolytic therapy 
Limitation of infarct size was greatest in patients with extensive ST-segment 
elevation in all trials (table II to IV). Limitation of infarct size by thrombolytic therapy 
was clearly related to treatment delay in the ISAM study (table IV), but was only 
marginally related to treatment delay in the European Cooperative study and the ICIN 
study (table II and III). Limitation of infarct size was proportional to the expected infarct 
size without thrombolysis (figure 1). 
"Expected infarct size without thrombolysis" and limitation of mortality by 
thrombolytic therapy 
Limitation of mortality by thrombolytic therapy is depicted in figure 2. The thick 
dashed line represents the line of identity or "no treatment effect". Patient subsets below 
the line of "no treatment effect" benefited from the treatment. Patient subsets with a 
small"expected infarct size without thrombolysis" were scattered around the line of "no 
treatment effect" and thus had little or no benefit of thrombolytic effect. Patient subsets 
with large "expected infarct size without thrombolysis" benefitted clearly from 
thrombolysis in the European Cooperative and the ICIN studies. The thin dotted lines 
in figure 2 represent linear regression lines, weighed for subgroup size, for early (within 
hours) or late (3 hours or later) treatment. Treatment effect is greatest if thrombolysis 
is started early and gain is largest in high risk patients. Since the regression lines cross 
the line of "no treatment effect", it is suggested by the model that patients at very low 
risk may be harmed by thrombolysis. 
According to figure 3, in both age categories, patients with a small "expected infarct size 
without thrombolysis" had little or no benefit of thrombolytic therapy, although in the 
...... 
N 
N 
TABLE V - One year mortality (%) in various categories of "expected infarct size without thrombolysis" stratified for treatment delay. 
rt-P A/Placebo rt-PA/PTCA ICIN ISAM 
Plac rt-PA rt-PA PTCA Control SK-IC Plac SK-IV 
N=366 N=355 N=184 N=183 N=264 N=269 N=882 N=859 
Expected Treatment 
infarct delay 
size (U/1) 
<1000 <3 hrs 5 ( 6/111) 3 ( 3/97) 4 (3/81) 7 (4/57) 10 (11/114) 6(7/111) 6 (15/246) 6 (16/259) 
:?:3 hrs 4 ( 4/100) 6 ( 7/120) 5 (2/37) 6 (3/50) 13(7/55) 10(7/74) 8 (25/311) 7 (20/279) 
missing ( 1/ 8) ( 2/ 10) 
all 5 (10/211) 5 (10/217) 4 (5/118) 7 (7/107) 11 (18/169) 8 (14/185) 7 (41/565) 7 (38/548) 
:?:1000 <3 hrs 14 (14/ 97) 5 ( 4/ 85) 5 (2/38) 17 (7/42) 26 (18/ 69) 12 ( 6/ 52) 18 (30/165) 17 (28/164) 
:?:3 hrs 17 (10/ 58) 11 ( 6/ 53) 11 (3/28) 9 (3/34) 27 ( 7/ 26) 19 ( 6/ 32) 18 (26/147) 19 (26/140) 
missing ( 2/ 5) ( 3/ 7) 
all 16 (24/155) 7 (10/138) 8 (5/66) 13 oon6) 26 (25/95) 14 (12/84) 18 (58/317) 18 (57/311) 
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elderly group, mortality in the second year tended to be lower in patients treated with 
thrombolysis. In patients with extensive "expected infarct size without thrombolysis" the 
benefit of thrombolytic therapy was evident in both age groups, but more pronounced 
in the elderly. The same results were obtained when the analysis was repeated in each 
trial separately. Even in the ISAM trial, without overall mortality reduction, the subset 
of elderly patients with large "expected infarction without thrombolysis" benefited from 
thrombolytic therapy. 
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Figure 2. One year mortality for two categories of "expected infarct size without 
thrombolysis" stratified for treatment delay for the trial of the European Cooperative 
Study Group, ICIN and ISAM trials. The thick dashed line represent the line of "no 
treatment effect"; the thin lines are the weighed regression lines for early and late 
treatment. 
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TABLE VI - Determinants of one year mortality in all trials combined#. 
% One year mortality 
Risk ratio 
N=3179 
Expected infarct size without thrombolysis (U/1) 
<800 6 ( 63/1131) 
800-1000 8 ( 73/ 882) 1.49 (1.08,2.05) 
1000-1200 14 ( 90/ 641) 2.52 (1.87,3.39) 
~1200 19 (1011 525) 3.45 (2.61,4.57) 
Killip 3 or 4 
no 8 (224/2754) -
yes 24 (103/ 425) 2.98 (2.41,3.68) 
Age (yrs) 
<60 7 (117 /1795) -
~60 15 (210/1384) 2.33 (1.89,2.87) 
Previous infarction 
no 9 (237 /2790) -
yes 23 ( 90/ 389) 2.72 (2.19,3.40) 
QRS >0.12 sec 
no 9 (217/2498) -
yes 33 ( 39/ 118) 3.81 (2.82,5.14) 
missing 13 ( 71( 563) 
Female 
no 
yes 
Constant 
10 (252/2640) -
14 ( 75/ 539) 1.46 (1.14,1.86) 
Logistic regression analysis 
Adjusted risk 
ratio# (95% CI) 
1.33 (0.93,1.89) 
2.30 (1.64,3.21) 
2.45 (1.71,3.51) 
2.02 (1.50,2.72) 
2.10 (1.65,2.65) 
2.68 (2.06,3.49) 
2.83 (1.92,4.17) 
1.33 (1.01,1.76) 
Coefficient 
(SE) 
0.30 (0.19) 
0.90 (0.19) 
0.98 (0.20) 
0.78 (0.17) 
0.80 (0.13) 
1.11 (0.15) 
1.19 (0.23) 
0.31 (0.15) 
-3.58 (0.29) 
#: Patients allocated to immediate PTCA were excluded because of an excess of, PTCA related, 
mortality). Indicator variables for treatment delay and their interaction terms with treatment delay are 
ommitted from the table. The reference categories refer to a patient treated with aspirin and heparin, but 
without thrombolytic therapy in the rt-PNplacebo trial. CI: confidence interval; #: adjusted risk ratio 
calculated according to Miettinen [18]. 
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DISCUSSION 
Subgroup analyses have been reported for nearly all major thrombolysis trials. 
This illustrates the interest of investigators to identify subsets of patients who benefit 
most of thrombolytic therapy. Nevertheless, precise indications of thrombolytic therapy, 
especially regarding the required ST-segment elevation on admission, infarct location, 
advanced age and maximal treatment delay and indicators of increased risk of 
thrombolytic therapy remain uncertain [22]. "Expected infarct size without 
thrombolysis", which may seem a complicated parameter on first sight, provide~ an 
estimate of infarct size for a patient who is treated with aspirin and heparin but without 
thrombolytic therapy (assessment of "expected infarct size without thrombolysis" is 
based on the trials of the European Cooperative Study Group in which all patients were 
treated with aspirin and heparin). It was found to be an important determinant of 
prognosis and it predicts the benefit of thrombolysis in terms of infarct size limitation 
and mortality reduction. 
Prediction of enzymatic infarct size in each trial 
The sum of ST -segment elevation contributed most to the prediction of enzymatic 
infarct size (table II to IV). Furthermore, QRS widening was an important determinant 
of infarct size, independent of ST-segment elevation. This was mainly due to right 
bundle branch block since patients with complete left bundle branch block were 
excluded. The contribution of QRS widening to enzymatic infarct size in the ISAM trial 
was larger than in the trials of the European Cooperative Study Group, mainly because 
ST-segment elevation was not assessed in ISAM, when QRS-widening was present. 
Prognostic value of "expected infarct size without thrombolysis" 
In the present analysis survival after myocardial infarction was found to be the 
resultant of patients' pre-existent condition (determined by age, gender and history of 
previous infarction), "expected infarct size without thrombolysis" and treatment effect 
of thrombolytic therapy. 
In a recent article the GISSI investigators related the low mortality and the lack of 
benefit from thrombolytic therapy among patients with inferior infarction to the infarct 
size in terms of the number of electrocardiographic leads with ST -segment elevation. 
Patients with anterior infarction and small area at risk had a similar low mortality [23]. 
This is in agreement with earlier reports [13,24] and with the present study in which 
infarct site did not contribute to the prediction of mortality when the "expected infarct 
size without thrombolysis" was entered in the modeL Heart failure was predictive for 
126 
1 
0) 
c 0.9 
"> 
"> 
!.-. 
:::J 0.8 
en 
c 
0 
"-+=' 0.7 
!.-. 
0 
0.. 
0 
!.-. 0.6 
0.... 
0.5 
1 
0) 
c 0.9 
"> 
"> 
!.-. 
:::J 0.8 
en 
c 
0 
""..j:j 0.7 
!.-. 
0 
0.. 
0 
!.-. 0.6 
0.... 
0.5 
0 
- .. 
618 
543 
319 
315 
------·---~-------
less then 60 years 
-------
.. ----.... ________ .. _______ _ 
586 
515 
289 
276 
365 
342 
347 
143 
169 
730 
Days after myocardial infarction 
60 years or older 
-------.. __ _ 
-.. --- .. -.. ___________ .. 
·-.. 
0 
I 
'... 
.. 
,......_ 
450 
402 
280 
252 
.. _ .. 
~~------- .. ______ _ 
406 
358 
224 
182 
365 
.. _______ ..... _____ ~ 
Days after myocardial infarction 
--... __ 
258 
233 
135 
104 
730 
Figure 3. Survival up to 2 years after myocardial infarction for two age categories, 
stratified for "expected infarct size without thrombolysis". The upper two curves in each 
plot represent patients with "expected infarct size of less than 1000 U/1; solid lines 
represent patients who received thrombolytic therapy, the dashed lines the controls. 
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one year mortality, apart from its effect on "expected infarct size without thrombolysis". 
QRS-complex widening appeared related to mortality after myocardial infarction in 
addition to its contribution to infarct size (table VI). This might be related to life 
threatening arrhythmias, which may occur in patients with acute myocardial infarction 
and bifascicular block [25]. Mortality at 5 weeks among low risk patients in the present 
trial was identical to mortality in control patients with a normal ECG in ISIS-2 [2], 
similar to the 3.0% mortality at 4 weeks among control patients with normal admission 
ECG in the ASSET trial [3] and corresponded well with the 1.5% mortality in a low risk 
group treated with plasminogen activator in TIMI-II [26]. 
"Expected infarct size without thrombolysis" and limitation of infarct size by 
thrombolysis 
Limitation of infarct size tended to be greater in patients with a large "expected 
infarct size without thrombolysis", especially in the ICIN and ISAM trial (figure 1). 
Differences in infarct size between the two treatment groups of the European 
Cooperative study Group in the various categories of "expected infarct size without 
thrombolysis" must be interpreted with caution, since they are imposed by the linear 
regression model for calculation of "expected infarct size without thrombolysis" 
developed in the same patient population. 
"Expected infarct size without thrombolysis" and limitation of mortality by 
thrombolytic therapy 
In figure 2, the regression lines crossed the line of "no treatment effect", 
suggesting the possibility that thrombolysis might harm patients in the low risk region. 
Myocardial infarction extension [27], especially in patients treated later than 3 hours 
after symptoms onset [28], lethal bleeding and complications related to acute 
catheterization in case of intracoronary streptokinase, may contribute. 
No improvement of survival by thrombolytic therapy was observed in patients with a 
small "expected infarct size without thrombolysis" (figure 3). This supports the 
hypothesis that thrombolysis improves outcome by preserving myocardium. This implies 
that strategies which will assist in myocardial salvage, for example by reducing 
reperfusion injury, are likely to confer additional benefits. In elderly patients, there was 
a tendency for better survival in treated patients in the second year of follow up. This 
may be related to better late patency of the infarct related vessel, which was shown to 
result in better survival [10,29,30]. 
Clinical implications of this analysis 
Thrombolytic therapy improves survival in most patients with evolving 
myocardial infarction. However, it is not rational to give thrombolytic therapy to patients 
with suspected acute myocardial infarction in whom mortality reduction by thrombolytic 
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therapy is expected to be less than the excess mortality associated to intracranial 
bleeding. This is likely to be the case in patients with good prognosis without 
thrombolytic therapy and with increased risk of intracranial bleeding. Patients with good 
infarct related prognosis have been identified earlier. In the next paragraph, the 
identification of patients with increased risk for intracranial bleeding is described. 
Estimation of risk of intracranial bleeding in individual patients 
The cumulative incidence of intracranial bleeding after thrombolytic therapy was 
derived from the literature [31] and from a recent registry in The Netherlands [8]. 
Determinants of intracranial bleeding were assessed in a case-referent analysis with 29 
patients with intracranial bleeding in the registry (predominantly intravenous 
streptokinase) and in the trials of the European Cooperative Study Group compared with 
58 controls (table VII). The following patient characteristics were found to be related 
to the occurrence of intracranial bleeding after thrombolytic therapy: body weight under 
70 kg, use of coumarins and age of 65 years or more. The rrrst risk factor may imply 
that the occurrence of intracranial bleeding is dose-related. A relation between dose per 
kg body weight and bleeding was reported for rt-PA and resulted in the recommendation 
of a body weight adjusted rt-PA dose [32]. Similarly a reduced dose of streptokinase 
migh be recommended in patients with a ow body weight, if these observations are 
conrrrmed by careful analysis of other data bases, e.g. ISIS-2. As long as we stick to a 
fixed streptokinase dose and as long as we don't know whether decreasing the dose will 
prevent intracranial bleeding in these patients, we have to consider body weight as a risk 
factor in the selection of patients for thrombolytic therapy. 
The risk of intracranial bleeding for each combination of risk factors was 
calculated from the overall bleeding incidence and likelihood ratio according to Bayes 
rule [31]. The likelihood ratio (probability of a certain risk profile among patients with 
intracranial bleeding divided by the probability of that risk profile in patients without 
intracranial bleeding) for each combination of risk factors was calculated from the 
logistic regression function [31]. 
The trade-off between death due to infarction and due to intracranial bleeding 
Intracranial bleeding after thrombolytic therapy is fatal in about 50% of cases 
[2,3,8]. Most deaths occur in the first weeks after thrombolytic therapy. Although part 
of the surviving patients continue to have neurologic deficits, complete recovery after 
intracranial bleeding due to thrombolytic therapy is possible [6]. For reasons of 
simplicity, we will assume that patients surviving the intracranial bleeding recover 
completely and that, on the other hand, there is no benefit of thrombolytic therapy apart 
from mortality reduction. Thus, both the reduced quality of life after intracranial 
bleeding and the improvement of quality of life in most patients after thrombolytic 
therapy [29,33] are disregarded. 
TABLE VII - Determinants of intracerebral bleeding after thrombolytic therapy for acute myocardial infarction. Main results 
of a case-referent analysis of patients with intracerebral bleeding in the trials of the European Co-operative Study Group and 
a registry The Netherlands in 1988-1990 [8]. 
% of pts with characteristic Logistic regression analysis 
Bleeders Non-bleeders Odds ratio# Adjusted odds Coefficient 
N=29 N=58 (95% Cl) ratio# (95% CI) (SE) 
Body weight (kg) 
<70 55 (16/29) 78 (13/58) 4.26 (1.67,10.85) 4.69 (1.68,13.13) 1.55 (0.53) 
:?.70 45 (13/29) 22 (45/58) 
Use of coumarins 
no 83 (24/29) 95 (55/58) 
yes 17 ( 5/29) 5 ( 3/58) 3.82 (0.91,16.10) 5.93 (1.12,31.29) 1.78 (0.85) 
Age (yrs) 
<65 59 (17/29) 81 (47/58) 
:?.65 41 (12/29) 19 (11/58) 3.03 (1.14,7.99) 2.98 (1.01,8.82) 1.09 (0.55) 
Constant -1.78 (0.41) 
CI: confidence interval. #: odds ratio can be interpreted as risk ratio due to the low incidence of intracerebral bleeding. 
...... 
~ 
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For a 50% mortality reduction by thrombolytic therapy, the net result of 
thrombolytic therapy for a patient is zero if the probability of dying in the first year due 
the myocardial infarction therapy without thrombolytic therapy equals the risk of 
intracranial bleeding (table VIII). For a 25% mortality reduction the net effect of 
thrombolytic therapy is zero if the probability of infarct related dying in the first year 
equals twice the probability ofintracranial bleeding in table Vill. With this simplified 
trade-off it is possible to determine whether a given patient should receive thrombolytic 
therapy, or whether he should not receive thrombolysis and for which patients the 
decision is not clear. 
For example, let us consider a male, less than 60 years old, without previous 
ainfarction, in good clinical condition, with a narrow QRS complex and with 3 mm ST-
segment elevation in leads III and aVF. According to table II the "expected infarct size 
without thrombolysis" is 595 U/1. In figure 4, the probability of death in the first year 
without thrombolytic therapy, but with aspirin and heparin, is 2.5% for a patient with 
an "expected infarct size without thrombolytic therapy" of 600 U/1. If the risk of 
intracranial bleeding would be also 2.5%, e.g. because he uses coumarins and his body 
weight is less than 70 kg (table VIII), this patient would not benefit from thrombolytic 
therapy, if the mortality reduction is expected to be 50%. 
TABLE VID - Probablity of intracranial bleeding for various combinations of risk 
factors for an overall cumulative incidence of intracranial bleeding of 0.5% and 0.9%. 
Risk profile 
age weight cou-
~65 yrs <70 kg marin 
+ 
+ 
+ 
+ + 
+ + 
+ + 
+ + + 
Likeli-
hood 
ratio# 
0.17 
0.50 
0.79 
1.00 
2.35 
2.97 
4.67 
13.94 
Probability@ of 
intracranial bleeding 
for an overall incidence of: 
0.5% 0.9% 
0.1% 0.2% 
0.3% 0.5% 
0.4% 0.7% 
0.5% 0.9% 
1.2% 2.1% 
1.5% 2.6% 
2.3% 4.1% 
6.5% 11.2% 
#: likelihood ratio is the probability of finding the risk profile among patients with intracebral bleeding 
divided by the probability to find the same risk profile among patients without intracerebral bleeding.@: 
calculated from the overall incidence and likelihood ratio with Bayes rule [22]. 
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Expected infarct size without thrombolysis (U/1) 
Figure 4a. Probability of death within the first year as a function of "expected infarct 
size without thrombolysis" according to logistic regression analysis for a patient without 
risk factors for infaract related death and below 60 years old. The dotted lines represent 
the 95% confidence limits. The dashed horizontal lines mark the probability of death 
within the first year without thrombolytic therapy for which the net benefit of 
thrombolytic therapy is zero in patients using coumarins and with low body weight For 
the lower dashed line, 0.5% incidence of intracranial bleeding and 50% mortality 
reduction by thrombolytic therapy is assumed; for the upper dashed line 0.9% incidence 
of intracranial bleeding and 25% mortality reduction. Patients without or with one risk 
factor for bleeding benefited from thrombolysis. 
The dashed horizontal lines in figure 4 represent the infarct related probability 
of death in the first year for which the net result of thrombolytic therapy is zero in a 
patient using coumarins and with low body weight The upper dashed line represents the 
threshold probability for the assumption that the overall incidence of intracranial 
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bleeding is 0.9% and that the mortality reduction by thrombolytic therapy is 25%, the 
lower dashed line for a intracranial bleeding rate of 0.5 and a mortality reduction by 
thrombolytic therapy of 50%. This patient will not benefit from thrombolytic therapy if 
his "expected infarct size without thrombolytic therapy is smaller than the value corres-
ponding to the crossing of the lower dashed and the solid line (450 U/1). For patients 
with an "expected infarct size without thrombolytic therapy" corresponding to values 
between the lower and the upper dashed line benefits are questionable. Patients with 
large "expected infarct size without thrombolysis" (> 1400 U/1, fgure 4a) should be 
treated. 
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Figure 4b. Similar to figure 4a, for a patient of 65 years or older. 
Conclusion 
"Expected infarct size without thrombolysis" is a concept that has the 
advantage of being directly related to the pathophysiologic mechanism by which 
thrombolysis exerts its beneficial effect, i.e. limitation of infarct size. It can be assessed 
on hospital admission using readily available criteria. It helps to separate high risk from 
low risk patients, it predicts who will benefit most of thrombolytic therapy and it is 
useful to identify a group of patients with increased risk of bleeding who do not benefit 
from thrombolytic therapy. 
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SUMMARY 
To assess the role of coronary angiography before hospital discharge in patients 
with myocardial infarction, a risk function describing the relationship between clinical 
characteristics, results of exercise test and radionuclide ventriculography and mortality 
after hospital discharge was compared to a similar risk function including parameters 
obtained from coronary angiography. The study population consisted of 1043 hospital 
survivors of the rt-PNplacebo and the rt-PNPTCA trial of the European Cooperative 
Study Group. Forty two of 1043 patients (4.0%) died during follow-up ranging from 300 
to 1100 days after 10 to 22 days angiography. 
With univariate analysis the following determinants of mortality were identified: 
age, use of diuretics and/or digitalis, history of previous infarction, enzymatic infarct 
size, inadequate systolic blood pressure increase during exercise testing, 
contraindications for an exercise test, radionuclide ejection fraction and multivessel 
disease. In a stepwise multivariate regression model (Cox), use of diuretics and/or 
digitalis, a history previous infarction and age exceeding 60 years were clinical risk 
factors. Of the exercise test results inability to perform the test and less than 30 mmHg 
systolic blood pressure increase were predictive for late mortality. Large enzymatic 
infarct size, radionuclide left ventricular ejection fraction below 40%, and multivessel 
disease were also determinants of mortality after hospital discharge. 
The risk function including coronary angiography was not better than the risk 
functions based on clinical data and the results of non-invasive testing. Patients without 
a history of previous infarction, not treated with diuretics and/or digitalis and with a 
systolic blood pressure increase of 30 mmHg or more during exercise had an excellent 
survival (98.6%) in the first year after hospital discharge, irrespective of whether 
symptoms of recurrent ischemia occurred. This low risk group formed 47% of the total 
patient population and does not benefit from coronary angiography. Predischarge 
exercise testing provides useful information for risk stratification before hospital 
discharge in patients. 
INTRODUCTION 
Mortality after acute myocardial infarction has decreased substantially in the last 
25 years. Early detection and treatment of life threatening arrhythmias in coronary care 
units and more recently the widespread use of thrombolytic therapy in combination with 
aspirin have reduced in hospital mortality [1-7]. Nevertheless, mortality in the first year 
after acute myocardial infarction remains an important problem with an incidence 
ranging from 6% to 19% [1,2]. 
Identification of patients at increased risk of dying after hospital discharge has been 
attempted by many investigators [8-16]. In the guidelines, published by the American 
College of Cardiology and American Heart Association Task Force [17], coronary 
angiography is only recommended in patients with completed myocardial infarction "if 
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prognosis is judged to be poor on the basis of non-invasively obtained parameters 
(clinical, electrocardiographic, radionuclide ventriculography and exercise test) and if 
clinical outcome is expected to be improved by urgent coronary bypass surgery or 
PTCA". It was recommended that low risk patients should not undergo coronary 
angiography. This recommendation seems reasonable, but the additional prognostic value 
of coronary angiography in low risk patients has not been tested in clinical studies and 
in many hospitals predischarge coronary angiography remains a routine procedure, 
especially in younger patients. Since the procedure is related to some morbidity and has 
a mortality rate of 0.2% [17], selection of patients who will benefit from knowledge of 
the coronary anatomy is an important issue. 
In the present analysis of 1043 hospital survivors of the rt-PNplacebo and the 
rt-PA/PTCA trials by the European Cooperative Study Group [6,18], the question is 
addressed whether the criteria for assessment of risk after myocardial infarction, 
established in the pre-thrombolysis era [8-16] remain valid in patients after thromboiytic 
therapy. Particular attention is given to the role of coronary angiography in risk 
assessment before hospital discharge. 
PATIENTS AND METHODS 
The patient population of the present analysis comprises individuals enroled in 
the rt-PNplacebo and rt-PNPTCA trials by the European Cooperative Study Group 
[6,18]. In the former trial patients were randomized to receive recombinant tissue 
plasminogen activator (rt-PA or alteplase) or placebo in addition to aspirin and 
intravenous heparin, while in the latter all patients received rt-PA, aspirin and 
intravenous heparin and were randomized to a non-invasive strategy without angiography 
or an invasive strategy of immediate coronary angiography and percutaneous 
transluminal coronary angioplasty (PTCA) of the residual infarct related stenosis, if 
suitable anatomy was found. 
Patients 
Patients less then 71 years with more than 30 minutes of chest pain suggesting 
myocardial ischemia and ST-segment elevation (60 msec after J-point) of 0.3 mV or 
greater in two or more of chest leads V1 to V4 and/or greater than 0.2 mV in two or 
more of leads I, II, III, aVL, aVF, V5, or V6, were eligible. Patients were also included 
with at least 0.1 mV ST-segment elevation in two of leads II, III, aVF, V5, V6 and at 
least 0.2 mV ST-segment depression in two or more of the chest leads V1 to V4• The 
usual contraindications for thrombolytic therapy were applied [6,18]. In addition, patients 
with a previous myocardial infarction at the same site or who had undergone coronary 
artery bypass surgery were excluded. Patients with heart failure or shock were not. 
Treatment should be started within 5 hours after the onset of symptoms. 
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Protocol 
After informed consent, patients were given an intravenous infusion of either 100 
mg rt-PA or placebo (in the rt-PNplacebo trial) in 3 hours; all patients received 250 mg 
of acetyl salicylic acid and 5000 ill of heparin intravenously, followed by a continuous 
infusion of heparin 1000 ill/hour. The treatment strategies in the rt-PA group of the rt-
PA/placebo trial and the non-invasive group of the rt-PA/PTCA trial were identical. In 
the rt-PA/PTCA trial, those patients allocated to the invasive strategy underwent 
immediate coronary angiography and subsequently angioplasty if a residual stenosis 
exceeding 60% was present. Until hospital discharge, all patients were anticoagulated 
with heparin, which could be replaced by coumarins after three days, provided that full 
anticoagulation was maintained. In addition, 75-125 mg acetyl salicylic acid was given 
every other day until hospital discharge. 
Exercise testing, radionuclide ventriculography, coronary angiography, and left 
ventriculography were performed before hospital discharge. Prior to the beginning of the 
trial, each clinic participating in the study was assigned a specific time window for the 
performance of these studies (10-14, 12-16, 14-18, 16-20 or 18-22 days). Beta 
adrenergic blocking agents were to be prescribed unless contraindications were present. 
Enzymatic infarct size 
Infarct size was determined by assessment of cumulative alpha-hydroxybutyrate 
dehydrogenase (HBDH) release by the heart during the first 72 hrs (HBDH-Q72). The 
methodology has been published previously [6,18,19]. 
Exercise testing 
Cardiovascular medication was not stopped before the test. A symptom-limited 
submaximal exercise protocol was used with either a bicycle ergometer (stepwise 
increments of 10 watts/min) or treadmill (Weld protocol). Twelve ECG leads were 
recorded every 60 sec or continuously. In 3 centers Frank orthogonal leads were used. 
Systolic blood pressure was measured with a cuff at rest, during peak exercise and at 
rest. The test was terminated when severe symptoms or one of the following occurred: 
significant arrhythmias, fall in systolic blood pressure > 15 mmHg or heart rate 
exceeding 200 minus age. The latter occurred in 24% of patients. The workload obtained 
during tread mill testing was translated into watts according to the following algorithm: 
number of watts = (duration of treadmill testing in min) x 10 [20]. 
Radionuclide ventriculography 
Radionuclide ventriculography was performed prior to exercise testing on the 
same day. Technetium-99m (15 mCI) was given 20 min after an intravenous injection 
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of stannous pyrophosphate. R-wave gated or gated list mode data collection was used 
with at least 20 frames per cycle and 5 min per view. Two regions of interest were used 
for the calculation of the ejection fraction. 
ECG scoring 
Electrocardiograms were required by the protocol on admission and between 10 
and 22 days after myocardial infarction. QRS and ST-segment measurements were 
performed centrally. Both the Selvester score and the Cardiac Infarction Injury Score 
were assessed. Details of the analysis are reported elsewhere [21]. 
DATA ANALYSIS 
The objective of the analysis was to find the combination of clinical patient 
characteristics, data form the exercise test, radionuclide ventriculography and contrast 
angiography, which most closely predicted late mortality after 10 to 22 days. The 
following clinical admission variables considered: age, sex, sum of ST-elevation at J-
point, time from symptom onset to treatment allocation, previous myocardial infarction, 
anterior infarction, Killip class, angina at rest and during effort between 24 hrs and 10 
to 22 days, clinical signs of heart failure, atrial fibrillation, pericarditis, use of beta-
blockers, digitalis, diuretics or a combination of the latter two between 24 hours and 10 
to 22 days angiography and enzymatic infarct size. Exercise test results evaluated were: 
systolic blood pressure rise from baseline to peak exercise, maximum heart rate during 
exercise, occurrence of angina, ST-segment depression and elevation during exercise and 
maximum workload and percentage of predicted workload achieved according to age and 
height. Finally, global left ventricular ejection fraction from radionuclide ventriculogra-
phy and contrast left ventriculography, extent and severity of coronary artery disease, 
end-diastolic and end-systolic volumes, regional wall motion assessed by the "Center-
line" model, the "Regional Contribution to ejection fraction" method and the "Radial 
axes" method were evaluated [22]. Mortality was displayed as the cumulative incidence 
of death during the follow-up period, beginning the day after coronary angiography was 
performed or scheduled. 
Univariate analysis 
For continuous variables patients were categorized into three subgroups of 
approximately equal size. Subsequently, mortality was assessed in each subgroup. The 
category with the lowest expected risk was chosen as reference group. The relative risk 
for the other categories was calculated as the mortality in the subgroup under study, 
divided by the mortality in the reference group (risk ratio). The 95% confidence interval 
for the risk ratio was calculated according to Miettinen [23]. 
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Multivariate analysis 
Multivariate regression analysis was used to develop a composite risk score based 
on patient characteristics found to be related to one year mortality in the univariate 
analysis. The Cox proportional hazard model was applied [24], which provides a 
conditional probability of death at each moment during follow-up, given a certain 
combination of risk factors Xl, X2, ... ,Xi, according to the function: 
1 - survival at 1 year = 1 - So(l year)"xp(bl x XI+ b2 x X2 .. bi x Xi.) 
S0(1 year) is the survival at one year for a patient without any risk factor and Bi 
represent the Cox regression coefficients, estimated from the data by the maximal 
likelihood method for indicator variables Xi representing risk factors. The probability of 
one year survival calculated for each patient individually according to the Cox function 
was used as a composite risk score. 
Besides above absolute risk estimates the Cox proportional hazard function 
provides relative risk estimates or hazard ratios. If indicator variables are used with 
value 1 if a patient has the property and 0 if not, a Cox regression coefficient represent 
the natural logarithm of the hazard ratio. For example, the Cox regression coefficient for 
use of diuretics and/or digitalis of 1.34 means that patients using diuretics and/or 
digitalis have a 3.8 fold increased (hazard of) mortality than patients without, conditional 
on all other risk factors retained in the model. The 95% confidence interval for this 
relative risk was derived from the standard error (SEi) of the coefficient by the natural 
antilogarithm of (Bi ± 1.96 x SEi) [25]. 
Five risk functions were designed, one for clinical data only, one for clinical data 
with exercise test results, one including enzymatic infarct size, one including data from 
radionuclide angiography, and one combining all non-invasive variables with findings 
of coronary angiography. In a stepwise procedure, variables were included in a model 
if the probability for inclusion was less then 0.10. A variable was removed if the 
associated probability exceeded 0.15. Clinical data, data of the exercise test, radionuclide 
angiography and angiographic data were first analyzed in clusters; those retained in the 
various models were combined in one final model. The Cox assumption of 
proportionality was checked in the data as described previously [26]. 
Comparison of the five risk functions 
Risk estimates for every individual patient were obtained with each of the five 
risk functions. Patients were categorized according to each of these five risk estimates 
in a low and high risk group. The optimal cutoff value between low and high risk in the 
five risk functions was determined with a receiver operator characteristic (ROC) curve 
[27]. In this curve the proportion of patients with a high risk score among the deaths 
("true positives" or sensitivity) is plotted against the proportion of patients with 
TABLE I- Mortality within first year after hospital discharge in various subgroups of 
patients. 
Mortality within first year 
rt-P A/placebo 
trial 
Plac rt-PA 
Diuretics and/or digitalis 
no 3/281 5/287 
yes 10/ 64 6/ 59 
History of infarction 
no 10/321 8/323 
yes 3/24 3/23 
Age (year) 
<60 6/211 3/194 
;;:::60 7/134 8/152 
Enzymatic infarct size (U/1) 
<1100 3/233 7/258 
;;:::1100 10/108 4/87 
mis 0/ 4 0/ 1 
rt-PAIPTCA 
trial 
rt-PA Invas 
5/138 3/124 
1/42 3/48 
5/168 5/160 
1/12 1/12 
3/135 3/112 
3/45 3/60 
3/141 4/123 
3/39 2/48 
0! 1 
Radionuclide ejection fraction (%) 
;;:::40 4/229 4/232 3/137 
<40 8/104 7/103 3/35 
mis 1/12 0/11 0/ 8 
1/117 
3/48 
2/ 7 
Blood pressure increase during exercise (mmHg) 
;;:::30 4/213 3/233 4/137 2/126 
<30 7/113 4/91 2/27 1/31 
mis 2/19 4/22 0/16 3/15 
Nr of coronary vessels with ;;:::SO% diameter stenosis 
<2 4/194 1/192 3/119 1/118 
;;:::2 8/142 8/141 3/54 3/41 
mis 1/ 9 2/13 0/ 7 2/13 
Treatment strategy 
plac 13/345 
rt-PA 11/346 
rt-PA 
In vas 
All 
6/180 
6/172 
Overall Risk ratio (95% CI) 
16/830 
20/213 
28/972 
8!71 
15/652 
21/391 
11nss 
19/282 
0/ 6 
12n1s 
21!290 
3/ 38 
13no9 
14/262 
9/72 
9/623 
22/378 
5/42 
36/1043 
4.9 (2.7 to 8.7) 
3.9 (1.9 to 8.0) 
2.3 (1.2 to 4.4) 
3.0 (1.6 to 5.5) 
4.3 (2.3 to 8.2) 
4.7 (1.5 to 14.7) 
2.9 (1.4 to 5.9) 
6.8 (3.3 to 14.0) 
4.0 (2.0 to 8.2) 
8.2 (3.3 to 20.4) 
0.8 (0.4 to 1.9) 
0.9 (0.3 to 2.3) 
0.9 (0.4 to 2.4) 
mis: missing; plac: placebo; rt-PA: recombinant tissue-type plasminogen activator. 
In vas: invasive strategy. Number of deaths divided by total number of patients in each 
subset. 
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a high risk score among those remammg alive ("false positives" or 100% minus 
specificity). Risk functions on the line of identity have no prognostic value, those in the 
left upper corner are most informative. 
The performance of the risk functions regarding the separation of low and high risk 
patients, as well as the relative efficacy of each of the five risk functions, were assessed 
by studying patient survival in both risk categories separately with Kaplan-Meier 
survival plots [28]. 
RESULTS 
Univariate analysis 
Forty two of 1043 patients (4.0%) died during follow-up, ranging from 300 to 
1100 days after 10 to 22 days angiography. Mortality rates in the first year were similar 
in all treatment groups (table I). Determinants of mortality after 10 to 22 days 
angiography were: use of diuretics and/or digitalis, age, history of previous infarction, 
enzymatic infarct size, radionuclide left ventriculography, inadequate systolic blood 
pressure increase during exercise, extent of coronary artery disease. Mortality in various 
categories of these determinants was similar in all treatment groups (table I). Missing 
data on systolic blood pressure increase during exercise testing were also predictive of 
mortality. This occurred in 72 patients of whom in 62 patients the exercise test was not 
started (in 33 patients for cardiac reasons). In addition, inability to perform coronary 
angiography was related to mortality. 
In figure 1 mortality, reinfarction and revascularization in the first year after hospital 
discharge are presented for subsets of patients without and with signs of recurrent 
ischemia during hospital stay (including reinfarction) categorized according to history 
of previous infarction, use of diuretics and/or digitalis and systolic blood pressure 
response during exercise test. There was no difference in the occurrence of reinfarction 
between the patients subsets. Revascularization procedures were more frequent in 
patients with signs of recurrent ischemia than in patients without, and in patients with 
a history of previous infarction or use of diuretics and/or digitalis. There was a 
preference for coronary bypass surgery over angioplasty in patients without adequate 
systolic blood pressure increase during exercise or missing exercise test data. 
Revascularization before 10 to 22 days was performed in 4 patients only (these are 
omitted in figure 1) and therefore is unlikely to influence mortality and reinfarction after 
hospital discharge. 
Multivariate analysis 
The probability of mortality within the first year for patients without any risk 
factor, estimated by Cox regression analysis, is reported in table II as well as the relative 
risk of each risk factor conditional on the other risk factors in the various risk functions. 
Coefficients of each risk function can easily be computed by taking the antilogarithm 
hospital survivors 
N=1043 
r 
I I 
no ischemia angina/reinfarction 
N=816 N=227 
first infarction repeat infarction first infarction repeat infarction I 
no diuretics/digitalis and/or no diuretics/digitalis and/or diuretics/digitalis diuretics/digitalis 
I I l I I exercise test I I exercise test I I exercise test I 1 exercise test 1 
mis <30 >=30 mis <30 >=30 mis <30 >=30 mis <30 >=30 
N=19 N=136 N=489 N=17 N=48 N=107 N=19 N=43 N=79 N=17 N=35 N=34 
mortality 5.3% 2.2% 1.4% 29.4% 6.3% 3.7% 5.3% 2.3% 1.3% 11.8% 20.0% 2.9% 
reinfarct - 2.9% 3.3% 5.9% - 5.6% 5.3% 4.7% 3.8% - 17.1% 
PTCA - 4.4% 5.7% - - 5.6% 21.1% 11.6% 10.1% 5.9% - 14.7% 
CABG 15.8% 4.4% 4.5% 11.8% 10.4% 10.3% 15.8% 20.9% 12.7% 2.4% 11.4% 8.8% 
both - - 0.6% - - 0.9% - 2.3% 1.3% 
Figure 1. Mortality, reinfarction and revascularization procedures within the first year in subsets of patients categorized according to clinical ........ 
+:--
data and exercise test results. \.>) 
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TABLE ll- Survival after one year after hospital discharge in patients without any risk 
factor predicted by various multivariate models and relative risk of each risk factor. 
Model including: 
Clinical + + + + 
Exercise + + + 
Enzymes + + 
LVEF + 
Angio 
Survival in patients without any risk factor at 365 days 
0.983 0.988 
Relative risk (95% CI) 
Diuretics and/or digitalis used after 24 hours 
no 79.6 
yes 20.4 3.8 (2.0-7.2) 3.2 (1.7-6.0) 
History of infarction 
no 93.2 
yes 6.8 2.9 (1.4-6.2) 
Age (year) 
<60 62.5 
::::::60 37.5 1.7 (0.9-3.2) 
Enzymatic infarct size (U/1) 
<1100 73.0 
::::::1100 27.0 
2.6 (1.2-5.5) 
1.6 (0.9-3.1) 
Radionudide ejection fraction (%) 
::::::40 68.6 
<40 27.8 
mis 3.6 
0.991 
2.5 (1.3-4.8) 
2.5 (1.1-5.3) 
1.8 (1.0-3.4) 
2.5 (1.3-4.8) 
Blood pressure increase during exercise test (mmHg) 
<30 68.0 
>30 25.1 
no 6.9 
2.2 (1.1-4.5) 
3.6 (1.5-8.3) 
2.0 (1.0-4.1) 
3.6 (1.5-8.3) 
Nr of coronary vessels with ::::::50% diameter stenosis 
<2 59.8 
::::::2 36.2 
mis 4.0 
Treatment strategy 
plac 33.0 
rt-PA 33.2 
rt-PA 17.3 
invas 16.5 
0.9 (0.4-1.9) 
0.9 (0.3-2.1) 
0.6 (0.2-1.7) 
0.9 (0.4-1.9) 
0.9 (0.3-2.2) 
0.7 (0.3-1.9) 
1.0 (0.5-2.2) 
0.9 (0.4-2.4) 
0.8 (0.3-2.1) 
0.991 
2.5 (1.3-4.8) 
2.0 (0.9-4.5) 
1.6 (0.9-3.0) 
2.8 (1.4-5.7) 
1.4 (0.4-5.7) 
2.0 (1.0-4.0) 
3.9 (1.5-9.7) 
1.0 (0.5-2.0) 
0.9 (0.4-2.4) 
0.8 (0.3-2.1) 
+ 
+ 
+ 
+ 
+ 
0.995 
2.4 (1.3-4.6) 
1.4 (0.7-2.6) 
2.9 (1.4-5.7) 
0.9 (0.2-3.9) 
1.9 (1.0-3.9) 
3.2 (1.2-8.5) 
3.1 (1.5-6.6) 
4.0 (1.1-15) 
1.0 (0.5-2.1) 
1.1 (0.4-2.8) 
0.9 (0.3-2.3) 
Relative risk for an indicator variable is the exponent of the coefficient of that indicator variable in 
the Cox regression model and represents a hazard ratio. 
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of each relative risk. The risk function with clinical data only contains the following 
parameters (in order of decreasing importance): use of diuretics and/or digitalis after 24 
hours, history of previous infarction and age. Prescription of diuretics and/or digitalis 
at discharge was also highly predictive of mortality, but was likely to be influenced by 
knowledge of the radionuclide and contrast angiography results. This parameter is 
therefore disregarded in the present analysis. Clinical signs of heart failure were 
associated with in-hospital mortality, but to a lesser extent with mortality thereafter. 
Symptoms of recurrent ischemia after the first 24 hours, at rest and during effort or 
during the exercise test, did not contribute to mortality prediction. In addition to clinical 
parameters, exercise test results contributed to the prediction of mortality. Systolic blood 
pressure rise from rest to peak exercise of less than 30 mmHg was associated with a 2.2 
fold increased mortality. ST-segment elevation or depression during or after exercise 
testing did not contribute to risk assessment. Inability to perform predischarge exercise 
testing was highly predictive of late mortality (relative risk 3.6, 95% CI 1.5 to 8.3). 
When enzymatic infarct size or radionuclide left ventricular ejection fraction were 
entered in the model low systolic blood pressure response to exercise and inability to 
perform exercise testing remained important determinants of late mortality (table II). 
When left ventricular ejection fraction below 40% and enzymatic infarct size were 
simultaneously considered in the stepwise regression, the former was entered as second 
parameter immediately after use of diuretics and/or digitalis; if left ventricular ejection 
fraction was not considered, enzymatic infarct size was entered instead. In the risk 
function with parameters of coronary angiography, multivessel coronary artery disease 
was a strong predictor of mortality after 10 to 22 days (relative risk 3.1) and was 
additive to the clinical determinants, the exercise test results and left ventricular ejection 
fraction. Residual stenosis and patency of the infarct related vessel were related to late 
mortality but were overshadowed by the other parameters. 
Comparison of the five risk functions 
In figure 2 the ROC curves are shown for each of the five risk functions. The 
function containing only clinical data was nearest to the line of "no prognostic value". 
Performance of the other risk functions was very similar. The best prognostic value of 
the risk function including angiographic data was obtained for a cutoff value of 0.032. 
This cutoff value was therefore chosen between the low and high risk category in figure 
3. Survival in the low risk category was better than in the high risk category for all five 
risk functions. The risk functions including non-invasive testing performed better in 
separation of patients with low and high mortality than the risk function containing 
clinical data only. The risk function including coronary angiographic data was not better 
than the risk functions without coronary angiography but including the exercise test 
results. 
Left main stem stenosis 
Left main stem diameter stenosis exceeding 50% was found in 9 patients out of 
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Figure 2. Receiver-operator characteristic curve for comparison of the risk function 
containing clinical data only (small dots), the risk function containing exercise test data 
(thick dots), the risk function with enzymatic infarct size (small dash), the risk function 
including radionuclide ventriculography (large dash) and the risk function with all 
parameters including those of the contrast angiography (solid line). The value 0.032 
represent the cutoff point for which the performance of the risk function including 
coronary angiography was best. 
1043 (0.9% ). In none of these patients was the left main stem infarct related. Two 
suffered from recurrent ischemia and underwent coronary bypass surgery. Of the 
remaining 7 patients without symptoms of recurrent ischemia, 3 patients were in the low 
risk group without history of previous infarction, treatment with diuretics or digitalis and 
with an systolic adequate blood pressure response during exercise. None of these 
underwent a revascularization procedure and none died. One patient with left main stem 
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Figure 3. Survival in patients categorized in a low and high risk group by the five risk 
functions (cutoff value of 0.032 for the probability of death within the first year). 
Symbols are identical to those in figure 2. 
stenosis and a history of previous infarction died 11 days after 10 to 22 days 
angiography without intervention, the remaining 8 patients survived during a follow-up 
ranging from 353 to 495 days after hospital discharge. 
Multivessel disease with poor left ventricular function 
Eighty six patients in the low risk group had a radionuclide left ventricular 
ejection fraction below 40%. Twenty eight of these 86 patients had also multivessel 
disease. Three of 28 patients underwent a revascularization procedure and only two of 
them died during follow up. 
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DISCUSSION 
The importance to identify patients at risk of dying after hospital discharge has 
been underscored by many investigators [8,9-11,15]. Patients at low risk can be 
reassured without additional diagnostic investigations or therapy; high risk patients might 
benefit from further treatment and closer follow-up. The present analysis indicates that 
the risk for mortality after hospital discharge can be determined using simple clinical 
data and parameters obtained by exercise testing before hospital discharge. Five hundred 
sixty eight patients without a history of previous infarction, not treated with diuretics 
and/or digitalis and with a systolic blood pressure increase of 30 mmHg or more with 
cuff measurement during exercise had an excellent survival (98.6%) in the first year 
after hospital discharge, irrespective of symptoms of recurrent ischemia (figure 1). 
Overall mortality after hospital discharge was less than half of the 10 to 15% that 
was reported in earlier studies [8]. This is explained in part by patient selection with an 
upper age limit of 71 years and allowing entry of patients with previous infarctions only 
if in a distant area. However, the risk associated with previous infarction in this study 
is similar to the risk associated with previous infarction in the study of Fioretti with a 
rate ratio of 3.9 (table I) and 3.5 [8] respectively, although more patients had a history 
of previous infarction in the latter study (24.8% versus 6.8%) in the latter trial. In 
addition, mortality reduction by rt-PA [5,6,34] and probably by aspirin [3] might have 
contributed to the difference in mortality within in the first year. The principle 
determinants of late mortality are related to impaired left ventricular function and not 
to residual ischemic myocardium, probably because patients with residual ischemia 
underwent revascularization procedures. As a consequence, little gain is to be expected 
from further revascularization procedures, although other treatment modalities like 
coumarins [32] or ACE-inhibition [33] may improve the prognosis in such patients. 
Clinical risk factors 
The use of diuretics and/or digitalis after 24 hours was the strongest clinical 
determinant of mortality after hospital discharge in the present analysis. Fioretti tested 
the prescription of digitalis at hospital discharge and also found this parameter to be 
highly predictive of late mortality [8]. Because prescription on hospital discharge may 
be influenced by the knowledge of non-invasive and invasive test results, in the present 
analysis only use of diuretics and/or digitalis prior to these tests were used. 
Exercise test before hospital discharge 
The present analysis confirms the value of a pre-discharge exercise test in 
patients treated with and without thrombolytic therapy. Previous studies have shown the 
usefulness of this investigation for patients prior to the widespread use of thrombolytic 
agents [8, 11-15]. As reported by Fioretti et al [8] and recently confirmed by others [16], 
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parameters suggesting residual ischemic myocardium (chest pain and/or ST-segment 
changes during exercise testing) were not associated with higher mortality after hospital 
discharge. This might be explained by the finding that 34% of patients with recurrent 
ischemia underwent revascularizatioil procedures versus 14% of patients without 
recurrent ischemia, which possibly has reduced the risk of mortality. 
Additional tests 
Coronary angiography did not improve the prediction of mortality when clinical 
data and exercise test results were available (figures 2 and 3). Therefore, low psk 
patients without symptoms of recurrent ischemia should not undergo routine coronary 
angiography before hospital discharge. These low risk patients comprised 47% of the 
study population. This is in agreement with the indications for angiography after acute 
myocardial infarction as proposed by the Joint Task Force of the American College of 
Cardiology and the American Heart Association [17]. These recommendations were 
tested in a large data base of patients with acute myocardial infarction and appeared 
useful to identify patients at high risk of mortality [30]. However, in that study, the 
value of coronary angiography in improving risk assessment was not determined and the 
simultaneous effect of several determinants of risk was not accounted for with 
multivariate regression analysis as in the present analysis. 
A possible benefit of coronary angiography in high risk patients who are using diuretics 
and/or digitalis, are not able to perform an exercise test or have an inadequate systolic 
blood pressure response during exercise, may have been missed in the present analysis, 
since revascularization might have improved survival in these high risk patients [38,39]. 
Agreement exists that patients with left main coronary artery stenosis should 
undergo bypass surgery, even if asymptomatic [29]. It should be realized that, in this 
study, 489 low risk patients underwent coronary angiography to detect 3 patients with 
a left main stenosis. Since coronary angiography is associated with 0.2% mortality [17], 
this must be balanced against the expected improvement in prognosis following bypass 
surgery in a few patients with severe left main stenosis. Therefore, it is unlikely that an 
invasive strategy for all patients will be superior to a strategy in which coronary 
angiography is restricted to high risk and symptomatic patients. 
Another strategy which has been proposed, with radionuclide ventriculography 
in the low risk group and subsequent coronary angiography in patients with left 
ventricular ejection fraction below 40%, would have resulted in coronary angiography 
in 86 additional patients. The present study does not give much support for the 
superiority of this strategy (figure 2). 
Initial treatment strategy 
In contrast to mortality during hospital stay [6,18], mortality after hospital 
discharge was not related to the initial treatment strategy conditional on enzymatic 
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infarct size, left ventricular function and coronary anatomy in the multivariate analysis. 
Similar findings have been reported for thrombolysis with intracoronary streptokinase 
[31]. To evaluate whether the relation between determinants and mortality was similar 
for all treatment strategies, the multivariate analysis was repeated for placebo and rt-PA 
treatment separately with similar results being obtained. 
Infarct related residual stenosis 
Mortality in patients with an occluded infarct-related vessel is reported to be 
higher than in patients with a patent infarct-related vessel [31,35-38]. Possible 
mechanisms are better scar formation in the infarct territory, less ischemia in the infarct 
territory and better collateral flow to distant myocardial areas especially in case of 
recurrent infarction due to occlusion of another coronary artery. In the present study 
population the residual stenosis in the infarct related vessel appeared to be related to late 
mortality [34], but in the stepwise regression analysis the contribution of the degree of 
residual stenosis was insufficient for inclusion in the model after prior entry of diuretics 
and/or digitalis, radionuclide left ventricular ejection fraction and extent of coronary 
artery disease. 
Limitations of the study 
Prediction of mortality was hampered by the small number of deaths in the 
present study. This has made the risk functions less reliable, will have influenced their 
performance (figure 2 and 3) and made assessment of their performance in more than 
two risk categories impossible. Secondly, in approximately 40% of patients undergoing 
revascularization procedures no symptoms of recurrent ischemia were present. In these 
patients the responsible physician decided to perform a revascularization procedure only 
because of the coronary anatomy, according to a retrospective questionnaire. This may 
have influenced the risk functions presented in this report. However, considering the 
small number of patients with left main stem stenosis and with a combination of 
multivessel disease with poor left ventricular function in the low risk group not 
identified by recurrent ischemia and the infrequent revascularization procedures among 
them (0 of 3 patients with main stem stenosis and 3 of 28 patients with multivessel 
disease and poor left ventricular function), revascularization procedures are unlikely to 
be responsible for the excellent survival in the low risk group. Another limitation of the 
study is that the risk functions were tested in the patient population in which the risk 
functions were developed. This may have resulted in over-estimation of the efficacy of 
the risk functions. Application of the findings in the present study to other patient 
populations with similar patient characteristics is valid only, if similar treatment 
strategies, including beta-blockade and revascularization strategies in post-infarct angina, 
are used. 
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Conclusion 
Mortality following hospital discharge may be predicted in patients with acute 
myocardial infarction, also after thrombolytic therapy. The pre-discharge exercise test 
retains its usefulness in these patients. Coronary angiography did not improve the 
prediction of mortality after hospital discharge. Low risk patients, characterized by the 
absence of symptoms of recurrent ischemia, without prescription of diuretics and/or 
digitalis and with a normal systolic blood pressure response to exercise, have an 
excellent prognosis and are unlikely to benefit from predischarge angiography. 
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SUMMARY 
Thrombolytic therapy is a major step forward in the treatment of acute 
myocardial infarction and may result in up to 50% mortality reduction, provided that it 
is administered early (chapter 1). In 80 to 85% of patients with suspected acute 
myocardial infarction, a coronary artery is blocked by a clot. With thrombolytic therapy 
the closed coronary artery is desobstructed in may cases, is infarct size limited and left 
ventricular function preserved. Several thrombolytic agents are available for clinical use: 
streptokinase, APSAC, urokinase and more recently recombinant tissue-type plasminogen 
activator (rt-PA or alteplase). The latter is the genetically engineered natural occurring 
plasminogen activator. Which agent is superior is still a matter of debate. Unlike 
streptokinase, APSAC and urokinase, rt-PA dissolves blood clots without degradation 
of circulating fibrinogen during in vitro and in animal experiments, provided that the 
dose does not exceed a certain threshold. This property of rt-PA is called fibrin-
specificity. 
In this thesis the effect ofrt-PA on coronary patency, infarct size, left ventricular 
function and clinical outcome is reported, as assessed in the clinical trials of the 
European Cooperative Study Group. In these trials patients with symptoms of acute 
myocardial infarction and fulfilling strict criteria forST-segment change were entered. 
In addition, more general questions are addressed in this thesis: whether all patients with 
suspected acute myocardial infarction should receive thrombolytic therapy and whether 
coronary angiography before hospital discharge is indicated in all patients receiving 
thrombolytic therapy. 
Fibrinogen degradation products, coronary patency and bleeding 
In chapter 2 the question is addressed whether rt-PA restores coronary patency 
in patients without marked degradation of circulating fibrinogen, as is suggested by in 
vitro and animal experiments. The second question was whether fibrinogen breakdown 
associated with increased bleeding risk. Coronary patency at 90 minutes after start of 
rt-PA infusion and bleeding rate are reported for 242 patients entered in the first three 
trials of the European Cooperative Study Group. All patients were treated with double 
chain rt-PA. Bleeding occurred more frequently in patients with increased serum levels 
of fibrin(ogen) degradation products, but coronary patency immediately after rt-PA 
infusion was not better, indicating that rt-PA, unlike streptokinase and urokinase, is 
effective in restoring coronary patency without increased serum levels of fibrin(ogen) 
degradation products. This is in agreement with the fibrin-specificity of rt-PA. 
Because the dose that induces fibrinogen degradation may vary considerably from 
patient to patient, a new way of dosing is proposed. Rt-PA can be administered until 
fibrinogen degradation products appear. This approach may be compared to the titration 
of insulin by measuring blood sugar levels. The development of a quick bedside test for 
measurement of fibrinogen degradation products is a prerequisite for this approach. 
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Effect of rt-PA on infarct size, left ventricular function and clinical outcome 
In chapter 3 the effect of rt-PA, in addition to aspirin and intravenous heparin, 
on infarct size, left ventricular function and survival in patients with suspected acute 
myocardial infarction is reported. Seven hundred twenty one patients were enroled in the 
rt-PNplacebo trial of the European Cooperative Study Group and were allocated at 
random to treatment with 100 mg rt-PA or placebo. Enzymatic infarct size was limited 
by 20%, left ventricular function was preserved and mortality was reduced by 51% at 
14 days (5.7% versus 2.8%) in comparison to a strategy of aspirin and intravenous 
heparin alone. Bleeding complications were commoner in patients treated with rt-P A. 
Intracranial bleeding occurred in 1.4% of patients. 
Additional benefit of immediate angioplasty 
Does immediate coronary angioplasty provide additional benefit in patients 
treated with rt-PA, aspirin and intravenous heparin? This question was addressed in the 
rt-PNPTCA trial (chapter 4). Three hundred sixty seven patients were at random 
allocated to an invasive strategy of rt-PA, aspirin, intravenous heparin combined with 
immediate coronary angiography and balloon dilatation of narrowings in the infarct 
related vessel or to a non-invasive strategy with rt-PA, aspirin and intravenous heparin 
alone. The invasive strategy was not superior in terms of infarct size, left ventricular 
function and clinical outcome to the non-invasive approach of rt-PA, aspirin and 
intravenous heparin alone and may even be detrimental, since mortality was higher in 
the invasive group. 
The lack of benefit of the invasive treatment strategy was explained by more 
frequent coronary reocclusion and reinfarction in the invasive treatment group. After 
exclusion of patients with these events, a small benefit in parameters of regional wall 
motion was found similar to the benefit in the rt-PNplacebo trial, also after adjustment 
for other determinants of regional wall motion by multivariate regression analysis 
(chapter 5). This suggests that an invasive strategy might be beneficial in selected 
patients, when additional treatment modalities to prevent reocclusion and reinfarction 
become available. 
Long term follow up after rt-PA 
Long term results of the rt-PA/placebo and the rt-PNPTCA trial are reported in 
chapter 6. The benefit of rt-PA in terms of mortality reduction was still present at one 
year follow up. Survival after hospital discharge in patients with completed myocardial 
infarction is determined by the remaining left ventricular function, the extent of coronary 
artery disease and by the degree of infarct related residual coronary artery narrowing. 
Differences in survival between patients treated with thrombolytic therapy and controls 
are explained in differences in these parameters induced by the treatment. 
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Patient selection 
Must all patients with acute myocardial infarction receive thrombolytic treatment? 
Since some patients have a very good prognosis without thrombolytic therapy and some 
patients may have an increased risk of intracranial bleeding, this is unlikely. In chapter 
7 a model is presented that was developed in the rt-PNplacebo and rt-PNPTCA trial 
and tested in patients of two other clinical trials with enzymatic infarct size assessment. 
This model can be used to predict the expected infarct size and associated prognosis for 
a patient who is not treated with thrombolytic therapy, based on the admission ECG and 
Killip class. A second risk function was developed to determine the risk of intracranial 
bleeding in individual patients. Based on these estimates the decision to administer 
thrombolytic therapy can be made for an individual patient. Patients with s.mall 
"expected infarct size without thrombolytic therapy", with a favourable prognosis 
without thrombolytic therapy should not receive thrombolytic therapy if they have 
increased risk of intracranial bleeding. Patient selection criteria were proposed based on 
these findings. 
Role of predischarge coronary angiography for risk assessment 
Is coronary angiography before hospital discharge needed for the identification 
of high risk patients after thrombolytic treatment? In chapter 8 this question is addressed 
in the 1043 patients of the rt-PNplacebo and the rt-PNPTCA trial, who were alive at 
the time of the predischarge angiography. Coronary angiography was not useful in 
patients without symptoms of recurrent ischemia and without risk factors as a previous 
infarction, use of diuretics and/or digitalis and with a adequate systolic blood pressure 
response to exercise of at least 30 mmHg. These patients (47% of the study population) 
have a very good prognosis; 98.6% of these patients are still alive after one year and 
prediction of mortality is not improved by knowledge of the coronary anatomy. 
Therefore, coronary angiography should be restricted to high risk patients who may 
benefit from coronary bypass surgery or balloon dilatation. Thus, after thrombolytic 
therapy patient management is similar as in patients not treated with thrombolytic 
therapy. 
Conclusion 
The fibrin specificity of rt-PA was confirmed in the clinical setting. Tissue 
plasminogen activator reduces enzymatic infarct size, preserves left ventricular function 
and reduces mortality. Thrombolytic therapy is life saving for many patients with 
symptoms of acute myocardial infarction, but in patients with good prognosis without 
thrombolytic therapy and with increased risk of intracranial bleeding it may be life 
threatening. Selection of patients for thrombolytic therapy can be made on hospital 
admission on the basis of clinical state and ECG. Patient management after thrombolytic 
therapy is not different from that in patients without thrombolytic therapy. 

SAMENV ATTING 
Trombolytische therapie voor het acute hartinfarct blijkt een waardevolle 
aanvulling van het therapeutisch arsenaal van de cardioloog en resulteert in 50% sterfte 
vermindering, wanneer de behandeling vroeg na begin van de klachten wordt 
aangevangen (hoofdstuk 1). Bij 80-85% van de patienten met symptomen van een acuut 
hartinfarct kan een door een stolsel afgesloten kransvat worden vastgesteld. Met 
trombolytische behandeling wordt deze afsluiting in vele gevallen opgeheven, wordt de 
infarctgrootte beperkt en de linkerhartkamerfunctie gespaard. Meerdere trombolytica zijn 
beschikbaar voor gebruik in de kliniek: streptokinase, APSAC, urokinase en recombinant 
weefsel plasminogeen activator (rt-PA of aiteplase). Rt-PA is het met recombinant DNA 
technieken geproduceerde natuurlijke weefsel plasminogeen activator. Over welk 
trombolyticum het beste is bestaat nog geen overeenstemming. Anders dan streptokinase 
en urokinase, lost rt-PA stolsels op zonder het circulerende fibrinogeen aan te tasten, 
tenzij zeer hoge doses worden gebruikt Deze eigenschap wordt fibrinespecificiteit 
genoemd. 
In dit proefschrift wordt het effect van rt-PA op de kransvatdoorgankelijkheid, 
de infarctgrootte, de linkerhartkamerfunctie en het klinisch beloop gerapporteerd. Het 
proefschrift is gebaseerd op de bevindingen in de onderzoekingen van de European 
Cooperative Study Group. In deze onderzoekingen werden aileen patienten toegelaten 
bij wie klachten, suggestief voor een hartinfarct, gecombineerd waren met ECG 
veranderingen. 
V oorts komen in dit proefschrift meer algemene vragen aan de orde: Is behandeling met 
trombolyse aangewezen bij aile patienten met een verdenking op een hartinfarct? Is 
coronairangiografie voor ontslag uit het ziekenhuis aangewezen bij aile patienten die 
trombolyse krijgen ter behandeling van een hartinfarct? 
Fibrinogeenatbraakprodukten, kransvatdoorgankelijkheid en bloeding 
In hoofdstuk 2 wordt de vraag behandeld of rt-PA stolsels kan oplossen bij 
patienten met een acuut hartinfarct zonder de circulerende stollingseiwitten af te breken, 
zoals in vitro en in dierexperimenteel onderzoek werd gesuggereerd. Een tweede vraag 
was of een verhoogde serumconcentratie van fibrinogeenafbraakproducten geassocieerd 
is met een verhoogde bloedingsneiging. De kransvatdoorgankelijkheid na 90 minuten na 
begin van de rt-PA toediening en het v66rkomen van bloedingen worden gerapporteerd 
voor 242 patienten die toegelaten zijn tot de eerste drie onderzoekingen van de European 
Cooperative Study Group. Allen werden behandeld met dubbelketen rt-PA. Bloedingen 
traden vaker op bij patienten met hoge serumwaarden van fibrinogeenafbraakprodukten 
dan bij patienten met lage waarden, terwijl de kransvatdoorgankelijkheid niet toenam. 
Er werd een nieuwe manier van dosering voorgesteld waarbij rt-PA geinfundeerd 
wordt tot fibrinogeenatbraakprodukten in het bloed optreden. Deze benadering is 
vergelijkbaar met de titratie van de insulinedosering met bloedsuiker bepalingen. De 
ontwikkeling van test, waarmee op een eenvoudige manier fibrinogeenafbraakprodukten 
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bepaald kunnen worden, is een voorwaarde voor deze benadering. 
Effect van rt-PA op infarctgrootte, linkerhartkamerfunctie en klinisch beloop 
In hoofdstuk 3 wordt verslag gedaan van het rt-PNplacebo onderzoek van de 
European Cooperative Study Group. Zevenhonderd een en twintig patienten met het 
klinische beeld van een acuut hartinfarct, werden gerandomiseerd tussen een 
behandelingsstrategie van rt-PA, gecombineerd met aspirine en heparine en een 
behandeling met placebo, aspirine en heparine. De trombolytische behandeling beperkte 
de infarctgrootte met 20%, spaarde de linkerhartkamerfunctie en verminderde de sterfte 
na het hartinfarct met 51% na 14 dagen (5.7% versus 2.8%) in vergelijking tot de 
behandeling met placebo, aspirine en heparine. 
Bloedingscomplicaties waren frequenter in patienten die met rt-PA werden behandeld. 
Intracraniele bloedingen binnen drie dagen na behandeling kwamen bij 1.4% van de 
patienten voor. 
Baten van onmiddellijke ballondilatatie 
Zijn er baten van een vroegtijdige ballondilatatie van het infarctgerelateerde 
kransvat bij patienten die behandeld worden met trombolyse voor een acuut hartinfarct? 
Een strategie van alteplase, heparine en aspirine, gevolgd door onmiddellijke 
kransvatangiografie en ballondilatatie van vemauwingen in het infarct gerelateerd 
kransvat, werd vergeleken met een niet-invasieve strategie van alteplase, heparine en 
aspirine in 367 patienten met symptomen van een acuut hartinfarct (hoofdstuk 4). De 
infarctgrootte en de linkerkamerejectiefractie waren eender in beide 
behandelingsgroepen, terwijl de sterfte hager was in de invasieve behandelingsgroep, 
zodat een algemene invoering van deze behandeling moet worden ontraden. 
De bevinding dat vroegtijdige ballondilatatie geen gunstig effect heeft, hangt 
samen met het vaker optreden van een hemieuwde kransvatafsluiting en reinfarcering, 
mogelijk door verdere beschadiging van de atherosclerotische vaatwand (hoofdstuk 5). 
In patienten zonder complicatie na de ballondilatatie werd een trend tot betere 
wandbeweging in het infarctgebied waargenomen, die qua grootte te vergelijken is met 
het effect van trombolytische behandeling met rt-PA. Dit suggereert dat deze invasieve 
benadering een plaats zou kunnen hebben, zodra additieve maatregelen om een 
hemieuwde afsluiting te voorkomen zijn ontwikkeld. In speciale gevallen blijft de 
ballondilatatie een belangrijke vorm van therapie, bijvoorbeeld bij patienten met een 
contraindicatie voor trombolytische behandeling, zoals uitgebreide hartmassage of een 
recente bloeding. 
Lange termijn overleving na rt-PA 
Gegevens betreffende de lange termijn overleving zijn in hoofdstuk 6 
gerapporteerd. De baten van rt-PA in termen van sterftevermindering waren na een jaar 
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nog steeds aanwezig. De overleving na ontslag uit het ziekenhuis wordt bepaald door 
de linkerhartkamerfunctie en door de uitgebreidheid van de atherosclerotische 
kransvatafwijkingen, zoals die voor ontslag uit het ziekenhuis kunnen worden 
vastgesteld. V erschillen in overleving tussen patienten die aileen met aspirine en 
heparine zijn behandeld en patienten die trombolytische behandeling hebben gekregen, 
zijn terug te voeren op verschillen in linkerhartkamerfunctie en coronair anatomie. 
Selectie van patienten 
Moeten aile patienten met een klinisch beeld van een acuut hartinfarct met 
trombolytica behandeld worden? Deze vraag komt in hoofdstuk 7 aan de orde. 
Trombolytische therapie, ongeacht welk trombolyticum wordt gebruikt is geassocieerd 
met het optreden van intracraniele bloedingen in 0.5 tot 0.9% van de patienten. Patienten 
ouder dan 65 jaar, patienten met een laag lichaamsgewicht en patienten die coumarines 
gebruiken, hebben een verhoogd risico op een intracraniele bloeding. Men zai daarom 
bij iedere patient met het klinisch beeld van een acuut hartinfarct de verwachte baten 
van trombolyse moeten afwegen tegen de risico's. In hoofdstuk 7 wordt een risico 
functie gepresenteerd om de kans op sterfte na het hartinfarct, gegeven een bepaaide 
verwachte infarctgrootte bij opname, te voorspellen. Met een tweede risico functie kan 
het risico op een intracraniele bloeding berekend worden. Op basis van deze kansen kan 
voor een patient een uitspraak gedaan worden of de verwachte baten van trombolyse 
groter zijn dan de risico's. 
Rol van coronairangiografie voor ontslag uit bet ziekenhuis 
In hoofdstuk 8 wordt een antwoord gegeven op de vraag of een coronair-
angiografie voor ontslag uit het ziekenhuis noodzakelijk is voor alle patienten die 
behandeld zijn met trombolytica voor een hartinfarct. Coronairangiografie voor ontslag 
uit het ziekenhuis bleek bij patienten zonder angina pectoris en zonder risicofactoren 
zoals een eerder hartinfarct, gebruik van diuretica en/of digitalis en met een 
bloeddrukstijging van tenminste 30 mmHg tijdens fietsergometrisch onderzoek, niet 
zinvol. Deze patienten (47% van de onderzochte populatie) hebben een zeer goede 
prognose; 98.6% van deze patienten is na een jaar nog in Ieven en voorspelling van 
sterfte bij deze patienten wordt niet verbeterd door kennis van de coronaire anatomie. 
Coronairangiografie moet dan ook worden gereserveerd voor patienten die opnieuw 
symptomen van ischemie krijgen en voor die patienten die een verhoogd risico hebben, 
en dan nog aileen wanneer men mag verwachten dat met een kransvatoperatie of een 
bailondilatatie dit risico kan worden verkleind. 
Conclusie 
De fibrinespecificiteit van rt-PA is bevestigd in patientgebonden onderzoek. Rt-
PA beperkt de infarctgrootte, spaart de linkerhartkamerfunctie en vermindert de sterfte 
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na een hartinfarct. Echter, in een aantal patienten met een verhoogd risico op een 
intracraniele bloeding, kan trombolyse levensbedreigend zijn. Het is de taak van de 
clinicus om bij iedere patient de verwachte baten en risico's af te wegen. De verwachte 
infarctgrootte zonder trombolytische behandeling is bij deze afweging van groot belang. 
Deze verwachte infarctgrootte kan op basis van de klinische toestand van een patient en 
bet ECG bij opname worden voorspeld. De nazorg van patienten met een acuut 
hartinfarct die trombolytische behandeling hebben gekregen verschilt niet van de 
behandeling van patienten met een acuut hartinfarct die geen trombolyse hebben 
gekregen. 
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ID nr: 
EUROPEAN CO-OPERATIVE STUDY GROUP FOR RECOMBINANT 
TISSUE-TYPE PLASMINOGEN ACTIVATOR {rt-PA) 
Inclusion criteria: 
1. age 21 - 70 years 
LV-FUNCTION STUDY 
CASE RECORD FORM 
(rt-PA versus placebo trial) 
2. EGG changes typical for AMI 
3. severe chest pain which lasted more than 30 minutes 
4. onset of attack less than 5 hours before experimental 
treatment can be started 
Exclusion criteria: 
1. age under 21 or over 70 years 
2. unable to give informed consent 
TIME-WINDO\~ FOR 
YOUR CLINIC: 
8 
A-1 
3. prolonged or traumatic cardiac massage BLOOD SAr1PLE FOR 
4. respirator required SPECIAL HEMOSTATIC 
5. transmural myocardial infarction less than 14 days ago TESTS: 
6. current treatment with coumarin anticoagulants 8 
7. pregnant or currently menstruating 
8. recent major trauma (especially head!) st•cker 
9. known bleeding disorder " 
10. previous coronary bypass surgery 
11. major non-heart surgery less than 3 months ago 
12. cerebrovascular accident less than 3 months ago 
13. gastro-intestinal bleeding less than 3 months ago 
14. genito-urinary bleeding less than 3 months ago 
15. known major hepatic disease (alcoholism) 
16. known major renal disease 
17. known proliferative diabetic retinopathy 
18. any known disease with anticipated survival less than 2 years 
19. anticipated problems with follow-up (i.e. no permanent address, 
living abroad, etc.) 
20. persistent hypertension at admission despite treatment (systolic above 200 mmHg) 
21. previous myocardial infarction in same localization 
22. previous participation in the rt-PA LV Function Study 
23. complete left bundle branch block 
24. not able to perform 10-22 day exercise test (bicycle or treadmill) 
for non cardiac reasons 
25. any other reason for excluding patient 
135.10 - February 26, 1986 These forms are copyrighted 
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ID nr: 
EUROPEAN CO-OPERATIVE STUDY GROUP FOR RECOMBINANT TISSUE-TYPE PLASMINOGEN 
ACTIVATOR (rt-PA) 
This form consists of THREE TYPES OF ITEMS: 
1. Sequentially numbered QUESTIONS, 
2. SPECIFIC INSTRUCTIONS, 
3. Boxed GENERAL PROCEDURAL INSTRUCTIONS, which appear between numbered items at the 
moment they must be observed. 
How to use this form 
--------------------
WORK THROUGH THIS FORM ITEM BY ITEM AND LINE BY LINE IN SEQUENTIAL ORDER, UNLESS 
OTHERWISE DIRECTED BY JU~1P INSTRUCTIONS (see below). USE CARD PROVIDED TO PREVENT 
SHOW-THROUGH (NCR PAPER!) 
Categorized questions etc.: TICK OFF APPROPRIATE SPACE, I.E. ( ). 
(~---+-GO TO ITEM 7, skip all items inbetween 
(st~---+- PATIENT IS INELIGIBLE, remainder of form need not be filled out. Discard 
original of form, retain red copy for your own reference and SEND BLUE COPY 
/ TO DATA CENTER 
(v) ---+-i.e. neither a number nor a 'stop', GO TO NEXT LINE 
Data entry: 
·E·Cl.·C:.•_• 
,_,fl,Q, 
:J_,Q/Q,!_Ifi,Q. 
d m y 
TEXT and LOCAL REGISTRATION NUMBERS are entered LEFT-JUSTIFIED, in 
CAPITALS, ONE CHARACTER PER SPACE 
NUMERICAL DATA are entered RIGHT-JUSTIFIED, but OBSERVE DECIMAL POINT 
Dates: OBSERVE DAY-MONTH-YEAR ORDER 
Times: USE 24-HOUR CLOCK, i.e. 9 o'clock p.m. = 2hL:Q~i? 
Correction of mistakes: 
draw empty space N(~~ YES NO /YES ~tick off space which applies 
r; (stop) ____.. (~() (s~ /3 ~ 13 :::::=put your initials in the margin 
,J.,fl,Q,l1,_,_,_, ____.. ·.B.·f.·f2·~· IS 
Cross-identification of study material 
In some countries, for legal reasons, all study material which is not retained by 
you must be anonymous as far as the patient is concerned. FOR FUTURE REFERENCE and 
FOLLOW-UP, OBSERVE THE FOLLOWING: 
1. Your own HOSPITAL's patient REGISTRATION NUMBER is essential and MUST BE LEGIBLE ON 
ALL FORM COPIES. 
2. To allow for future linkage between numbers and names; the PATIENT ID PAGES MUST BE 
FULLY COMPLETED. 
3. Forms, tubes for blood sampling, and treatment packages are already numbered and 
peel-cff stickers are provided. THESE MUST BE USED AS DIRECTED. 
Notification of serious complications 
In case of serious complications telephone in first instance within 24 hours: 
Dr. R.J. Lennane: 49 6132 77 2420 (tel. private: 49 6704 2519); 
If not available report to: 
Dr. W.E. Welbers: 49 6132 77 2152 (tel. private: 49 6121 567169); 
Dr. Taylor : 49 6132 77 3141 (tel. private: 49 6132 2894); 
Dr. W. Feuerer : 49 7351 54 4292 (tel. private: 49 7351 28165). 
For emergency film return and urgent questions 
Telephone "TPA- film service" (24 hours a day), tel: 31 20 161771. 
Important addresses 
1. Dr. W. Feuerer, Dr. K. Thomae GmbH, Postfach 1755, D-7950 Biberach 1, Germany. 
2. TPA DATA CENTER, c/o Stichting Cardialysis, Westzeedijk 120, 3016 AH Rotterdam, 
The Netherlands. In case of questions: call the data center at 31 10 4360511. 
FLOI•I CHART: rt-PA LV-FUNCTION STUDY, rt-PA versus PLACEBO 
Selection procedure 
ECG 
Physical examination 
BP +pulse rate 
Informed consent 
Blood sample central 
enzyme analysis (ENZ) 
Blood sample local 
hematology and chemistry 
Blood sample special 
hemostatic tests (HEM) 
(OPTIONAL) 
Heparine bolus + 
heparine infusion 
Acetyl salicylic acid 
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Make appointments 10-22 day 
LV-function tests 
(TIME-WINDOW on cover) 
Exercise test 
Radionuclide angiography 
Catheterization 
Blood sample antibody 
test (ANT) 
1ETF : 10-22 day Exercise Test Form 2RAF : 10-22 day Radionuc1ide Angiography Form 
3CAF : 10-22 day Catheterization Form 
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two days 
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> w 
I 
! 
Table 1 Classification hemodynat.lic state 
M!RU/KILL!P class I II Ill IV 
HHIODYNAMIC CLASSIFICATION 
Hyperdynami c3 norma 1 mild failure overt fa i1 ure b shockb 
Heart rate > 80 60- 80 80-100 90-!iO > !10 
MAPd > 100 90-100 80- 90 60- so 60 
LVFPe 11 < 12 11- 16 16- 20 > 20 
Cardiac Index > 4.0 3.0-4.0 2.5-3.0 2.0-2.5 < 2.0 
SW!f >4000 3000-4000 1200-3000 1200-2000 < 1200 
CLIII!CAL CLASSIFICATION 
Hyperdynamic norma 1 mild failure overt failure shock 
Mental state ar1xiety norma 1 tense anxiety restless 
Skin dry, warm dry, warm warm cool clammy 
Pulse norma 1 normal norma 1 weak very weak 
Lungs clear clear basa 1 rhonchi rhonchi 1 ung edema 
Heart sounds norma 1 norma 1 53 ? s3 + s4 s3 + s4 
Urine > oO roll /h >50 ml/h 40-oO ml /h ZC-40 ml /h < 20 ml/h 
a. A subset of patients suffers from hypovolemia, LVFP < 5 rrmHg 
b. Right ventricular infarction may cause hypotension and tachyca1~d1a with elevated central venous 
pressure and low LVFP. 
c. MIRU = Myocardial Infarction Research Unit 
d. MAP = l~ean Arterial Pressure 
e. LVFP =Left Ventricular Filling Pressure 
f. SWI = Stroke \~ork Index 
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THERAPEUTIC GUIDELINES CHART 
GU!DEL!IIES FOR TREATf.IEIIT OF PATIENTS WITH ACUTE HYOCARDIAL INFARCTION, 
PARTICIPATIIIG HI THE T\~0 RELATED STUDIES OF THE EFFECT OF rt-PA ON INFARCT SIZE, 
LEFT VENTRICULAR FUNCTION AND CLINICAL FOLLOIHP. 
Treatment of pain and anxiety 
For pain at admission: sublingual nitroglycerine and/or nifedipine. 
For persistent pain: i .v. morphine or thalamonal. 
If the patient was treated with beta-blockers, nitrates or· calciun1 antagonists 
befot•e admission these should be continued during the first 24 hours, unless 
contraindicated by the hemodynamic state. 
Hemodynamic monitoring with Swan Ganz catheters and intta-arterial line should 
be performed in patients with ovErt heart failure (see table 1) or cardiogenic 
shock. Other patients can be monitored according to local protocol. 
Do not introduce catheters via the subclav10n vein! 
Anticoagulation with i .v. heparine should be undertaken ~lith a dosage of 1000 
IU/hour, after an initi[ll bolus of 5000 IU. 
Hepat•in may be followed by oral anticoagulation at the third c.dy, provided that 
complete anticoagulation is maintained. 
Correction of her10dynamic abnormalities 
In order to reduce rnyoca1·dial ischemia, 't·le should aim at prompt co1Tection of 
hemodynamic abnonM 1 i ties, ~1hen present. 
In order to achieve this, the guidelines of tables I and II should be follm·1ed. 
Treatment of arrhythmias 
Ventricular or suptaventricular tachyarrhythmias 1~hich cof'lpromise circulation: 
cat·dioversion as treatment of choice. 
In case of ventriculat· tachycardia 1·1ithout hemodynamic impairment, lidocainE 
bolus 1 mg/kg i.v. (2 injections of 50 111g each) followed by 2-4 mg/min. i.v. 
infusion. 
In cases unresponsive to lidocaine, disopyramide, procaineamide, 111exiletine or 
other drugs should be used according to the local experience. Amiodarone i.v. 
(1200 mg/24 hours) may be used in patients unresponsive to class I drugs. 
THERAPEUTIC GUIDELINES CHART 
In case of supraventricular tachyarrhythmias without hemodynamic impairment 
digoxine or verapamil i .v. should be used. 
Pacemakers should be inserted for complete heartblock, f·1obitz type II block, 
sinus bradycardia 60 bpm and hypotension not responsive to atropine, and in 
case of new right bundle branch block 1·1ith left anterior or inferior hemiblock. 
Recurrent angina or transient ischemia should be treated with beta-blockers 
(unless heart rate during the episodes of ischemia is less than 60 bpm) and 
nitt·ates. Calcium-blockers will be used as thira line drugs. 
Ot•al anticoagulants should be used up to angiography and should thereafter be 
continued in cases of left ventricular aneurysm, mitral insufficiency, or persistent 
atrial fibl'illation, unless the hospital decides to give anticoagulants to all 
patients. 
Long term use of antiarrhythmics should be 1 imited to patients 1vith recurrent 
symptomatic tachyarrhythmias aftet• the first 48 hours of infarction. 
Long term use of digitalis should be limited to patients with persistent signs of 
heart failure or with paroxysmal supraventl'icular tachyarrhythmias after the first 
48 hours of infarction. 
Hypertension should be treated with beta-blockers, if needed 1~ith additional 
diuretics and as a further choice with vasodilators. 
Between the lOth and the 22th day an exercise test, cardiac catheterization with 
left ventriculography and radionuclide angiography should be performed. All 
clinically prescribed medication should be continued during these procedures. 
Aftet• completion of the exercise test and cat·diac catheterization, all patients 
should be treated 1·1ith beta-blockers (recommended dose metoprolol 2xl00 mg) since 
such treatment favourably influence~ prognosis after myocardial infarction, unless a 
contraindication is present. 
Coronary artery bypass surgery or PTCA will be reconsidered only in patients with 
recurrent angina despite therapy with beta-blockers. The sole exception is a mainstem 
lesion (diameter obstruction >50%), ~lhich is an indication for bypass surgery (or 
PTCA) even in the absence of symptoms. 
> I 
Ul 
A-6 ID nr: 
EUROPEAN CO-OPERATIVE STUDY GROUP FOR RECOMBINANT TISSUE-TYPE PLASMINOGEN 
ACTIVATOR (rt-PA) 
THIS PAGE MUST BE COMPLETED FOR EVERY PATIENT CONSIDERED FOR INCLUSION. 
HOWEVER, IF YOU CANNOT SUPPLY THE DATA CENTER AND THOMAE WITH THE PATIENT'S NAME AND 
ADDRESS, YOU ARE ALLOWED TO CUT OFF THE BOTTOM PART OF THE WHITE AND BLUE COPIES OF 
THE FORM BEFORE SENDING THEM IN. 
YOUR OWN RED COPY MUST ALWAYS BE FILLED OUT AND STORED FOR FUTURE REFERENCE, 
SEPARATELY FROM PATIENT'S HOSPITAL FILE. 
P A T I E N T I C L I N I C I D E N T I F I C A T I 0 N 
1. Give clinic identification: 
1.1 Name: --------------------------
1. 2 City: -------------------------
2. Give patient identification: 
2.1 Hospital registration number: 
2.2 Date of birth: , I , I , 
-d--m-y-
2. 3 Sex: ( ) rna 1 e 
( ) fema 1 e 
3. Give patient name and address: 
,_,_,_,_,_,_,_,_._,_._. (double check!) 
Family name: ,_,_,_,_._,_,_._._,_,_,_,_._,_._,_,_,_,_,_._,_. 
Initials: 
Maiden name: (if married) 
Street ,_,_,_,_,_,_,_,_,_,_,_,_,_,_,_,_,_,_,_,_,_, Nr: ,_,_,_,_,_, 
City ._,_._._,_,_,_,_,_,_,_,_,_,_._._._,_,_,_,_, 
Country: ,_,_,_,_,_,_,_,_,_,_,_,_,_,_,_, 
Telephone: ,_,_,_,_,_, ,_,_,_,_,_,_,_, 
._._._,_. 
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ID nr: A-7 
EVALUATE FOR ELIGIBILITY ALL PATIENTS THAT FULFIL THE FOLLOWING CRITERIA: 
1. Age 21-70 years. 
2. EGG-changes typical for AMI and severe chest pain which lasted more than 30 minutes. 
3. Onset of attack less than 5 hours before experimental treatment can be started. 
COMPLETE SELECTION PROCEDURE AND PROCEED TO EXPERIMENTAL TREATMENT INFUSION AS SOON 
AS POSSIBLE!! ---
THERAPEUTIC GUIDELINES (for more details see "Therapeutic Guidelines Chart"): 
- For chest pain at admission: sublingual nitroglycerine and/or nifedipine. 
-For persistent chest pain: i.v. morphine or Thalamonal. 
- Antiarrhythmics only on indication. 
- If the patient was on maintenance treatment with S-blockers, nitrates or calcium 
antagonists before admission these should be continued during the first 24 hrs, 
unless contra1ndicated. 
- Other supportive medication may be given as required. 
- Prophylactic S-blockers should not be given until after 10-22 days LV function 
assessments. 
- Hemodynamic monitoring may be done according to local routine. 
4. Time of admission to CCU: 1 : 1 
-h--m-
5. Do you consider catheterization (day 10-22} contraindicated 
or anticipate technical problems? 
If yes, why: -------------------
6. Did the patient have at least one major attack of severe chest 
pain typical for AMI that lasted more than 30 min.? 
7. Is the onset of the major attack that lasted more than 30 min. 
definable in time? 
9. Can infusion of experimental treatment be started 
within 5 hours from onset of major attack? 
10. Is it likely that the patient has had a previous myocardial 
infarction IN THE SAME LOCALIZATION? 
CONTINUE NEXT PAGE 
NO 
(6} 
NO 
(stop} 
NO 
(stop} 
NO 
(stop) 
NO 
(11) 
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YES 
(stop} 
YES 
(7) 
YES 
(8} 
YES 
(10} 
YES 
(stop) 
A-8 ID nr: 
11. Evaluate most recent standard 12-lead ECG made after CCU admission: 
11.2 Complete left bundle branch block? 
NO 
( ) 
11.3 Evaluation of ST-segment 60 msec after J-point: Complete all 3 columns 
AT LEAST 2 mm AT LEAST 1 mm 
ST ELEVATION ST ELEVATION 
NO YES NO YES 
I? ( ) ( ) 
II? ( ) ( ) II? ( ) ( ) 
III? ( ) ( ) III? ( ) ( ) 
aVL? ( ) ( ) 
aVF? ( ) ( ) aVF? ( ) ( ) 
AT LEAST 3 mm AT LEAST 2 mm 
ST ELEVATION ST DEPRESSION 
NO YES NO YES 
V1? ( ) ( ) V1? ( ) ( ) 
V2? ( ) ( ) V2? ( ) ( ) 
V3? ( ) ( ) V3? ( ) ( ) 
V4? ( ) ( ) V4? ( ) ( ) 
AT LEAST 2 mm 
ST ELEVATION 
NO YES 
VS? ( ) ( ) VS? ( ) ( ) 
V6? ( ) ( ) V6? ( ) ( ) 
v v v 
START HERE 2x YES? 2x YES? 2x YES? [ NO (stop) AND FOLLOW ~ [ NO ( ) YES ( ) [ NO (stop) ARROWS: YES ( ) 1 YES ( }1 
CONTINUE CONTINUE 
- STORE ORIGINAL OF THIS ECG FOR TRANSFERRAL TO DATA CENTER 
- MARK WITH DATE, TIME AND ID NR PEEL-OFF STICKER 
- IF YOU NEED ECG FOR PATIENT FILE, REPEAT ECG OR MAKE COPY 
YES 
(stop} 
sys: , , , mmHg dia: _,_,_, mmHg pulse rate: _,_,_, bpm 
12.2 Systolic blood pressure over 200 mmHg? 
NO 
(13} 
YES 
(12.3} 
12.3 If yes, treat blood pressure (see "Therapeutic Guidelines Chart") and reevaluate: 
sys: _,_,_, mmHg dia: _,_,_, rnmHg 
12.4 Systolic blood pressure now under 200 mmHg? 
pulse rate: _,_,_, bpm 
NO 
(stop} 
YES 
(13} 
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ID nr: 
13. Evaluate clinical hemod~namic state: 
13.1 Tick one aspect in.each horizontal row: 
Mental state: ( ) normal ( ) tense ( ) anxiety ( ) 
Skin ( ) dry, warm ( ) warm ( ) cool ( ) 
Pulse ( ) norma 1 ( ) weak ( ) 
Heart sounds: ( ) normal ( ) weak s3 ( ) 53 + 54 
Lungs ( ) clear ( ) crepitations ( ) crepitations ( ) 
(::;; 10 em) ( > 10 em) 
13.2 Give an overall impression of hemodynamic state (tick all that apply): 
( ) normal 
( ) mild left heart failure 
( ) overt left heart failure 
( ) shock 
( ) right heart failure 
IF: - heartrate under 60 or over 90 bpm or 
- systolic blood pressure under 100 or over 140 mmHg or 
- signs of heart failure: 
+ INITIATE CORRECTION IMMEDIATELY (SEE "Therapeutic Guidelines Chart") 
14. Was correction of hemodynamic state initiated? 
14.1 If yes, specify:-------------------
15. Verify absence of remaining reason(s) for exclusion (check all): 
15.1 age under 21 or over 70 years 
15.2 unable to give informed consent 
15.3 prolonged or traumatic cardiac massage 
15.4 respirator required 
15.5 transmural myocardial infarction less than 14 days ago 
15.6 current treatment with coumarin anticoagulants 
15.7 pregnant or currently menstruating 
15.8 recent major trauma (especially head!) 
15.9 known bleeding disorder 
15.10 previous coronary bypass surgery 
15.11 major non-heart surgery less than 3 months ago 
15.12 cerebrovascular accident less than 3 months ago 
15.13 gastro-intestinal bleeding less than 3 months ago 
15.14 genito-urinary bleeding less than 3 months ago 
15.15 known major hepatic disease (alcoholism) 
15.16 known major renal disease 
15.17 known proliferative diabetic retinopathy 
15.18 any known disease with anticipated survival less than 2 years 
15.19 anticipated problems with follow-up (i.e. no permanent 
address, living abroad, etc.) 
15.20 previous myocardial infarction in same localization 
15.21 previous participation in the rt-PA LV Function Study 
15.22 not able to perform 10-22 day exercise test (bicycle or 
treadmill) for non cardiac reasons 
15.23 any other reason for excluding patient 
NO 
(15) 
NO 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
A-9 
restless 
clammy 
very weak 
lung edema 
YES 
(14.1) 
YES 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
Give pertinent details below: ANY "YES" STOP 
-ALL "NO": CONTINUE 
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16. Obtain consent 
16.1 Time attempted: , : , 
-h--m-
ID nr: 
By Dr : 
Witness: 
____ ._._._,_,_,_,_,_._,_._, 
,_,_._,_._._,_._._,_._._,_,_._. 
Signature:----------
Signature:----------
16.2 Was consent obtained? 
16.3 FILL OUT PATIENT CONSENT FORM (if required in your clinic) 
17. Execute the following (give times and measurements as indicated): 
17.1 Make standard 12-lead ECG IF THE LAST ONE WAS MADE MORE 
THAN 30 MIN AGO (store original for transferral to data 
center, mark with date, time, ID nr peel-off sticker). 
17.2 Obtain blood sample (5 ml) for central G 
enzyme analysis. Use provided tube 
(marked ENZ). Put peel-off sticker with 
·tube number in box (all 3 copies!). sticker 
Centrifuge blood immediately (10-20 min, 
2500-4000 RPM). Transfer plasma with 
pipette to tube with same number and 
store at -20°C. 
17.3 Obtain blood samples for local hematology and chemistry; 
at least: hemoglobin, hematocrit, platelet count, serum Na, 
K, creatinine, SGOT, SGPT, LDH, a-HBDH, CK, CK-MB if 
available. 
17.4 OPTIONAL (see STICKER on cover): G 
Obtain blood sample (5 ml) for special 
hemostatic tests. Use provided tube . 
(marked HEM). Put peel-off sticker st~eker 
with tube number in box (all 3 copies!). 
Store on ice until centrifugation. 
17.5 Measure blood pressure and pulse rate: 
sys: _,_,_, mmHg dia: _,_,_, mmHg pulse rate: 
' ' ' 
18. Give heparin; i.v. bolus 5.000 IU, start heparin infusion 
(1000 IU/hour) and continue until catheterization or at 
least for 4 days until therapeutic effect of oral coumarins 
has been achieved (see "Therapeutic Guidelines Chart") 
19. Give acetyl salicylic acid; 75-125 mg and continue 
once every \TWO DAYS. 
bpm 
NO 
(stop) 
TIME 
Indicate dosage used: ,_,_,_, mg 
** ERRATUM CASE RECORD FORM PAGE 5 ** 
CONTINUE NEXT PAGE 
Item 19: Give acetyl salicylic acid: 
250 mg INTRAVENOUSLY (Aspisol, Aspegic) 
Continue with 75-125 mg orally 
once every TWO DAYS until discharge. 
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YES 
(16.3) 
A-ll 
ID nr: 
20. Obtain treatment allocation: 
Dial (international access code) 31 20 839601, call will be responded by: 
'TPA allocation service'. DO NOT USE THIS TELEPHONE NU~1BER FOR ANY OTHER PURPOSE! 
Dictate the following information (in the order given): 
-Your clinic name and city (allow time at other end to search for appropriate file) 
- Your name 
- Patient's hospital registration number, sex, date of birth (item 2) 
- ID nr (see top of page) 
TELEPHONE OPERATOR WILL GIVE YOU THE NUMBER OF THE TREATMENT PACKAGE TO BE USED 
~WARNING: PATIENTS NOT ALLOCATED THROUGH ALLOCATION SERVICE ~ILL NOT BE EVALUATED!! 
20.1 Was allocation obtained?: 
If no, why not? -----------------
20.2 Note number of treatment package: I I I I I 
TIME 
20.3 Time and date allocation obtained: 
THE PATIENT IS NOW IRREVOCABLY ADMITTED TO THE TRIAL. 
NO 
(stop) 
YES 
(20.2) 
IF YOU DECIDE NOT TO ADMINISTER EXPERHlENTAL TREAH1ENT, ALL OBSERVATIONS AND 
MEASUREMENTS MUST BE COMPLETED AS ~lUCH AS POSSIBLE ('INTENTION-TO-TREAT' PRINCIPLE!!) 
USE SEPARATE INTRAVENOUS LlNE FOR INFUSION OF EXPERIMENTAL TREATMENT. 
DO NOT ADMINISTER OTHER DRUGS THROUGH SAME LINE!! 
21. Open treatment package which bears number obtained from allocation service (item 20). 
Put peel-off sticker in box (all 3 copies!). 
MAKE UP INFUSION AND ADMINISTEK 
EXPERIMENTAL TREATMENT AS DIRECTED 
BY TREATMENT PACKAGE INSERT. 
21.1 Did you start experimental treatment infusion? 
21.2 IF NO, reason:-------------------
COMPLETE MEASUREMENTS AND OBSERVAT~ONS IF AT ALL POSSIBLE 
GO TO ITEM 22 
TIME 
21.3 Indicate time INFUSION STARTED: 
CONTINUE NEXT PAGE 
NO 
(21.2) 
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YES 
(21.3) 
A-12 ID nr: 
22. Chest pain present at start of experimental treatment infusion? 
22.1 If no, indicate time pain disappeared: 
GO TO ITEM 23 
22.2 If yes, indicate type (tick one): 
( ) typical ischemic chest pain 
( ) atypical chest pain 
IF EXCESSIVE BLEEDING OCCURS, HANDLE AS FOLLOWS: 
- INTERRUPT INFUSION 
- WHEN ADDITIONAL MEASURES ARE REQUIRED: 
- give fresh whole blood or fresh frozen plasma 
NO 
(22.1) 
TIME 
-give tranexamic acid 10 mg/kg slow i.v.; if necessary repeat after 30 min. 
-OR give aprotinin (Trasylol®) 500.000 KIU slow i.v.;' if necessary followed 
by 100.000 KIU every 2 hours. 
DO NOT BREAK DOUBLE BLINDING UNLESS ABSOLUTELY NECESSARY 
TREAT OTHER COHPLICATIONS ACCORDING TO LOCAL PROTOCOL 
23. 120 min .. after start of ex erimental treatment infusion, 
execute the following: give actual times 
23.1 Measure blood pressure and pulse rate: 
sys: _,_,_, mmHg dia: _,_,_, mmHg pulse rate: , , , bpm 
23.2 OPTIONAL (see STICKER on cover): 
Obtain blood sample (5 ml) for 
special hemostatic tests. Use pro-
vided tube (marked HEM). Put peel-
off sticker with tube number in box 
(all 3 copies!). Store on ice until 
centrifugation. 
TIME 
AS SOON AS EXPERINENTAL TREATMENT INFUSION HAS BEEN COMPLETED, PROCEED AS FOLLOWS: 
24. Indicate time experimental treatment infusion was stopped: 
24.1 Was full dose of experimental treatment infusion given? 
24.2 If no, why not?------------------
Indicate amount given: , , , , ml 
~ COMPLETE MEASUREMENTS AND OBSERVATIONS IF AT ALL POSSIBLE 
25. Was double-blind code broken? 
25.1 If yes, why? -------------------
TIME 
NO 
(24.2) 
NO 
(26) 
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YES 
(22.2) 
YES 
(25) 
YES 
(25.1) 
A-13 
ID nr: 
26. Make standard 12-lead ECG (store original for transferral to data 
center, mark with date, time, ID nr peel-off sticker). 
TIME 
27. Measure cuff blood pressure (diastolic= disappearance of sound) and pulse rate 
sys: _,_,_, mmHg dia: _,_,_, mmHg pulse rate: _,_,_, bpm 
28. Evaluate clinical hemodynamic state: 
Tick one aspect in each horizontal row: 
Mental state ( ) normal ( ) tense ( ) anxiety ( ) restless 
Skin ( ) dry,warm ( ) warm ( ) cool ( ) clammy 
Pulse ( ) normal ( ) weak ( ) very weak 
Heart sounds ( ) normal ( ) weak s3 ( ) 53 + 54 
Urine, if known: ( ) >50 ml/h ( ) 40-50 ml/h ( ) 20-40 ml/h ( ) <20 ml/h 
Lungs ( ) clear '( ) crepitations ( ) crepitations ( ) 
( ~10 em) (>10 em) 
29. Give an overall impression of hemodynamic state (tick all that apply): ( ) normal 
( ) mild left h.eart failure 
( ) overt left heart failure 
( ) shock 
( ) right heart failure 
12 HOURS AFTER TELEPHONE ALLOCATION, PROCEED AS FOLLOWS: 
lung edema 
(It is allowed to take the following blocd sample slightly earlier, but not later 
than 12 hours after allocation) 
30. Execute the following (give actual times as indicated): 
30.1 Obtain blood sample {5 ml) for 
central enzyme analysis. Use 
provided tube (marked ENZ). 
Put peel-off sticker with tube 
number in box (all 3 copies!). 
Centrifuge blood immediately 
(10-20 min, 2500-4000 RPM). 
Transfer plasma with pipette 
to tube with same number 
and store at -20°C. 
EJ 
30.2 Obtain blood samples for local hematology and chemistry. 
At least: hemoglobin, hematocrit, platelet cour.t, 
serum Na, K, creatinine, SGOT, SGPT, LDH, ~-HBDH, 
CK, CK-MB if available. 
24 HOURS AFTER TELEPHONE ALLOCATION, PROCEED AS FOLLOWS: 
TIME 
(It is allowed to take the 24 hours blood sample slightly earlier or later, provided 
that the timespan between the previous blood sample (at 12 hours) and the blood sample 
at 24 hours does not exceed 12 hours). 
31. Execute the following (give actual times as indicated): 
31.1 Make standard 12-lead ECG (store original for 
transferral to data center, mark with date, time, 
ID nr peel-off sticker). 
TI~1E 
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A-14 
ID nr: 
( 31. continued) 
31.2 Obtain blood sample (5 ml) for central 
enzyme analysis. Use provided tube 
(marked ENZ). Put peel-off sticker with 
tube number in box (all 3 copies!). 
Centrifuge blood immediately (10-20 min, 
2500-4000 RPM). Transfer plasma with 
pipette to tube with same number and 
store at -20°C. 
EJ 
31.3 Obtain blood samples for local hematology and chemistry. At least: 
hemoglobin, hematocrit, platelet count,serum Na, K, creatinine, 
SGOT, SGPT, LDH, a-HBDH, CK, CK-MB if available. 
31.4 OPTIONAL (see STICKER on cover): 
Obtain blood sample (5 ml) for special 
hemostatic tests. Use provided tube 
(marked HEM). Put peel-off sticker 
with tube number in box (all 3 copies!). 
Store on ice until centrifugation. EJ 
GIVE BELOW INTERIM CLINICAL HISTORY UP TO 24 HOURS AFTER TELEPHONE ALLOCATION 
32. 
in use within admission allocation 
TIME 
TIME 
TIME 
after 
72 h before 72 h before till ti 11 end of end of 
admission admission allocation infusion infusion 
- antiplatelet drugs ( ) ( ) ( ) ( ) ( ) 
- analgesics (opiates) ( ) ( ) ( ) ( ) ( ) 
- beta-blockers ( ) ( ) ( ) ( ) ( ) 
- calcium antagonists: - oral ( ) ( ) ( ) ( ) ( ) 
- i. v. ( ) ( ) ( ) ( ) ( ) 
-nitrates: - s.l. ( ) ( ) ( ) ( ) ( ) 
- i .v. (continuous) ( ) ( ) ( ) ( ) ( ) 
- other vasodilators ( ) ( ) ( ) ( ) ( ) 
- antiarrhythmics ( ) ( ) ( ) ( ) ( ) 
-digitalis ( ) ( ) ( ) ( ) ( ) 
- dopamine/dobutamine ( ) ( ) ( ) ( ) ( ) 
- other positive inotropics ( ) ( ) ( ) ( ) ( ) 
- diuretics ( ) ( ) ( ) ( ) ( ) 
- thrombolytic agents other than 
trial medication, specify: 
( ) ( ) ( ) ( ) ( ) 
- any other medication, specify: 
( ) ( ) ( ) ( ) ( ) 
( ) ( ) ( ) ( ) ( ) 
( ) ( ) ( ) ( ) ( ) 
( ) ( ) ( ) ( ) ( ) 
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ID nr: 
(continued) INTERIM CLINICAL HISTORY UP TO 24 HOURS AFTER TELEPHONE ALLOCATION 
33. Indicate total amount of opiates (if any) given up to 24 hours after 
allocation (tick all that apply). If none were given indicate with zero: 
( ) morphine 1_1_1_1 
( ) Thalamonal 1 1 1 1 
( ) others 
mg, number of i nj ecti ons: 1 1 1 
ml, number of injections: 1 1 1 
mg, number Of injections: 1 1 1 
specify: ______________________________ __ 
34. Were any bleeding complications observed up to 24 hours after 
allocation? 
NO 
(35) 
A-15 
YES 
(34.1) 
34.1 If yes, tick appropriate complication/time 
combination(s) and give site: allocation after 
before till end of end of 
allocation infusion infusion 
- major (more than 5 em diameter) hematoma 
e.g. at puncture site. 
Give site: 
- prolonged (more than 30 mins) bleeding 
e.g. at puncture site. 
Give site: 
- retroperitoneal hematoma 
- cerebral or subarachnoidal hemorrhage 
Give site: 
- hematemesis 
- melena 
- hemoptysis 
- hematuria 
- other, specify: 
34.2 Were any special measures taken? 
34.3 If yes, tick all that apply and give details: 
( ) blood (product) transfusion 
( ) 
( ) 
( ) 
( ) 
( ) 
( 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
NO 
(35) 
Indicate number of units equivalent to 0.5 liter whole blood: 
( ) surgery 
( ) other, describe: -----------------------
35. Were any clinical signs of reocclusion observed up to 24 hours 
after allocation? 
35.1 If yes, indicate time: 1 : 1 and date: 1 I 1 I 1 
-h- -m- -d- -m--y-
35.2 Diagnosis based on (tick all that apply): 
( ) reappearance of chest pain 
NO 
(36) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
YES 
(34.3) 
YES 
(35.1) 
( ) exacerbation of chest pain 
( ) reappearance of ST elevation]• IF YES, STORE ORIGINAL ECG(s), MARK WITH 
( ) increase of ST elevation TIME, DATE AND ID NR PEEL-OFF STICKER 
( ) other, describe: 
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IO nr: 
(continued) INTERIM CLINICAL HISTORY UP TO 24 HOURS AFTER TELEPHONE ALLOCATION 
NO YES 
36. Were any other complications observed up to 24 hours 'after (37) (36.1) 
allocation? 
36.1 If yes, tick appropriate complication/time combination(s): 
after 
end of 
infusion 
- (exacerbation of) chest pain ~ l - systolic blood pressure under 90 mmHg ( ) ( ) 
- cardiogenic shock ( ) ( ) ( ) 
- pulmonary edema ( } ( ) ( ) 
- peripheral edema ( } ( ) ( ) 
- hepatomegaly ( ) ( ) ( ) 
- elevated CVP ( } ( ) ( ) 
- bradycardia (pulse rate under 50 bpm) ( ) ( ) ( ) 
- second degree AV-block ( } ( ) ( ) 
- third degree AV-block ( ) ( ) ( ) 
- IV conduction defect ( ) ( ) ( ) 
- atrial fibrillation/SVT ( ) ( ) ( ) 
- accelerated idioventricular rhythm 
(100 bpm or less) ( ) ( ) ( ) 
- ventricular tachycardia (100 bpm or more) ( ) ( ) ( ) 
- ventricular fibrillation ( ) ( ) ( ) 
- mitral regurgitation ( ) ( ) ( ) 
- papillary muscle rupture ( } ( ) ( ) 
- LV aneurysm ( ) ( ) ( ) 
- LV free wall rupture ( ) ( ) ( ) 
- ventricular septum rupture ( ) ( ) ( ) 
- cerebro vascular accident ( ) ( ) ( ) 
- pulmonary embolus ( ) ( ) ( ) 
- pericarditis (i.e. at least two of the following 
three: pain with breathing, friction rub, fever) ( ) ( ) ( ) 
- other.: ( ) ( ) ( ) 
NO YES 
37. Were any allergic reactions observed? (38) (37.1) 
37.1 If yes, describe and indicate time period(s) 
of occurrence by putting tick mark(s) in 
appropriate column(s): after 
end of 
infusion 
1. ( ) 
2. ( ) ( ) ( ) 
3. ( ) ( ) ( ) 
4. ( ) ( ) ( ) 
NO YES 
37.2 Were any special measures taken? (38) (37.3) 
37.3 If yes, specify: 
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(continued) INTERIM CLINICAL HISTORY UP TO 24 HOURS AFTER TELEPHONE ALLOCATION 
38. Were any of the following procedures--allowed only in case 
of a medical emergency--done between admission and 24 hours 
after allocation? 
38.1 If yes, tick all that apply and give date (first time only) 
and indication: 
NO 
(39) 
DATE TIME INDICATION 
( ) catheterization 
( ) PTCA 
( ) bypass surgery 
( ) other cardiac surgery 
( ) intra-aortic balloon pumping 
( ) respirator used 
( ) electrical counter shock 
( ) temporary pacemaker used 
( ) permanent pacemaker insertion 
( ) other, specify: 
_,_/ _,_/ -'-
_,_/ _,_/ _,_ 
_,_/ _,_/ _,_ 
_,_/ _,_/ _, _ 
_,_/ _,_/ _, _ 
_,_/ _,_/ _, _ 
_,_/ _,_/ _,_ 
_,_/ _,_/ _,_ 
_,_/ _,_/ _, _ 
_,_:_._ 
_._:_._ 
_ ,_:_,_ 
_ ,_:_._ 
_ ,_:_._ 
I : I 
_ ,_:_,_ 
_,_/_,_/_,_ ' . ' d m y -h--m-
39. Give details on clinical history at admission: (check all) 
39.1 angina pectoris since more than 4 weeks? 
39.2 angina pectoris since less than 4 weeks? 
39.3 arrhythmias or heart block? 
39.4 heart failure? 
39.5 heart surgery other than CABG? 
39.6 previous myocardial infarction? 
if yes, specify (year, etc.):-------------
39.7 other? 
if yes, specify: ------------------
40. Make an appointment for: 
NO 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
A-17 
YES 
(38.1) 
YES 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
1. Catheterization on day: 10-14, 12-16, 14-18, 16-20, 18-22 (refer to the sticker 
on the cover of the form for your clinic's prefixed time window). Use biplane 
equipment if available. 
2. Symptom limited exercise test on the day BEFORE catheterization. All tests in 
patients from one clinic should be performed on the same time of the day. Do not 
combine exercise test with radionuclide angiography or Thallium scintigraphy. 
3. Radionuclide angiography on the day BEFORE catheterization. 
41. Indicate time and date of appointments: 
- symptom limited exercise test 
radionuclide angiography 
catheterization 
CONTINUE NEXT PAGE 
DATE TIME 
_,_/ _,_/ _,_ 
_,_/ _,_/ _,_ 
-·-·-·-
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MAKE SURE THAT THE APPROPRIATE FORMS ACCOMPANY THE PATIENT WHEN HE/SHE GOES TO CENTER 
WHERE THE ABOVE TESTS ARE PERFORMED, i.e. 10-22 day Exercise Test Form 
10-22 day Radionuclide Angiography Form 
10-22 day Catheterization Form. 
ADD COPY OF ADMISSION ECG (item 11) TO THE CATHETERIZATION FORM. 
B-BLOCKERS, CALCIUM ANTAGONISTS AND NITRATES MUST BE STOPPED THE NIGHT BEFORE 10-22 DAY 
CATHETERIZATION. COUMARINS (ORAL ANTICOAGULANTS) MUST BE REPLACED BY HEPARIN 1000 IU/L. 
42. Supply name and signature of responsible physician: 
Dr: ,_,_,_,_,_,_,_,_,_,_,_, Signature:--------
THANK YOU FOR YOUR CO-OPERATION! 
~ DO NOT FORGET TO OBTAIN BLOOD SAMPLES FOR CENTRAL ENZYME ANALYSIS 36, 48, 
72 and 96 HOURS AFTER ALLOCATION (item 43). 
~[DO NOT FORGET TO OBTAIN BLOOD SAMPLES FOR LOCAL HEMATOLOGY AND CHEMISTRY 36, 
48, 72 and 96 HOURS AFTER ALLOCATION (item 65). 
THIS PART OF THE FORM SHOULD BE COMPLETED AND RETURNED 24 HOURS AFTER ALLOCATION 
OF THE PATIENT. 
STORE RED COPY OF FORM TOGETHER WITH PATIENT CONSENT FORM, READY FOR LATER REFERENCE 
(NOT IN PATIENT's FILE, USE SPECIAL STUDY BINDER). 
SEND ORIGINAL TO THOMAE (USE ENVELOPE PROVIDED). 
SEND BLUE COPY TOGETHER WITH ORIGINAL ECGs (item 11, 17.1, 26, 31.1 and 35.2 (if 
applicable)) TO DATA CENTER (USE ENVELOPE PROVIDED). 
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BETWEEN 24 AND 4x24 HOURS AFTER ALLOCATION, PROCEED -AS FOLLOWS: 
43. 
• 
Obtain blood sam~les (5 ml each) for central enzyme analysis 36, 48, 72 and 
96 hours after a locat1on. Use provided tubes (marked ENZ). Put peel-off sticker 
with tube numbers in box (all 3 copies!). Centrifuge blood immediately (10-20 min, 
2500-4000 RPM). Tranfer plasma with pipette to tube with same number and store 
at -20°C. 
NOTE: BLOOD SAMPLES AFTER 24 HOURS MAY BE TAKEN AT A FIXED TIME IN THE MORNING 
AND EVENING, e.g. 8.00 a.m. and B.OO p.m. RECORD ACTUAL TIMES!! 
sticker 
36 hours 
Date: _,_/ _,_/ _,_ 
d m y 
Time: I : I 
_h_m_ 
sticker 
48 hours 
Date: , I , I , 
-d--m--y-
Time: I : I 
-h--m-
sticker 
72 hours 
Date: , I , I , 
-d--m--y-
Time: 
' . ' 
-h--m-
sticker 
96 hours 
Date: , I , I , 
-d--m--y-
Time: 
' . ' 
-h--m-
r
DO NOT FORGET TO OBTAIN BLOOD SAMPLES FOR LOCAL HEMATOLOGY AND CHEMISTRY 36, 
~ 48, 72 and 96 HOURS AFTER ALLOCATION (item 65). 
STORE RED COPY OF FORM TOGETHER WITH PATIENT CONSENT FORM, READY FOR LATER REFERENCE (NOT IN PATIENT's FILE, USE SPECIAL STUDY BINDER). 
SEND ORIGINAL TOGETHER WITH REMAINDER OF THE FORM TO THOMAE (USE ENVELOPE PROVIDED). 
SEND BLUE COPY TOGETHER WITH REMAINDER OF THE FORM TO DATA CENTER (USE ENVELOPE 
PROVIDED). 
DO NOT FORGET TO STOP S-BLOCKERS, CALCIUM ANTAGONISTS AND NITRATES THE NIGHT BEFORE 
10-22 DAY CATHETERIZATION. COUMARINS (ORAL ANTICOAGULANTS) MUST BE REPLACED BY 
HEPARIN 1000 IUIH. 
REFER TO THERAPEUTIC GUIDELINES CHART FOR RECOMMENDED THERAPY AT DISCHARGE. 
** ERRA TUI'I CASE RECORD FORI'I PAGE 14, 1 35. 1 0 ** 
l'lake standard 12-lead ECG within 10-22 days 
time-window (see sticker an cover) .. 
Store original, mark with date, time and ID-nr 
peel-off sticker. 
DATE: _ _! _ _! __ 
d m y 
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THIS PART OF THE FORM MUST BE COMPLETED FOR ALL PATIENTS AT DISCHARGE 
REFER TO THE STICKER ON THE COVER OF THE FORM FOR YOUR CLINIC'S PRE-FIXED TH1E WINDOW. 
44. Was the symptom limited pre-discharge exercise test performed? 
44.1 If no, why not (tick all that apply): 
( ) persistent angina pectoris 
( ) heart failure 
( ) other cardiac, specify:---------------
( ) non cardiac, specify:---------------
()other, specify:---------------GO TO ITEM 45 
44.2 Date performed: , I , I , 
-d--m--y-
NO 
(44.1) 
44.3 Clinic where test was done:---------------
YES 
(44.2) 
NO YES 
44.4 Is the above date within your clinic's pre-fixed time window? (44.5) (45) 
44.5 If no, why not:--------------------
45. Was radionuclide angiography performed? 
45.1 If no, give reason (tick all that apply): 
( ) cardiac, specify: 
( ) non cardiac, specify: 
( ) other, specify: 
GO TO ITHl 46 
45.2 Date performed: , I , I , 
-d--m--r 
45.3 Clinic where test was done:---------------
NO 
(45.1) 
YES 
(45.2) 
NO YES 
45.4 Is the above date within your clinic's pre-fixed time window? (45.5) (46) 
45.5 If no, why not: --------------------
46. Was pre-discharge cardiac catheterization (coronary angiography 
and left ventriculography) performed? 
46.1 If no, give reason (tick all that apply): 
( ) cardiac, specify: 
( ) non cardiac, specify; 
( ) other, specify: 
GO TO ITEM 47 
46.2 Date performed: , I , I , 
-d--m--y-
NO 
(46.1) 
46.3 Clinic where test was done:---------------
YES 
(46.2) 
NO YES 
46.4 Is the above date within your clinic's pre-fixed time window? (46.5) (47) 
46.5 If no, why not: -------------------
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The information you are asked to provide below should relate to the PATIENT'S 
STATUS AT DISCHARGE FROM.YOUR HOSPITAL {NOT NECESSARILY YOUR CCU!). 
-If the patient was transferred from your CCU to another ward in your hospital, 
the information given should also cover that part of the hospitalization. 
-If the patient was transferred to another hospital, this is considered a new 
hospitalization and information is only required up to the time the patient left 
your hospital. 
47. Was the patient discharged alive from your hospital? 
IF YES: COMPLETE ITEMS 48-51 AND 57-66 
IF NO : COMPLETE ITEMS 52-56 AND 57-66 
NO 
( ) 
A-21 
YES 
( ) 
P A T I E N T D I S C H A R G E D A L I V E F R 0 M Y 0 U R H 0 S P I T A L 
(date): , I , I , 48. Discharged from CCU on (time):_,_:_,_ 
h m -d--m--y- If discharged directly 
49. Discharged from hospital on (date): _,_/_,_/_,_ 
d m y 
50. Destination at discharge {tick one): 
( ) home 
( ) other hospital 
( ) rehabilitation clinic 
( ) other institution 
( ) destination unknown 
51. Functional state at discharge (tick one): 
(57) no limitations of physical activity 
from CCU: fill out same 
date at 48 and 49 
(51.1) slight limitations of physical activity but comfortable at rest 
{51.1) marked limitation of physical activity but comfortable at rest 
(51.1) inability to carry on any physical activity, with or without symptoms at rest 
(57) unknown 
51.1 Limitation due to (tick one): 
( ) angina pectoris ( ) congestive heart failure 
( ) both 
( ) other 
~ GO TO ITEM 57 
P A T I E N T D I E D I N Y 0 U R H 0 S P I T A L 
52. Patient died on (time): , : , 
-h--m-
53. Place of death (tick one): (53.1) other ward 
{54) ccu 
53.1 Patient discharged from CCU on (time): , : , 
-h--m-
54. Describe briefly the circumstances of death: 
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55. Was an autopsy performed? 
55.1 IF YES, ATTACH COPY OF REPORT 
56. Which factors contributed to death (tick all that apply) 
( ) reinfarction ( ) electrical standstill 
( ) congestive heart failure ( ) thromboembolism 
( ) cardiogenic shock ( ) cardiac surgery 
( ) ventricular septum rupture ( ) PTCA 
NO 
( ) 
YES 
(55.1) 
( ) papillary muscle rupture ( ) other cardiac, describe: ---------
( ) tamponade ( ) non-cardiac, describe: ( ) ventricular fibrillation ( ) unknown ---------
( ) electro-mechanical dissociation 
A L L P A T I E N T S 
THIS PART MUST BE COMPLETED FOR ALL PATIENTS IRRESPECTIVE WHETHER DISCHARGED ALIVE OR 
DIED IN-HOSPITAL. 
Unless otherwise stated, information is required for the time span between 24 hours 
after telephone allocatior. and eventual hospital discharge or death. 
Indicate eventual (discharge or pre-death) diagnosis: 
57. MYOCARDIAL INFARCTION AT ADMISSION? 
57.1 If yes, site (tick one): 
( ) anterior 
( ) infero-posterior 
( ) lateral 
( ) impossible to determine 
57.2 If yes, diagnosis based on (tick one): 
( ) both ECG and enzymes typical 
( ) typical ECG pattern only 
( ) typical enzyme pattern only 
( ) other grounds, describe:-------------
58. MYOCARDIAL (RE)INFARCTION LATER DURING HOSPITALIZATION? 
58.1 If yes, site (tick one): 
( ) anterior 
( ) infero-posterior 
( ) lateral 
( ) impossible to determine 
58.2 If yes, diagnosis based on (tick one): 
( ) both ECG and enzymes typical 
( ) typical ECG pattern only 
( ) typi ca 1 enzyme pattern only 
( ) other grounds, describe:-------------
58.3 If yes, send copy of your laboratory data sheet for CPK, 
CPK-MB (if avaiTable), SGOT, SGPT, LDH and a-HBDH together 
with this form to the Data Center. 
59. OTHER CARDIAC DIAGNOSIS? 
59.1 If yes, describe:-----------------
NO 
(58) 
NO 
(59) 
NO 
(60) 
YES 
(57.1) 
YES 
(58.1) 
YES 
(59.1) 
60. NON-CARDIAC DIAGNOSIS? (61) (60.1) 
60.1 If yes, describe: -----------------
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61. Were any bleeding complications observed between 24 hours after 
allocation and discharge (or death)? 
NO 
{62) 
61.1 If yes, indicate date first noticed and site (tick all that apply): 
) major (more than 5 em diameter) hematoma 
e.g. at puncture site 
( ) prolonged (more than 3D mins) bleeding 
e.g at puncture site 
( ) retroperitoneal hematoma 
( ) cerebral or subarachnoidal hemorrhage 
( ) hematemesis 
( ) melena 
( ) hemoptysis 
( ) hematuria 
( ) other: -------------
61.2 Were any special measures taken? 
61.3 If yes, tick all that apply and give details: 
( ) blood (product) transfusion 
DATE 
_I_/ _I_/ _1_ 
_I_/ _I_/ _I_ 
_I_/ _I_/ _I_ 
_I_/ _I_/ _I_ 
_I_/ _I_/ _I_ 
_I_/ _I_/ _I_ 
_I_/ _I_/ _I_ 
_I_/ _I_/ _I_ 
I I I I I 
-d--m--y-
SITE 
NO 
{62) 
Indicate number of units equivalent to 0.5 liter whole blood: 
( ) surgery 
( ) other: 
1. ______________________________ __ 
2. ------------------------------------
62. Were any of the following cardiovascular complications observed 
between 24 hours after allocation and discharge (or death)? 
62.1 If yes, tick all that apply and give date first noticed: 
( ) angina at rest without (re)infarction 
( ) effort angina without (re)infarction 
( ) chest pain, suggesting (re)infarction 
( ) systolic blood pressure under 90 mmHg 
( ) cardiogenic shock 
( ) pulmonary edema 
( ) peripheral edema 
( ) hepatomegaly 
( ) elevated CVP 
( ) bradycardia (pulse rate under 50 bpm) 
( ) second degree AV-block 
( ) third degree AV-block 
( ) IV conduction defect 
( ) atrial fibrillationiSVT 
( ) accelerated idioventricular rhythm {100 bpm or less) 
DATE: 
NO 
{63) 
_I_/ _1_1 _I_ 
_I_) _1_1 _I_ 
_I_) _I_) _I_ 
_I_) _1_1 _I_ 
_I_) _I_/ _I_ 
_I_/ _I_/ _I_ 
_I_) _1_1 _I_ 
_I_/ _1_1 _I_ 
_I_) _I_) _I_ 
_I_) _1_1 _I_ 
_I_) _I_) _I_ 
_I_) _I_) _I_ 
_I_) _1_1 _I_ 
_I_) _I_/ _I_ 
I I I I I 
-d--m--y-
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YES 
(61.1) 
YES 
(61.3) 
YES 
(62.1) 
A-24 
lD nr: 
(62. continued) DATE: 
( ) ventricular tachycardia (100 bpm or more) 
( ) ventricular fibrillation 
( ) mitral regurgitation 
( ) papillary muscle rupture 
( ) LV aneurysm 
( ) LV free wa 11 rupture 
( ) ventricular septum rupture 
( ) cerebra vascular accident 
( ) pulmonary embolus 
( ) pericarditis (i.e. at least two of the following 
three: pain with breathing, friction rub, fever) 
( ) other: -------------------------------
_._;_._!_._ 
_,_; _._; -·-
_._; _._; -·-
_._; _._; -·-
_._; _._; -·-
_._; _._! -·-
_._; _._; -·-
_._; _._; -·-
_._; _._; -·-
63. Give details of use of medication between 24 hours after allocation and 
discharge or death (tick appropriate drug/time combination(s)): 
- anticoagulants - heparin 
- coumarin 
- antiplatelet drugs 
- analgesics (opiates) 
- beta-blockers 
- calcium antagonists: - oral 
- i. v. 
-nitrates: - s.l. 
- i. v. (continuous) 
- other vasodilators 
- antiarrhythmics 
- digitalis 
- doparnine/dobutamine 
- other positive inotropics 
- diuretics 
- thrombolytic agents other than 
trial medication, specify: 
- any other medication, specify: 
* if patient is discharged alive 
after prescribed at 
24 hours discharge* 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) ( ) 
( ) ( ) 
( ) ( ) 
( ) ( ) 
( ) ( ) 
( ) ( ) 
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64. Were any of the following additional procedures done between 
24 hours after allocation and discharge (or death)? 
64.1 IF YES, tick all that apply and give date (first time only) 
and indication (write 'routine' if the procedure at issue is 
part of your routine work-up): 
DATE INDICATION 
( ) catheterization other than as 
according to the protocol _,_/ _,_/ _,_ 
( ) PTCA _,_/ _,_1 _,_ 
( ) bypass surgery _,_/ _,_/ _,_ 
( ) other cardiac surgery _,_1 _,_/ _,_ 
( ) intra-aortic balloon pumping _,_1 _,_/ _,_ 
( ) respirator used _,_; _,_/ _,_ 
( ) electrical counter shock _,_/ _,_/ _,_ 
( ) temporary pacemaker used _,_/ _,_/ _,_ 
( ) permanent pacemaker insertion _,_1_,_1_,_ 
( ) blood pool scintigraphy other than 
as according to the protocol _,_/ _,_/ _,_ 
( ) perfusion scintigraphy _,_/ _,_/ _,_ 
( ) ergometry other than as according 
to the protocol _,_/ _,_/ _,_ 
( ) Holter ECG _,_/ _,_/ _,_ 
( ) echocardiography I I I I I 
-d- -m--y-
CONTINUE NEXT PAGE!! 
NO 
(65) 
STORE RED COPY OF FORM, READY FOR LATER REFERENCE (NOT IN PATIENT's FILE, USE SPECIAL 
STUDY BINDER). 
SEND ORIGINAL TO THOMAE (USE ENVELOPE PROVIDED). 
SEND BLUE COPY TOGETHER WITH RANDOMIZATION ENVELOPE TO DATA CENTER (USE ENVELOPE 
PROVIDED). 
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YES 
(64.1) 
65. Give results of laboratory tests at 0, 12, 24, 36, 48, 72 and 96 hours after treatment allocation. Note actual 
time and date samples were obtained. OBSERVE DECIMAL POINT! 
TIMES: 
DATES: 
Hb (mmol/l) 
Ht {%} 
Thrombo 1 s {109/l) 
Na + (mmol/1) 
K+ (mmol/1) 
Urea (mmol/l) 
Creat ( mol /l) 
ASAT(GOT} (U/l) 
ALAT(GPT) (U/l) 
LDH (U/1} 
cx-HBDH ( U/l } 
CK (U/l} 
CK-MB {U/1} 
0 hours 
I • I 
-h--m-
_1_/_1_/_,_ 
d m Y 
-~-~-1 
_l_l 
_j_j_j 
_l_l_j 
_f_l 
12 hours 
I ! I 
-h--m-
_1_/_1_/_,_ 
d m Y 
_l_f_l 
_j_J 
_j_j_j 
_j_j_J 
_f_j 
24 hours 
-h--m-
_1_/_1_/_,_ 
d m y 
_l_f_l 
_J_J 
_l_l_l 
_j_j_j 
_f_j 
36 hours 
I : I 
-h--m-
_,_1_,_/ _,_ 
d m Y 
_J_f_l 
_J_J 
_J_J_J 
_j_j_j 
_J_J 
_I _1. _J _j _1. _j _I _1. _j _j _1. _j 
_j_j_j _j_j_j _j_j_J _j_j_j 
_J_J_J _j_j_j _J_J_J _j_j_j 
_j_j_j _J_J_J _j_j_j _j_J_J 
_j_j_j_J _j_j_j_j _j_j_j_j _j_j_j _j 
_j_j_j_j _j_j_j_j _j_j_j_J _j_j_j _j 
_j_j_j_j _j_j_J_J _j_j _j_j _j_j _j_J 
_J_j_j_J _J _j_j_J _j_j _j _j _j_j_j _j 
66. Supply name and signature of responsible physician: 
Date 
48 hours 
I : I 
-h--m-
_,_1_,_/_,_ 
d m Y 
_l_f_l 
_J_J 
_j_J_J 
_j_j_J 
_f_J 
_j_j._J 
_j_J_J 
_j_j_j 
_j_j_j 
72 hours 
I • I 
-h--m-
_,_/_1_/_1_ 
d m y 
_J__cj_J 
_j_J 
_j_J_j 
_j_j_j 
_J_J 
_l_l._j 
_J_J_J 
_J_J_J 
_j_j_j 
96 hours 
I ! I 
-h--m-
_1_/_,_/_1_ 
d m y 
_J_f_J 
_j_j 
_j_j_j 
_J_J_J 
_j._J 
_j_l._j 
_j_j_j 
_J_J_j 
_j_J_J 
_j_j_j_j _j_J_J_J _j_j_j _j 
_j_J_j_j _j_j_j_j _J_J_j _J 
_J _J _J _J _j_j_J_J _j _J_j _J 
_j _j _j _j _j _j _j _j _j _J _j _j 
Dr: ,_,_,_1_,_1_,_,_1_1_,_1 Signature: signed: _1_/_1_/_1_ 
d m y 
SEE INSTRUCTIONS PAGE 20! THANK YOU FOR YOUR CO-OPERATION! 
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EUROPEAN CO-OPERATIVE STUDY GROUP FOR RECOMBINANT 
TISSUE-TYPE PLASMINOGEN ACTIVATOR (rt-PA) 
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(rt-PA versus placebo trial) 
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ID nr: 
EUROPEAN CO-OPERATIVE STUDY GROUP FOR RECOMBINANT TISSUE-TYPE PLASMINOGEN 
ACTIVATOR (rt-PA) 
IF YOU CANNOT SUPPLY THE DATA CENTER AND THOMAE WITH THE PATIENT'S NAME AND ADDRESS, 
YOU ARE ALLOWED TO CUT OFF THE BOTTOM PART OF THE WHITE AND BLUE COPIES OF THE FORM 
BEFORE SENDING THEM IN. 
YOUR OWN RED COPY MUST ALWAYS BE FILLED OUT AND STORED FOR FUTURE REFERENCE, 
SEPARATELY FROM PATIENT'S HOSPITAL FILE. 
P A T I E N T I C L I N I C I D E N T I F I C A T I 0 N 
1. Identification of clinic where patient was admitted: 
1.1 Name: --------------------------
1. 2 City: -----------------------
2. Give patient identification: 
2.1 Hospital registration number: 
2.2 Date of birth: _,_}_,_}_,_ 
d m y 
2.3 Sex: ( ) male ( ) female 
3. Give patient name and address: 
Family name: 
~1a i den name: (if married) 
I I I I I I I I I I I I (double check!) 
Initials: 
City ,_,_,_,_,_,_,_,_,_,_,_,_,_,_,_,_,_,_,_,_,_, 
Country: I I I I I I I I I I I I I I I I 
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1 0 - 2 2 D A Y E X E R C I S E T E S T F 0 R M 
BICYCLE PROTOCOL STEPWISE INCREMENTS OF 10 WATTS/MIN SITTING POSITION. 
TREADr~ILL PROTOCOL MODIFIED BRUCE {WELD): TIME 
(min) 
1-3 
4-6 
7-9 
10-12 
13-15 
16-18 
RECORD ECG EITHER cmm NUOUSL Y OR INTERMITTENTLY. 
SPEED 
(mph/kmh) 
1. 7/2.9 
1.7/2.9 
1.7/2.9 
2.5/4.3 
3.4/5.8 
4.2/7.1 
SLOPE (%) 
0 
5 
10 (=BRUCE 1) 
12 (=BRUCE 2) 
14 (=BRUCE 3) 
16 (=BRUCE 4) 
MAKE COPIES OF THE MOST ABNORNAL ECG DURING THE TEST AND OF THE ECGs AT PEAK 
EXERCISE AND AFTER 6 MINUTES RECOVERY. 
STORE ORIGINALS FOR TR.O.NSFERRAL TO THE DATA CENTER, MARK \o!ITH DATE, TI~iE, AND 
ID NR PEEL-OFF STICKER. 
A-29 
CONTINUE EXERCISE UNTIL SYMPTOMS, DROP OF SYSTOLIC BLOOD PRESSURE, SEVERE ARRHYTHMIAS, 
OR SIGNIFICANT ST-CHANGES OCCUR OR UNTIL THE PATIENT'S HEART RATE EXCEEDS 200 MINUS AGE. 
DO NOT STOP MEDICATION DURING THE TEST. 
DO NOT COMBINE EXERCISE TEST WITH RADIONUCLIDE ANGIOGRAPHY OR THALLIUM SCINTIGRAPHY. 
4. Make standard 12-lead ECG (store original for transferral to data center, 
mark ~lith date, time, ID nr peel-uff sticker). ERRATUMEXERCISETESTFORMPAGE2, 135.10 
Date: , I , I , Time: , . , 
-d- -m--y- -h- -m-
5. Indicate patient's height and weight: 
Height: , , , , em 
Make 12-lead ECGs at rest, at maximum ST-shift, 
at peak exercise and at 6 min recovery {or make 
continuous 12-lead ECG registration). For all 
these ECGs patient must be in the same position. 
Weight: '-'-'-' kg Add calibration marks (1 em • 1 mV) 
6. Perform symptom limited pre-discharge exercise test: 
6.1 Which equipment is used (tick one)? 
( ) bicycle (sitting position) 
( ) bicycle (supine) 
( ) treadmill 
6.2 Indicate ECG leads used (tick all that apply): 
( ) ( ) a VR ( ) V1 { ) V4 ( ) X 
{ ) I I ( ) a VL ( ) V2 ( ) V5 ( ) y 
( ) III { ) aVF ( ) V3 { ) V6 ( ) Z 
6.3 Which protocol is used? (tick one): 
( ) bicycle, 10 Watts/min increments 
other, specify: () _____ _ 
() _____ _ 
() _____ _ 
( ) bicycle, other. Indicate: ,_,_, Watts/,_,_, min increments 
( ) treadmill (modified Bruce) 
( ) treadmill, other specify:-----------------
135.10- 10-22 day Exercise Test Form/LV Function Study, page 2 of (4) -February 26, 1986 
A-30 10 nr: 
6.4 Give results of exercise test (measure ST-changes 80 msec after J-point): 
at start of 
exercise test 
onset of 
symptoms 
1mm 
ST-depression 
or -elevation 
peak 
exercise 
- min after start of 
exercise 
- bicycle: Watt 
-treadmill: slope 
I 
I 
_I_ 
-·-·-
I 
_I_ 
1 .min I 
_I_ I 
I Watt I 
-·-·-
I 
I % I 
_I_ I 
speed (km/h) 
(mph) 
- systolic blood pressure 
I 
_I_ I km/h I _._, 
I I I I 
- heart rate 
·-·-·-· 
6.5 Any symptoms during the test? 
mmHg 
bpm 
I 
I 
I I I 
-·-·-
I 
-·-·-
I 
mph I 
_I_ I 
mmHg I 
-·-·-
I 
bpm I 
-·-·-
I 
If yes, tick the appropriate symptom/test-phase combination(s) 
and give time relative to beginning of test-phase: 
During Onset During 
exercise of Sl:mptoms recoverl: 
dyspnea ( ) min ( ) 
typical angina ( ) I 
_I_ I min ( ) 
a-typi ca 1 angina ( ) I I I min ( ) 
chest discomfort ( ) I 
_I_ I min ( ) 
other ( ) 
' ' ' 
min ( ) 
6.6 Indicate maximum workload achieved: Watts/Bruce: 
6.7 Indicate expected "normal" value 
' 
_,_ 
' 
Watts/Bruce: 
' 
_I_ 
6.8 ~/hat was the workload according to the patient (tick one)? 
( ) submaximal 
( ) near maximal 
( ) maximal 
6.9 Was the test terminated by the patient? 
If yes, tick reason: 
( ) angina 
( ) dyspnea 
( ) general fatigue 
( ) fatigue in the legs 
( ) other: -------------------
6.10 Was the test terminated by the physician? 
' 
min I 
-·-· Watt I _._,_ I 
% I _,_, 
km/h I 
_I_ I 
mph I 
-·-· 
mmHg I 
-·-·-bpm I 
-·-·-
NO 
(6.6) 
Onset 
of symptoms 
I 
_I_ I 
I 
_I_ I 
I _,_ 
' 
' 
_,_ 
' 
min 
min. 
NO 
(6.10) 
NO 
(6.11) 
min 
min 
min 
min 
min 
I 
I 
min 
Watt 
% 
km/h 
mph 
mmHg 
bpm 
YES 
( ) 
YES 
( ) 
YES 
( ) 
If yes, tick reason: 
( ) arrhythmias 
ERRATA EXERCISE TEST FORM PAGE 3-4, 135.10 
( ) conduction defects 
( ) ST-T changes 
( ) abnormal blood pressure response 
( ) heart rate over (200 - age) 
( ) other: 
1. Item 6.10: abnormal blood pressure respbnse 
is at least a 15 mmHg drop in 
systolic blood pressure 
2. Item 6.11: ventricular tachycardia is 
100 bpm or more 
3. Item 6.13: add generic name and dosage 
135.10 - 10-22 day Exercise Test Form/LV Function Study, page 3 of (4) - February 26, 1986 
ID nr: 
(6. continued) 
6.11 Were any arrhythmias seen? 
If yes, tick appropriate arrhythmia/time combination(s): 
before 
- premature supraventricular complexes 
- uniform premature ventricular complexes 
- multiform premature ventricular complexes 
- bigemini 
- couplets 
- short run ventricular tachycardia (3-10 complexes) 
- ventricular tachycardia (more than 10 complexes) 
- other: 
6.12 Were any repolarization changes 
If yes, tick all that apply: 
( ) junction depression 
( ) ST-depression 
( ) ST-elevation 
seen? 
LEADS 
test 
\)" 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
If ST-elevation or depression (measure 80 msec after J-point): 
- during exercise: maximum: I mm, at: I I I min 
- during recovery: maximum: 1_1_1 mm, at: 1_1_1 min 
NO 
(6.12) 
during 
exercise 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
NO 
(6.13) 
6.13 Give details of use of medication before and durin exercise test 
tick appropriate drug/time combination s : 
maintenance 
therapy 
- beta-blockers 
- calcium antagonists 
- nitrates 
- antiarrhythmics 
-digitalis 
7. Clinic where test was performed: 
Date performed: 1 I 1 I 1 
-d--m--y-
( ) 
( ) 
( ) 
( ) 
( ) 
8. Supply name and signature of responsible physician: 
added 
during test 
( ) 
( ) 
( ) 
( ) 
( ) 
Date 
YES 
( ) 
A-31 
during 
recovery 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
YES 
( ) 
Dr: 1_1_1_1_ 1_ 1_1_1_1_1_1_1 Signature:-------- signed: 1 I 1 I 1 
-d--m--y-
THANK YOU FOR YOUR CO-OPERATION! 
RETURN RED COPY OF FOR~1 TO CLINIC WHERE PATIENT HAS ADMITTED 
SEND ORIGINAL TO THOMAE (USE ENVELOPE PROVIDED) 
SEND BLUE COPY AND ORIGINAL ECGs TO DATA CENTER (USE ENVELOPE PROVIDED) 
135.10 - 10-22 day Exercise Test Form/LV Function Study, page 4 of (4) - February 26, 1986 
A-32 ID Nr: 
EUROPEAN CO-OPERATIVE STUDY GROUP FOR RECOMBINANT 
TISSUE-TYPE PLASMINOGEN ACTIVATOR (rt-PA) 
1 0 - 2 2 D A Y R A D I 0 N U C L I D E A N G I 0 G R A P H Y F 0 R M 
L V - F U N C T I 0 N S T U D Y 
(rt-PA versus placebo trial) 
135.10 - February 26, 1986 These forms are copyrighted 
ID nr: 
EUROPEAN CO-OPERATIVE STUDY GROUP FOR RECOMBINANT TISSUE-TYPE PLASMINOGEN 
ACTIVATOR (rt-PA) 
IF YOU CANNOT SUPPLY THE DATA CENTER AND THOMAE WITH THE PATIENT'S NAME AND ADORES~ 
YOU ARE ALLOWED TO CUT OFF THE BOTTOM PART OF THE WHITE AND BLUE COPIES OF THE FORM 
BEFORE SENDING THEM IN. 
YOUR OWN RED COPY MUST ALWAYS BE FILLED OUT AND STORED FOR FUTURE REFERENCE, 
SEPARATELY FROM PATIENT'S HOSPITAL FILE. 
P A T I E N T I C L I N I C I D E N T I F I C A T I 0 N 
1. Identification of clinic where patient was admitted: 
1.1 Name: -------------
1.2 City:------------
2. Give patient identification: 
2.1 Hospital registration number: I I I I I I I I I I I I (double check!) 
2.2 Date of birth: , I , I , 
-d--m-y-
2.3 Sex: ( ) male ( ) female 
3. Give patient name and address: 
Family name: 
~1a i den name: 
(if married) 
I I I I I I I I 1 I I I I I I I I I I I I I I I 
I I I I I I I I I I I I I I I I I I I I I I I I 
Initials: 
Street __ ,_,_,_,_,_,_,_,_,_,_,_,_,_,_,_,_,_,_,_, Nr: ,_, ___ _ 
City I I I I I I I I I I I I I I I I I I I I I I 
Country: I I I I I I I I I I 1 I I I I I 
Telephone: ,_,_,_,_,_, ,_,_,_,_,_,_,_, 
A-33 
135.10 - 10-22 day Radionuclide Angiography FormiLV Function Study, page 1 of (3) - 2612186 
A-34 
ID nr: 
1 0 - 2 2 D A Y R A D I 0 N U C L I D E A N G I 0 G R A P H Y F 0 R M 
GIVE 1 AMPUL STANNOUS PYROPHOSPHATE INTRAVENOUSLY. 
WAIT 20 MINUTES AND ADMINISTER 15 mCI OR MORE TECHNETIUM-99m. DO NOT GIVE STANNOUS 
PYROPHOSPHATE AND TECHNETIUM THROUGH SAME INTRAVENOUS LINE! 
START DATA COLLECTION AFTER ADMINISTRATION OF TECHNETIUM: 
- R-WAVE GATED MODE OR GATED LIST MODE. 
- A MINIMUM OF 20 FRAMES PER CYCLE AND A MINIMUM OF 5 MINUTES PER VIEW. 
-VIEWS: RAO 25°(20°-30°), LAO 45°(30°-60°), SELECT LAO VIEW WITH ±10° TILT FOR 
OPTIMAL SEPARATION LEFT AND RIGHT VENTRICLE, LAO LATERAL (65°-90°). 
- USE TWO REGIONS OF INTEREST FOR CALCULATIONS OF EJECTION FRACTION IF AVAILABLE. 
4. Perform radionuclide angiography: 
4.1 Indicate results (tick the appropriate): 
RAO 25°: 
1. antero-basa 1 
2. antero-lateral 
3. apex 
LAO 45°: 
4. antero-septal 
5. apex 
6. postero-lateral 
7. right ventricle 
LAO 65°: 
8. apex 
9. inferior 
10. posterior 
LAO 45° LAO 65° 
~ ',, 
t ) __ / .. ;~-
,' , L. /g ~, ./ ;J 
5 8 I 
NORMAL HYPOKINETIC AKINETIC DYSKINETIC UNKNOWN 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
135.10 - 10-22 day Radionuclide Angiography Form/LV Function Study, page 2 of (3) - 26/2/86 
ID nr: 
(4. continued) 
4.2 Indicate ejection fraction: left ventricle : 1 1 1 % 
4.3 Did you determine quantitative regional ejection fraction? 
4.4 Did patient have angina pectoris during radionuclide angiography? 
NO 
( ) 
NO 
( ) 
4.5 Give details of use of medication before and durin radionuclide an io 
tick appropriate drug time combination s : 
maintenance 
therapy 
- beta-blockers 
- calcium antagonists 
- nitrates 
- antiarrhythmics 
-digitalis 
( 
( ) 
( ) 
( ) 
( ) 
added 
during angio 
( 
( ) 
( ) 
( ) 
( ) 
YES 
( ) 
YES 
( ) 
A-35 
5. Clinic where radionuclide angiography was performed:-------------
6. Supply name and signature of responsible physician: 
Dr: I 1 I I I I I I I I I I Signature:--------
THANK YOU FOR YOUR CO-OPERATIONl 
RETURN RED COPY OF FOR~1 TO CLINIC \JHERE PATIENT WAS ADMITTED 
SEND ORIGINAL TO THOMAE (USE ENVELOPE PROVIDED) 
SEND BLUE COPY TO DATA CENTER (USE ENVELOPE PROVIDED). 
Date 
signed: 1 I 1 I 1 
-d- -m--y-
135.10- 10-22 day Radionuclide Angiography FormiLV Function Study, page 3 of (3) - 2612186 
A~6 ID Nr: 
EUROPEAN CO-OPERATIVE STUDY GROUP FOR RECOMBINANT 
TISSUE-TYPE PLASMINOGEN ACTIVATOR (rt-PA) 
1 0 - 2 2 D A Y C A T H E T E R I Z A T I 0 N F 0 R M 
L V - F U N C T I 0 N S T U D Y 
(rt-PA versus placebo trial) 
135.10 - February 26, 1986 These forms are copyrighted 
ID nr: 
EUROPEAN CO-OPERATIVE STUDY GROUP FOR RECOMBINANT TISSUE-TYPE PLASMINOGEN 
ACTIVATOR (rt-PA) 
IF YOU CANNOT SUPPLY THE DATA CENTER AND THOMAE WITh THE PATIENT'S NAME AND ADDRESS, 
YOU ARE ALLOWED TO CUT OFF THE BOTTOM PART OF THE WHITE AND BLUE COPIES OF THE FORM 
BEFORE SENDING THEM IN. 
YOUR OWN RED COPY f4UST ALWAYS BE FILLED OUT AND STORED FOR FUTURE REFERENCE, 
SEPARATELY FROM PATIENT'S HOSPITAL FILE. 
P A T I E N T I C L I N I C I D E N T I F I C A T I 0 N 
1. Identification of clinic where patient was admitted: 
1.1 Name: --------------------------
1. 2 City: ------------------
2. Give patient identification: 
2.1 Hospital registration number: 
2.2 Date of birth: , I , I , 
-d-m--y-
2.3 Sex: ( ) male ( ) female 
3. Give patient name and address: 
I I I I I I I I I I I I (double check!) 
Family name: ,_,_._,_,_,_._,_,_._,_._,_,_,_._,_,_,_,_,_,_,_, 
A-37 
Initials: I I I I I 
Maiden name: 
(if married) 
Street __ ,_,_._,_._,_._,_,_,_,_,_._,_._,_._,_,_, Nr: ,_, ___ _ 
City ,_._,_,_,_,_,_,_,_,_,_,_._,_,_,_,_,_,_,_._. 
Country: 
Telephone: ,_,_._,_,_, ._,_._,_,_,_,_, 
135.10 - 10-22 day Catheterization FormiLV Function Study, page 1 of {6) - February 26, 1986 
A-38 
ID nr: 
1 0- 2 2 DAY C A.T HE T E R I Z AT I 0 N F 0 R M 
-USE BIPLANE X-RAY EQUIPMENT, IF AVAILABLE! 
- LEFT VENTRICULOGRAPHY MUST PRECEED CORONARY ANGIOGRAPHY 
- USE NON-IONIC CONTRAST MATERIAL AT 37°C 
- USE 35 mm CINEFILM, MINIMUM FILM SPEED 50 frames/sec 
- BREATH SHOULD BE HELD IN MID-INSPIRATION 
- POSITION IMAGE INTENSIFIER AGAINST THE CHEST DURING LEFT VENTRICULOGRAPHY (OF MAJOR 
IMPORTANCE FOR CALIBRATION) 
- NITRATES MAY NOT BE GIVEN ROUTINELY 
LEFT VENTRICULOGRAPHY: 
- CONTRAST: 0.5-1 ml/kg, flow 6-20 ml/sec. 
-PROJECTIONS: 1. RAO 30°, 2. LAO 60°. (IF MONOPLANE SYSTEM IS USED: RAO FIRST) 
- IF MORE THAN ONE CONTRAST INJECTION IS GIVEN: WAIT AT LEAST 10 min OR UNTIL 
END DIASTOLIC LEFT VENTRICULAR PRESSURE HAS RETURNED TO PRE-ANGIOGRAM VALUE 
- AT LEAST TWO CONSECUTIVE SINUS BEATS MUST BE FILMED 
- NOTE DISTANCE X-RAY TUBE TO IMAGE INTENSIFIER AND FIELD SIZE OF IMAGE INTENSIFIER 
AT THE TIME OF RAO LEFT VENTRICULOGRAPHY (Item 6.4) 
4. Obtain blood sample (5 ml) for 
anti-body tests. Use provided 
tube (marked ANT). Put peel-
off sticker with tube number 
in box (all 3 copies!). 
Store on ice until centrifugation. 
5. Indicate details angioroom: 
5.1 Angioroom number: ,_,_, 
5.2 System used (tick): ( ) monoplane 
( ) biplane 
6. Perform left ventriculography: 
6.1 Indicate patient's height and weight: 
Height: ,_,_,_, em Weight: , , , , kg 
6.2 Technique used (tick): ( ) femoral 
( ) brachial 
6.3 Measure pressures and heart rates before each projection: 
peak systolic pressure 
end diastolic pressure 
heart rate 
MONOPLANE BIPLANE 
RAO LAO RAO/LAO 
' ' ' ' ' ' ' ' ' 
' ' ' ' ' ' 
' ' ' 
mmHg 
mmHg 
bpm 
TIME DATE 
_,_/ _,_} _,_ 
d m y 
135.10 - 10-22 day Catheterization Form/LV Function Study, page 2 of (6) - February 26, 1986 
ID nr: 
(6. continued) 
Distance X-ray - Field size 
View: Time: image intensifier: image intensifier: 
1. RAO 30° _,_:_,_ I I I em I I I inch 
2. _,_:_,_ em I I I inch 
3. LAO 60° I : I inch 
----
4. I : I I I I inch 
-h--m-
6.5 Give additional information about left ventriculography: 
volume of contrast injected : 1 1 1 ml 
rate of injection I I I ml/sec 
Trade name contrast material: -'--------
Manufactured by 
6.6 Assess segmental wall motion using the drawing below and tick in the 
diagram all that apply: 
1. anterobasal segment 
2. anterolateral segment 
3. apical segment 
4. diaphragmatic segment 
5. posterobasal segment 
1 2 3 4 5 
6. septal wall 
7. posterolateral 
6 7 
( ) ( ) 
( ) ( ) 
( ) ( ) 
( ) ( ) 
A-39 
normal 
hypokinetic 
akinetic 
dyskinetic 
other abnormality 
undefined 
( ) ( ) ( ) ( ) ( ) 
( ) ( ) ( ) ( ) ( ) 
( ) ( ) ( ) ( ) ( ) 
( ) ( ) ( ) ( ) ( ) 
( ) ( ) ( ) ( ) ( ) 
( ) ( ) ( ) ( ) ( ) ( ) ( ) Specify: -------( ) ( ) 
135.10 - 10-22 day Catheterization Form/LV Function Study, page 3 of (6) - February 26, 1986 
A-40 
ID nr: 
(6. continued) 
6.7 Is mitral regurgitation present? 
If yes, indicate grade (tick one): 
( ) I, regurgitant jet with minimal opacification of the 
· left atrium which clears rapidly 
( ) II, regurgitant jet ~lith moderate opacification of the 
left atrium which clears rapidly 
( ) III, no jet, the left atrial opacification is as intense 
as that of the left ventricle and aorta on the late 
films; usually the left atrium is greatly enlarged 
( ) IV, the left atrial opacification is more intense than 
that of the left ventricle and aorta, and the intense 
&pacification persists throughout the entire series 
of films; left ventricular dilatation and marked 
left atrial enlargement 
Is mitral regurgitation catheter related? 
6.8 Was global ejection fraction measured? 
If yes, indicate: , , , % 
NO 
(6.8) 
NO 
( ) 
NO 
(7) 
YES 
( ) 
YES 
( ) 
YES 
( ) 
STORE END SYSTOLIC AND END DIASTOLIC CONTOURS FOR LATER REFERENCE (IN CASE FILM IS LOST) 
7. Perform coronary angiography 
7.1 I~dicate type of catheter(s) used (tick): 
Right Coronary: ( ) Judkins 
( ) Sones 
Left Coronary: ( ) Judkins 
( ) Sones ( ) other: ____ _ ()other: ___ _ 
French size: ___ _ 
Manufactured by: ----------------
7.2 List filming sequence of visualization coronary angiogram: 
MINIMUM REQUIRED: - 3 VIEWS LEFT CORONARY 
- 2 VIEWS RIGHT CORONARY 
Artery: Artery: 
1. 6. ----
2. 7. ----
3. 8.----
4. 9. ----
5. 10.----
7.3 Indicate time first view: , : , 
-h--m 
View: 
7.4 Did you use the same contrast for coronary angiography 
as for left ventriculography? 
If no, indicate trade name:------------
Manufactured by: 
=r 0.. 
"' 
~· ~ ~ 
.., 0 
-
0 
.., 
..... 
~ ~· 
-
n 
"' 
~ ,. 
"' ! " 
NO 
( ) 
..... 
-"' 
"' 
0 ~* ~ 0 -0 ~ ~ ..... ~· n n 
0 ~ 
.., 0 
0 .., 
=> 
-~ 
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.., n 
~ 
"' m.., 
=> "' ! = 0 ~· 0 0 c =.., 
ii 
=r 
"' ~
.., 
-.., 
~ 
-
"' 
YES 
(8) 
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= = ,.. 
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5§• 
·~ 
~ 
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-< 
n 
~ 
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~ 
-~ 
~ 
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~ 
C> 
135.10- 10-22 day Catheterization Form/LV Functi~n Study, page 4 of (6) -february 26, 1986 
ID nr: 
8. FILM CALIBRATION SPHERE, when patient has left the table: 
8.1 If monoplane system is used: 
Reproduce same d1stance X-ray tube to image intensifier as used for RAO left 
ventriculography (item 6.4). Hold calibration sphere with short distance-marker 
against image intensifier (perpendicular). Film sphere for 5 sec. 
8.2 If bi~lane system is used: 
Repro uce arm angulations as during left ventriculography. Reproduce same 
distance X-ray tube to image intensifier as used for RAO left ventriculography. 
Hold calibration sphere in the isocentric point. Film sphere for 5 sec. 
A-41 
9. Was catheterization procedure interrupted? 
NO 
(10) 
YES 
(9.1) 
9.1 If yes, why?------------------
.. COMPLETE MEASURENENTS AND OBSERVATIONS IF AT ALL POSSIBLE 
10. Did any complications occur? 
10.1 If yes (tick all that apply, give details): 
( ) death ( ) arrhythmia 
( ) MI ( ) vascular 
( ) CVA ( ) other 
11. STORE FILM FOR LATER CENTRAL ANALYSIS 
INDICATE ANGlO REGISTRATION NUMBER I I I I I I I I I I I 
NO 
(11) 
LABEL OUTSIDE OF FILM BOX WITH ID NR PEEL-OFF STICKER AND STORE FILM FOR LATER 
CENTRAL ANALYSIS 
12. Are you able to identify "infarct related" vessel? 
(see admission ECG) 
NO 
(12.1) 
12.1 If no, why not:------------------
12.2 If yes, give number of vessel segments considered "infarct related": 
(refer to picture below). 
RCA 
y 
2 
MAIN lAD 
STEM 
CFX 
(for intermediate, 2nd marginal branch, or deviation from this sketch: 
indicate on drawing). 
I I I 
YES 
(10.1) 
YES 
(12.2) 
135.10 - 10-22 day Catheterization Form/LV Function Study, page 5 of (6) - February 26, 1986 
A-42 
ID nr: 
13. Indicate grade of perfusion of the "infarct related" segment (tick one): 
(13.1) grade 0: non per-fusion 
(13.1) grade 1: penetration with minimal perfusion (contrast fails to opacify the 
entire coronary bed distal to the stenosis for the duration of 
the cine run) 
(13.2) grade 2: partial perfusion (contrast opacifies the entire coronary bed 
distal to the stenosis. However, the rate of entry and/or clearance 
is slower in coronary bed distal to the obstruction than in comparable 
areas not perfused by the infarct related vessel) 
(13.2) grade 3: complete perfusion (filling and clearance of contrast equally rapid 
in coronary bed distal to stenosis as in other coronary beds) 
13.1 Indicate with a dot in picture (item 12) site of grade 0 or 1 obstruction. 
13.2 Is there a diameter stenosis of more than 60% in the 
"infarct related" segment? 
NO 
( ) 
13.3 Give details of use of medication before and durin catheterization 
tick appropriate drug time combination s : 
maintenance 
therapy 
- beta-blockers 
- calcium antagonists: - oral 
- i. v. 
- i .c. 
-nitrates: - s.l. 
- i.v. 
-i.e. 
- any other medication, specify: 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
added 
during cath 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
( ) 
14. Clinic where catheterization was performed:-------------
Date performed: 1 I 1 I 1 
-d--m--y-
15. Supply name and signature of responsible physician: 
Dr: ~-~-~-~-~-~-~-~-~-~-~-~ Signature:---------
THANK YOU FOR YOUR CO-OPERATION! 
YES 
( ) 
CENTRIFUGE BLOOD FOR SPECIAL ANTI-BODY TEST (item 4). TRANSFER PLASMA WITH PIPETTE TO 
TUBE FROM SET WITH CORRESPONDING NUMBER AND STORE SAMPLE AT -20°C UNTIL FURTHER NOTICE. 
RETURN RED COPY OF FORM TO CLINIC WHERE PATIENT WAS ADMITTED. 
SEND ORIGINAL TO THOMAE (USE ENVELOPE PROVIDED). 
SEND BLUE COPY TO DATA CENTER (USE ENVELOPE PROVIDED). 
135.10 - 10-22 day Catheterization Form/LV Function Study, page 6 of (6) - February 26, 1986 
ID Nr: 
EUROPEAN CO-OPERATIVE STUDY GROUP FOR RECOMBINANT 
TISSUE-TYPE PLASMINOGEN ACTIVATOR (rt-PA) 
L V - F U N C T I 0 N S T U D Y 
ONE-YEAR FOLLOW-UP FORM 
135. 10 - Apri 1 6, 1987 These forms are copyrighted 
A-43 
A-44 
ID Nr: 
THIS PAGE MUST BE COMPLETED FOR EVERY PATIENT ADMITTED TO THE STUDY. 
HOWEVER, IF YOU CANNOT SUPPLY THE DATA CENTER AND THOMAE WITH THE PATIENT'S NAME 
AND ADDRESS, YOU ARE ALLOWED TO CUT OFF THE BOTTOM PART OF THE WHITE AND BLUE 
COPIES OF THE FORM BEFORE SENDING THEM IN. YOUR OWN RED COPY MUST ALWAYS BE FILLED 
OUT AND STORED FOR FUTURE REFERENCE, SEPARATELY FROM PATIENT'S HOSPITAL FILE. 
P A T I E N T / C L I N I C I D E N T I F I C A T I 0 N 
1. Give clinic identification: 
1.1 Name: 
1.2 City: 
2. Give patient identification: 
2.1 Hospital registration number: • • • • • • • • • • • • • (double check!) 
2.3 Sex: ( ) male 
( ) female 
3. Give patient's name and address: 
Family name: ----------------- Initials 
Maiden name: (if married) -----------------
Street Number 
City Posta 1 code: ___ _ 
Country 
Telephone 
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A-45 
ID Nr: 
THIS FORM MUST BE COMPLETED ONE YEAR AFTER ALLOCATION FOR EVERY PATIENT ADMITTED 
TO THE STUDY AND ALIVE AT THREE-MONTH FOLLOW-UP. INFORMATION IS REQUIRED FOR THE 
TIME SPAN BETWEEN THREE-MONTH FOLLOW-UP AND ONE YEAR AFTER ALLOCATION OR DEATH. 
ARRANGE OUT-PATIENT CLINIC VISIT ONE YEAR AFTER ALLOCATION (BETWEEN 12 AND 13 
MONTHS). OBTAIN STANDARD 12-LEAD ECG MADE ON THAT DATE. IF IT IS IMPOSSIBLE TO SEE 
PATIENT, TRY TO OBTAIN AS MUCH INFORMATION AS YOU CAN. 
4. Target date for one-year follow-up: 
5. Actual date of one-year follow-up: 
6. Was patient alive at actual date of 
one-year follow-up? 
6. l If unknown, what was date patient 
last known to be alive? 
(e.g. date last out-patient clinic visit) 
GO TO ITEM 17 
6.2 If deceased, COMPLETE ITEMS 7-11 AND ITEMS 16-17 
6.3 If alive, COMPLETE ITEMS 12-17 
P A T I E N T D I E D 
7. Date patient died: 1 I 1 I 1 
-d- -m--Y-
8. Place of death (tick one): ( ) in hospital 
( ) home 
( ) other: 
9. Describe briefly the circumstances of death: 
10. Was an autopsy performed? 
10.1 If yes, ATTACH COPY OF REPORT 
11. Which factors contributed to death (tick all that apply): 
( ) re-infarction ( ) arrhythmias, describe: 
( ) congestive heart failure ( ) other cardiac, describe: 
( ) cardiac surgery ( ) non-cardiac, describe: 
( ) PTCA ( ) unknown 
UNKNOWN NO YES 
(6. l) (6.2) (6.3) 
NO YES 
(11) (10.1) 
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ID Nr: 
P A T I E N T A L I V E 
12. Was patient seen at your out-patient clinic at the 
actual date of one-year follow-up? 
12.1 If no, indicate how information was obtained (tick one): 
( ) telephone contact with patient 
( ) through patient's family 
( ) through general practitioner 
( ) cardiologist elsewhere 
( ) other means, specify: 
13. Obtain standard 12-lead ECG (including 1 cm=l mV calibration) 
(forward original to data center, mark with date, time, and 
ID nr peel-off sticker) 
14. Indicate current state at one-year follow-up: 
14.1 Tick all that apply: 
( ) no complaints 
( ) dyspnea 
( ) angina at rest 
( ) effort angina 
NO 
( 12. 1) 
Date of 
re-i nf-3.rct ion 
_!_!_ 
YES 
(13) 
14.2 Did a definite (re)infarction occur between 
three-month and one-year follow-up? 
NO YES 
( 14. 4) ( 14. 3) 
14.3 In case of definite (re)infarction, give details: 
Site of infarction (tick one): 
( ) anterior 
( ) infero-posterior 
( ) lateral 
( ) impossible to determine 
Diagnosis based on (tick one): 
( ) both ECG and enzymes typical 
( ) typical ECG pattern only 
( ) typical enzyme pattern only 
( ) other grounds, describe: 
SEND ORIGINAL ECG(s), MARKED WITH TIME, DATE AND ID NR PEEL-OFF STICKER, 
AND COPY OF YOUR LABORATORY DATA SHEET FOR CARDIAC ENZYMES, TOGETHER WITH 
THIS FORM TO THE DATA CENTER 
14.4 Indicate functional state at one-year follow-up (tick one): 
( 15 ) unknown 
( 15 ) no limitation of physical activity 
(14.5) slight limitation of physical activity but comfortable at rest 
(14.5) marked limitation of physical activity but comfortable at rest 
(14.5) unable to carry out any physical activity, with or without 
symptoms at rest 
14.5 Limitations due to (tick one): 
( ) angina pectoris 
( ) congestive heart failure 
( ) both 
( ) other, describe: 
135.10 - One-year Follow-up Form/LV Function Study, page 3 of (4) - April 6, 1987 
ID Nr: 
15. Indicate which medication patient currently uses (tick all that apply): 
( ) anticoagulants (coumarins) 
( ) antiplatelet drugs 
( ) beta-blockers 
( ) calcium antagonists 
( ) long acting nitrates 
( ) digitalis 
( ) diuretics 
( ) any other medication, specify: 
( ) none 
A L L P A T I E N T S 
NO YES 
A-47 
16. Has patient been admitted to hospital for any reason 
between three-month and one-year follow-up or death? (17) (16.1) 
16.1 If yes, give indication, dates of hospital admission and 
duration of hospital stay (tick all that apply, if more 
than one admission indicate by different admission dates): 
( ) angina at rest without (re)infarction 
( ) re-infarction 
( ) congestive heart failure 
( ) rhythm disturbances, specify: 
( ) pericarditis 
( ) thrombo-embolism, specify: 
( ) catheterization 
( ) PTCA 
( ) bypass surgery 
( ) other cardiac surgery, specify: 
( ) other, specify: 
( ) unknown 
17. Supply name and signature of responsible physician: 
DATE 
ADMITTED 
_,_1_,_1_,_ 
_,_1_,_1_,_ 
_•_l_•_l_•_ 
_•_l_•_l_•_ 
_,_1_,_1_,_ 
_,_1_,_1_,_ 
_,_1_,_1_,_ 
_,_1_,_1_,_ 
_,_1_,_1_,_ 
_,_1_,_1_,_ 
_,_1_,_1_,_ 
_,_1_,_1_,_ 
d m y 
Date 
DURATION OF 
HOSPITAL STAY 
(in days) 
I I I I 
I I I I 
I I I I 
I I I I 
I I I I 
I I I I 
I I I 1 
I I I 1 
Dr:---------- Signature: signed: ' I ' I ' 
-d- -m--y-
STORE RED COPY OF FORM, READY FOR LATER REFERENCE, SEPARATELY FROM PATIENT's 
HOSPITAL FILE. SEND ORIGINAL TO THOMAE (USE PROVIDED ENVELOPE). SEND BLUE COPY, 
TOGETHER WITH ORIGINAL ECGs (ITEM 13 AND ITEM 14.3, if applicable) AND COPY OF 
LABORATORY DATA SHEET (ITEM 14.3, if applicable) TO DATA CENTER (USE PROVIDED 
ENVELOPE). 
THANK YOU FOR YOUR CO-OPERATION! 
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